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ABSTRACT 
 
Kappa opioid (KOP) receptors have been shown to be involved in the control of several 
abuse related effects of central nervous system stimulants.  KOP receptor agonists have been 
shown to modulate the activity of dopamine neurons and decrease self-administration of cocaine 
in a variety of species, while KOP receptor antagonists have the potential to be utilized as opioid 
abuse therapies and in the treatment of relapse.   
With this in mind, investigations were performed on the novel KOP receptor agonist 
neoclerodane diterpene salvinorin A. This natural product is the active component of the 
hallucinogenic mint plant Salvia divinorum and the first non-nitrogenous natural product having 
high affinity and efficacy at KOP receptors.  Salvinorin A contains a furan ring, which in other 
furan containing natural products such as teucrin A and aflatoxin B1 has been identified to cause 
hepatotoxicity.  In efforts to develop a more desirable pharmacological tool, structural 
modifications were made to salvinorin A in efforts explore the role of the furan ring in affinity 
and activity at KOP receptors and to reduce its potential for hepatotoxicity.  Several ketone 
analogues were found to retain affinity at KOP receptors relative to salvinorin A and were 
versatile intermediates for the synthesis of other analogues.  Surprisingly, benzisoxazole (187) 
was found to have increased affinity for MOP receptors.  2-Furanyl salvinorin A (185) was found 
to have similar efficacy and activity compared to salvinorin A.  In addition, Captisol® was 
identified as a new vehicle for salvinorin A administration in pharmacological assays to 
eliminate some of the drawbacks of currently used vehicles.  These studies assist with the 
identification of the pharmacophore of salvinorin A as well as the determination of structure-
activity relationships, all of which will increase the potential for identification of novel opioid 
therapeutics. 
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CHAPTER I: INTRODUCTION 
Ancient History of Natural Products 
The use of natural products and natural product extracts in medicine has taken place since 
ancient times.1  Throughout history, natural products have played an important role in 
ethnopharmacology with the earliest recorded medicinal therapies based on natural product 
extracts.1,2  Civilizations in Mesopotamia began around 3500 BCE with one of the earliest being 
the Sumerian civilization which lasted until 2600 BCE.2  Evidence of medicinal practices from 
the Sumerian civilization has been preserved on cuneiform clay tablets relating to the concept of 
a medical practitioner and prescription regimes.2  Artifacts of Egyptian medicine from 2900 BCE 
have been found along with evidence of trade between Mesopotamia, Egypt, and southern 
Arabia.1,2  Much of this trade focused on aromatic woods, spices, and aromatic gums.2  Aromatic 
gum myrrh, isolated from the trees Cammiphora abyssinica and Commiphora momol, was a key 
component of ancient trade.3  Historically, myrrh was used in drug preparations for its analgesic 
properties.3  Additional evidence of the importance of natural products from a historical 
perspective is seen in ancient Chinese and Indian cultures around 1000 BCE.1  Indian Ayurvedic 
medicine has been around for over four thousand years and today is still utilized in medicine, 
especially in India.1,4  Several labs around the world are presently identifying a number of the 
pharmacological active compounds of Ayurvedic therapies.4  Plant alkaloids have predominantly 
been identified as the active components of ancient therapeutics.4  Still today, over 75% of the 
world population relies on traditional remedies for medicinal therapeutics.3  Even in developed 
nations, many people continue to use traditional medicinal approaches to bring healing and well-
being including Hypericum perforatum (St. John’s wort) and Ginkgo biloba L. 
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Natural Products in Medicine 
Before the identification of single pharmaceutical compounds, natural extracts were used 
for treatments ranging from pain to infections.5  With the advancement in scientific technology, 
the active components of natural extracts were able to be identified and characterized resulting in 
the modernization of pharmaceutical therapy.6  Natural products have greatly influence modern 
pharmaceutical industry and to date, the majority of drugs developed in pharmaceutical industry 
are based on natural product leads or modification of a natural product scaffold.7-10  Natural 
products are single chemical compounds produced by a living organism that occur naturally and 
are often unique for a particular class of organisms.  Natural products themselves, along with 
modified derivatives, have resulted in clinical agents in almost all therapeutic areas.7  In 2000, 
approximately one-third of the top-selling drugs were natural products or derivatives of natural 
products.5  In addition to providing a number of drugs, natural products have also greatly 
influenced what is known about therapeutic targets and biological pathways.11  Natural products 
provide biochemical tools to elucidate specific pathways of disease.7  Natural product medicinal 
chemistry has directly shaped our knowledge of the body and illness and how we currently treat 
disease.11   Structural diversity found throughout natural products make them a priceless source 
of original lead compounds for therapeutic use.10 
Biological activity found with natural products is attributed to their evolutionary 
purpose.8  Bacteria have been around for over three billion years and secondary metabolites have 
developed as a response to their local environments.8  If the metabolites were useful for the 
survival of the bacterial species then the gene products were propagated and further optimized in 
future generations.8  The evolution of organisms including plants, animals and microbes have 
 
3 
 
developed venoms and other protective secondary metabolites for defensive and survival 
purposes.12 
 
Figure 1: Structures of Selected Antibiotic Agents 
 
Given the rationale for secondary metabolite evolution, the number of natural products 
with biological activity is not surprising.  Specifically, natural product research has significantly 
influenced the areas of anti-cancer and anti-infective therapeutics, with the majority of these 
compounds being identified from plant or microbial sources.8,13  Natural products in medicine 
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have had great success by drastically improving the average quality of life and doubling life 
expectancy.8 
Approximately 80% of antibacterial agents are related to natural product scaffolds.8,9  
The beginnings of the golden age of antibacterial pharmaceuticals began in 1928 with Alexander 
Fleming’s discovery of the first medicinally useful penicillin (1) (Figure 1) antibiotic resulting 
from a contamination of Penicillium notatum in a bacterial colony.14  Isolation and purification 
of the fungi took over a decade and it was not until 1941 that the first clinical trial with crude 
penicillin was successful in humans.  Large-scale fermentation and isolation of penicillin 
required the development of new technologies and was pushed forward by the needs of World 
War II.  By 1943, large quantities of penicillin were being produced for the troops and scientific 
exploration into this class of natural products was expanding quickly.  In 1948, cephalosporin C 
(2), a ring-expanded derivative of penicillin was isolated from Cephalosporium sp.15  Through 
semi-synthesis and total synthesis efforts, over 100,000 penicillin and cephalosporin derived 
molecules have been produced.16 
In addition to penicillins and cepalosporins, aminoglycosides (3), tetracyclines (4), 
glycopeptides (5), and macrolides (6) are all antibiotic classes originating from natural sources.15  
Advances in synthetic chemistry and sustained research into natural product scaffolds that have 
been known for decades such as the -lactam, tetracycline, and erythromycin scaffolds have 
continued to result in the identification of new agents.  New compounds continue to be identified 
from these scaffolds that overcome the drawbacks of current therapeutics and yield new clinical 
candidates.17 
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Figure 2: Structures of Selected Natural Product Derived Anticancer Agents 
 
Natural products have had an enormous role in anti-cancer therapeutics.  Approximately 
80% of cancer chemotherapies on the market from 1981 – 2006 are natural products or are 
derived from natural sources.9  The success of natural products in cancer therapeutics can be seen 
with the increased five-year survival rate of patients jumping from 50% in 1975 to 70% in 2004.  
Diverse natural products as cytotoxic agents have been identified including alkylating agents, 
tubulin polymerization agents, and topoisomerase inhibitors.7  Examples include taxol (7), 
vinblastin (8), camptothecin (9), and anthracycline doxorubincin (10) (Figure 2).18-27  In addition 
to providing novel therapeutics, natural products have lead to an increase in understanding 
cancer pathology and have elucidated previously unknown biological pathways and targets to 
explore for improved therapeutics. 
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Figure 3: Structures of Selected Natural Product Derived ACE Inhibitors  
 
Many natural product drugs or natural product derived drugs target the therapeutic areas 
of antibiotics and anticancer agents due to their evolutionary purposes, however almost all areas 
of medicine are affected by natural products.9  Therapeutic targets for the treatment of high-
blood pressure were identified based on natural products and investigations into the 
pharmacological effects of pit viper (Bothrops jaraca) venom.28,29  The pit viper venom acts by 
lowering the blood pressure of the prey, ultimately leading to death.  Angiotensin converting 
enzyme (ACE) in the renin-angiotensin system was identified as the enzyme targeted by the 
peptide toxin of the pit viper.30  Small molecule therapeutics were developed based SAR studies 
of the toxin resulting in a new class of therapeutics ACE inhibitors for the treatment of 
hypertension including captopril (11) and enalapril (12) (Figure 3).31-33 
 
Figure 4: Natural Products and Natural Product Derived Compounds to Treat Malaria 
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Natural products have had a huge impact on antimalarial agents with the examples of the 
alkaloid quinine (13) and derivative chloroquine (14) (Figure 4), along with sesquiterpene 
lactone artemisinin (15).34  The first mention of using cinchona bark, active component quinine, 
to treat malaria was around the start of the 1500s and with colonization of South America by the 
Europeans.  At approximately the same time, the use of cinchona bark to treat malaria quickly 
spread to Europe.  After use in its crude form for hundreds of years, quinine was first isolated 
from the Cinchona genus in 1820.35  In 1854, the Dutch set up Cinchona plantations in Java to 
handle the therapeutic demand.  The fascinating story of natural product quinine and its impact 
on world history continued in World War II when the Japanese troops cut off the Allied forces 
from their main supply of quinine.35  Partially, as a result of the loss of the Cinchona plantations, 
a large amount research was performed that ultimately identified the synthetic compound 
chloroquine as a therapeutic for malaria.36  Exploiting the same mechanism of action as quinine, 
chloroquine has been the most influential and successful drug for the treatment of malaria in the 
last fifty years.35-37  However, over time chloroquine resistance spread requiring the need for new 
therapeutic agents.36  Natural sources have continued to provide diverse structural scaffold with 
unique mechanisms of action as leads for the treatment of malaria.34,38  Artemisinin, isolated 
from Artemisia annua, was identified as an anti-malarial agent.39,40  Artemisinin lead to the 
development of analogues artemether (16) and arteether (17), which have become widely used 
particularly in areas with high-levels of chloroquine-resistance.33,41-43 
Relatively recent investigations into marine natural products have opened in an entirely 
new environment for natural product isolation and identification.44  A recent example of natural 
products success in CNS therapeutics and marine natural products includes the FDA approval of 
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Ziconotide (Prialt) (18) (Figure 5), which is a first-in-class drug for the management of severe 
chronic pain without generating tolerance that is associated with opioid pain management.44-47  
Ziconotide is a peptide neurotoxin that selectively and potently inhibits N-type voltage gated 
calcium channels (Cav2.2) and is isolated from Conus magus.
48  Cone snails are marine mollusks 
from the genus Conus and have evolved to produce an estimated 100,000 different small peptide 
toxins known as conotoxins.48-51  Cone snails are predatory marine organisms that use conotoxins 
to immobilize and kill their prey.50,51  Several other conotoxins are in clinical trials for pain 
management at Cav2.2 receptors but what makes these toxins even more exceptional is that 
different classes of conotoxins have different mechanisms of action.  These conotoxins show the 
potential of therapeutic pain management through a neurotensin receptor agonist or reversible, 
non-competitive norepinephrine transport inhibitor.49  Additionally, other conotoxin subclasses 
antagonize nicotinic acetylcholine receptors in competitive or noncompetitive manners or target 
NMDA receptors.49,52  Conotoxins are being evaluated for their antinociceptive, antiepileptic, 
cardiotherapeutic, and neuroprotective therapeutic potential.49 
 
Figure 5: Structure of the Cone Snail Toxin Marketed as Prialt 
 
Drawbacks of Natural Products 
Even with the success of natural product based therapeutics, pharmaceutical industry has 
continued to decrease its investments in natural product research, with the majority of Big 
Pharma companies closing their natural products divisions.6,10  Many of these decisions are based 
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on the difficulties associated with discovering a natural product drug candidate.  Natural product 
chemistry requires reliable access and supply of the source plant or microorganism, which in 
itself can be challenging.   Political concerns associated with the intellectual property rights of 
the local governments in which the source was identified and the regulations established by the 
1993 Rio Convention on Biodiversity can make access to the plant difficult.6,10,13,53  In 2010, the 
Nagoya Protocol was established that extended the previous treaty clarifying specifics on how to 
compensate nations, properly access material, and preserve biodiversity.54  The consequences of 
the Nagoya Protocol are still unknown but hope to limit bureaucratic challenges in obtaining new 
biomass.  Additionally, seasonal and environmental changes that effect species composition can 
result in assay inconsistency and the possibility of species extinction also contribute to 
difficulties with achieving the necessary supply.6 
If a reliable supply of the medicinal species is obtained, other factors still limit the 
success of natural product research.  Often natural products exhibit high potency and selectivity 
for a desired target but poor pharmacokinetic properties including solubility, bioavailability, 
exposure, stability, and detrimental metabolic profiles that can limit their potential for success 
and therapeutic utility.55  Semi-synthetic structural modifications of these complex natural 
products have previously resulted in the discovery of compounds with improved 
pharmacological properties.55  However, difficulties arise in working with natural products.  
Frequently natural products are highly complex with numerous oxygen-containing functional 
groups and many chiral centers.6,10  The structural complexity of natural products can lead to 
obstacles and challenges in performing simple chemical transformations to make the compounds 
more therapeutically applicable.55  Their complexity causes significant time requirements due to 
challenges in working with natural products, the necessity of indentify the active component, and 
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extensive structural elucidation.5,6,10  Once the desired component is elucidated, the high risk of 
duplicity and identification of a known compound that is not patentable is a huge risk for 
pharmaceutical companies.5,11 
Additionally, the advent of high-throughput screening further jeopardizes the success of 
natural product identification in pharmaceutical industry.5  The focus of pharmaceutical industry 
has drastically changed and demands large numbers of compounds to fully utilize the capabilities 
of their high-throughput screens, which is not agreeable with natural products.6,9,56  The quantity 
of compounds desired and the speed of identifying a hit successfully is only achievable though 
large library synthesis.5,9 
Natural products are not very amenable to HTS for a number of reasons.  Natural 
products are often found in low concentration that may not be effectively detected by the high-
throughput screen.6  Natural product extracts can have multiple components that result in 
synergistic or antagonist activity and consequently result in the interpretation of greater activity 
or less activity than is actually present.6  There is also the challenge with fluorescent or colored 
compounds, which can lead to a misinterpretation of data.  Poor solubility and stability in the 
assay system can cause difficulty in data analysis or the complete oversight of a potential 
therapeutic.6 
Even with the challenges in natural product research, natural products still remain the 
greatest source of structural diversity and seemingly limitless potential.53  With advances in 
scientific methodology, natural products have a chance for resurgence in pharmaceutical 
industry.11  Technological advances in areas including bioassay-guided fractionation, 
fermentation, HPLC, solid-phase extraction, NMR, and mass spectrometry have all contributed 
to a decrease in time required for dereplication, isolation and structure identification.11,57 
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Additional advancements in synthetic methodology, molecular biology, genomics, 
combinatorial biosynthesis, and assay development all lead to a renewed interest in natural 
product research.  Combination of these scientific areas has the potential to isolate and optimize 
novel natural product scaffolds in an efficient and lucrative manner.  With only a small percent 
of the world’s biodiversity previously tested for biological activity, an immeasurable number of 
natural sources remain available for medicinal use.13,58,59 
 
Opioids 
Despite some of the drawbacks associated with natural product research, natural products 
have continued to have great influence on modern medicine.  One of the most explored uses of 
natural products is found with opium.  Extracts of the opium poppy Papaver somniferum L. 
(Papaveraceae) have been used for centuries to treat pain and induce sleep.60  Historical evidence 
links opium use as far back as 3500 BCE in the Sumerian culture and Greek writings around 200 
BCE describe the importance of opium in their medicinal practices.61  Crude opium extracts were 
used until the active component of the opium poppy was identified in the early 1800s.  The 
alkaloid morphine (19) (Figure 6) was first isolated from the opium poppy in 1806 by Sir 
William Setürner.62 However, due to its structural complexity, the structure was not proposed 
until 1923 by Robinson and the first synthesis did not occur until 1952 by Gates and Tschudi.62  
Setürner’s isolation of morphine resulted in a paradigm shift in standards for pharmaceutical 
industry as morphine was the first pharmacological active pure compound to be isolated from its 
medicinal extract.6  This changed pharmaceutical industry from extracts and elixirs to pure 
chemical agents of exact doses and consistency in chemical composition. 
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Figure 6: Structures of Some of the Most Commonly Used Opioids 
 
For over 2,000 years, opioids have remanded some of the most therapeutically useful 
agents for the treatment of pain.60  Mild to moderate pain is treated first with non-steroidal anti-
inflammatory agents (NSAIDs) and is followed by the addition of narcotic analgesics if the pain 
persists.60  The use of narcotic analgesics is not without severe side effects including 
constipation, respiratory depression, tolerance, and physical dependence.60,63-65  These effects are 
related to their agonist activity at MOP receptors.60  The most clinically relevant side effect of 
chronic opioid use is constipation.66-68  Agonist activity of MOP receptors in the bowel decreases 
peristaltic waves resulting in retention of bowel contents.  Respiratory depression is one of the 
most severe side effects associated with opioid use and results from the interaction of opioids 
with the respiratory center in the brain stem.60,69  Death resulting from overdose is most 
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commonly a result of respiratory depression.63  Long-term use of opioids often results in 
tolerance and physical dependence.60  After continuous exposure, opioids decrease in 
effectiveness and larger doses are required to achieve the same therapeutic response.  Physical 
dependence occurs when the body adapts to the drug and cessation causes withdrawal symptoms.  
Other less serious side effects include nausea, vomiting, pruritis, and drug-drug interactions.60,70 
The negative side-effects associated with morphine and other opioids have caused 
limitations in their therapeutic use.  However, opioid analgesics derived from the natural product 
morphine are still the most prescribed class of analgesics.60  In efforts to identify new derivatives 
with fewer adverse effects, the structure of morphine has been extensively explored.  Some of 
the most commonly used narcotic agents, (largely developed as a result of SAR studies of 
morphine) include morphine (19), codeine (20), hydromorphone (21), oxycodone (22), 
meperidine (23), fentanyl (24), methadone (25), propoxyphene (26), and naltrexone (27) (Figure 
6).  In addition to the identification of new therapeutic agents, these studies have increased 
understanding of opioid receptors. 
 
Opioid Receptor Background 
Opioid receptors are member of the G-protein coupled receptor (GPCR) superfamily.60  
Typically, opioid receptors couple to Gi/o proteins but in in vitro models, opioid receptors 
additionally have been shown to couple with Gs proteins.
71,72  Coupling with Gi/o proteins results 
in a decrease in cAMP production (leading to inhibition of adenylate cyclase) and a decrease of 
intracellular calcium.73,74  The  subunit causes intracellular effects by interacting with 
potassium channels.74 
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Although morphine had been used as a potent analgesic since its isolation by Setürner in 
1806, the concept of opioid receptors was not proposed until 1954 and it was not until the early 
1970’s that opioid receptors in mammalian brains tissue were identified.75-77  Binding 
experiments using radiolabeled naloxone antagonized the pharmacological effects of morphine 
and verified the existence of opioid receptors.60  The work of Martin in 1976 determined that 
opioids with structure variation, such as morphine (19), ketocyclazocine (28), and N-
allylnormetazocine (SKF 10047) (29) (Figure 7), resulted in different pharmacological 
effects.78,79  Due to these pharmacological differences, Martin classified opioid receptors into 
three subtypes:  opioid (MOP) receptors,  opioid (KOP) receptors, and  opioid (DOP) 
receptors.60,78-81 
HO
N
H
O
Ketocyclazocine (28) SKF 10,047 (29)
(N -allylnormetazocine)
HO
N
H O
HO
N
O
OH
Naloxone (32)
Leu-Enkephalin (30)
Met-Enkephalin (31)
-Endorphin (33)
Dynorphin A (34)
Tyr-Gly-Gly-Phe-Leu
Tyr-Gly-Gly-Phe-Met
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-
Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln  
Figure 7: Selected Opioid Ligands and Peptides 
 
Each opioid receptor subtype differs in receptor density, receptor distribution, and their 
endogenous ligands.82  In 1975, leucine-enkephalin (30) and methionine-enkephalin (31) were 
the first peptides to be isolated from brain tissue showing opioid activity determined through 
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antagonism with naloxone (32).  Met-enkephalin and leu-enkephalin are DOP receptor agonists 
and are pentapeptides that only differ in their C-terminal amino acid.83  -Endorphin (33) was 
isolated from pituitary glands in 1976 and determined to be the endogenous ligand for MOP 
receptors.84  The endogenous peptide for KOP receptors is dynorphin A (34) and was isolated by 
Goldstein and coworkers from pituitary glands.85,86  Dynorphin A is a tridecapeptide and has the 
highest degree of selectivity for KOP receptors relative to other dynorphins.85,86 
Pharmacological differences of opioid receptor subtypes were described in the 1970’s but 
it was not until the 1990’s when each subtype was cloned and purified to further confirm the 
existence of the three distinct receptor populations.  Receptor subtypes have been suggested and 
identified by ligand binding and physiological studies but have yet to be identified by gene 
products.87-90  The first opioid receptor cloned was the DOP receptor and occurred in 1992 
concurrently in two labs: Briggitte Kiefer in France and Chris Evans at the University of 
California at Los Angeles.91  Closely following, in 1993, the MOP receptor was cloned in the 
Uhl laboratory at the National Institute of Health and the KOP receptor was cloned in the Akil 
lab at University of Michigan.92,93 
 
Therapeutic Potential of KOP Receptor Modulation 
Morphine and structure-activity relationship studies based on this scaffold have been 
thoroughly investigated over the past 200 years, with specific focus on the MOP receptor 
subtype.60  The therapeutic utility of opioids is still limited due to its negative side effect profile.  
Identification of novel opioid ligands with diverse scaffolds show promise in having different 
pharmacological and side effect profiles.94-96  These scaffolds include neoclerodane diterpenes, 
flavonoids, sesquiterpenes, peptides, and other alkaloids.  With the past focus on MOP receptor 
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modulation and extensive research into opioid receptor pharmacology, currently there are not 
any therapeutics on the market that selectively target KOP receptors.   KOP receptor modulation 
shows immense therapeutic potential and KOP receptors have been implicated in the treatment 
of drug abuse, peripheral pain management, and depression.60,75,97-100  Several areas of research 
that could benefit from KOP receptor modulation are highlighted below. 
 
Figure 8: Compounds 35 – 42  
 
KOP Receptor Agonists in Drug Abuse 
KOP receptor modulation of the dopamine system has shown the potential utility of KOP 
receptor therapeutics for the treatment of cocaine abuse.60  Cocaine (35) (Figure 8) blocks the 
reuptake of norepinephrine, serotonin and dopamine, but the behavioral effects after acute 
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administration are generally attributed to the increase in extracellular dopamine levels in the 
nucleus accumbens.60,101  Several neurochemical pathways, including KOP receptors, modulate 
the central dopamine system.  A substantial amount of literature illustrates that KOP receptor 
agonists decrease dopamine levels and therefore act as functional antagonists of cocaine.60,101,102 
KOP agonists produce effects that are opposite of those produced by dopamine 
agonists.101  Additionally, KOP agonists have been shown to decrease self-administration of 
cocaine, decrease cocaine-induced reinstatement, and to inhibit cocaine place preference and 
locomotor sensitization.96,101,103-107  Glick et al. were the first to determine that self-
administration of morphine and cocaine were decreased by acute administration of KOP receptor 
agonists U50,488 (36) and spiradoline (37).104  Lower doses were able to significantly decrease 
morphine and cocaine self-administration without significantly altering bar-pressing rates to 
access water.  In some rats, decrease in self-administration could be seen for 5 – 6 days.  
Pretreatment of norBNI (38) antagonized the effects of U50,488 linking KOP pathway activation 
to modulation of self-administration.  Schenk and coworkers showed that U69,593 (39) 
attenuates cocaine self-administration and the reinstatement of drug-seeking behavior in response 
to an experimenter-administered dose of cocaine.101  U69,593 had a greater effect to attenuate 
self-administration when cocaine doses were self-administered in descending order opposed to 
ascending order.  When cocaine was given in descending order, U69,593 significantly reduced 
responding at lower doses of cocaine (0.03 – 0.125 mg/kg per infusion) but responding was 
maintained for higher cocaine doses (0.25 – 1.00 mg/kg per infusion).  After a period of cocaine 
self-administration and extinction, U69,593 reduced the ability of cocaine to reinstate the 
extinguished lever-pressing behavior at high doses of cocaine (20.0 mg/kg).  Other studies have 
expanded these finding to monkeys.105,106  KOP agonists only seem to consistently decrease 
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cocaine self-administration when rats are trained to self-administer with a cue (conditioned 
reinforcement) opposed to unconditioned drug reinforcement.108,109 
KOP agonists have been reported to block cocaine-induced conditioned place 
preference.103,110,111  In 1995, Crawford and coworkers investigated the effects of U50,488 on 
cocaine-induced locomotor activity and cocaine-induced place preference.103  U50,488 was given 
subcutaneously at 5 mg/kg and cocaine was administered i.p. at 10 mg/kg based on pilot studies.  
Rats pretreated with saline opposed to U50,488 had significantly greater photobeam interruptions 
following cocaine administration that was measured for twenty minutes.  The effects of acute 
versus chronic administration of U50,488 were also evaluated and it was found that chronic and 
acute administration of U50,488 similarly affected cocaine-induced locomotor activity.  In the 
cocaine-induced place preference paradigm, pretreatment of U50,488 was found to attenuate the 
preference for the cocaine-paired chamber.  When U50,488 was given on its own, rats did not 
show significant aversion from the non-preferred chamber, which is very promising due to the 
known aversive potential of other KOP agonists.112,113  Investigations into the cocaine-induced 
conditioned place preference paradigm continue to show that KOP agonists appear to minimize 
the rewarding effects of cocaine.108,114 
Also of interest is that it appears KOP receptors modulate MOP opioid receptors by 
opposing their actions.108,115  Dynorphin or U50,488 have been shown to dose-dependently 
antagonize morphine analgesia in rodent models of the tail-flick and hot-plate tests.116-121  
Studies also suggest that KOP receptors play a role in morphine tolerance.115  Tolerance is a 
frequent side-effect of long term opioid use that results in a decrease in analgesic effect and an 
increase in abuse potential.122-124  Tolerance is a result of many cellular processes including 
superactivation of the cAMP pathway, receptor desensitization, and receptor down 
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regulation.115,124-127  Coadministration of U50,488 with morphine has been shown to prevent 
morphine tolerance.118,120,128,129  KOP receptors have also been implicated in the attenuation of 
morphine reinforcing effects.104,130-132  Further understanding of the interactions of MOP and 
KOP receptors could result in new therapeutics for the treatment of drug abuse. 
 
KOP Receptor Antagonists in Drug Abuse 
It has also been shown that KOP receptor antagonists have potential utility in the 
treatment of drug abuse.  KOP receptor antagonism through pharmacological antagonism or gene 
disruption of KOP receptors have been implicated to modulate a component of stress-induced 
drug craving, which is one model of drug relapse.133  Depression and stress have been linked as a 
potential motivating factor in cocaine relapse.134  Therapeutic agents that attenuate depression 
and the effects of stress have potential to treat relapse in cocaine abuse.  Beardsley and 
coworkers investigated the ability of KOP receptor antagonist JDTic (40) to block reinstatement 
of cocaine-seeking behavior by footshock-induced stress.135  JDTic doses of 10 and 30 mg/kg 
significantly reduced the number of lever presses relative to vehicle while the dose of 3 mg/kg 
was nearly significant (p = 0.0575).  JDTic did not block cocaine-primed reinstatement of 
responding at any tested dose demonstrating that JDTic does not suppress all behavior.  
Additionally, 10 and 30 mg/kg doses of JDTic blocked the diuretic effects of U50, 488H further 
implicating KOP receptor antagonism as the mechanism of action. 
 
KOP Receptor Ligands in Pain Management 
Opioid drugs associated with pain management work primarily at MOP receptors and 
remain the prototypical standard when treating severe pain.99  Unfortunately, a number of 
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negative side effects are associated with agonism of MOP receptors including previously 
mentioned constipation, respiratory depression, tolerance, and physical dependence diminish 
their therapeutic utility.99  Development of a KOP receptor ligand with antinociceptive effects 
would results in the identification of an analgesic without the negative side effects associated 
with MOP receptor agonists.136  However, KOP receptor agonists have drawbacks of their own 
including sedation, dsyphoria, and in some cases, hallucinogenic effects.137-142  These negative 
side effects are associated with KOP receptor activation in the CNS.  KOP receptors are located 
in the CNS and in the periphery.  Therefore, the development of a peripherally restricted KOP 
agonist would be lacking the CNS neuropsychiatric effects.98,99 
A number of pain models have been established which investigate different types of pain 
stimuli including mechanical, thermal, electrical, or chemical.99  KOP agonists have shown 
antinociceptive effects in a number of these pain models.99  KOP agonists have been found to 
have antinociceptive effects in cutaneous and mechanical visceral nociceptive models and to 
inhibit inflammation induced hyperalgesia.143-145  Additionally, in a colorectal distension rodent 
model, KOP agonists increased the threshold to colorectal distention and attenuated the 
magnitude of the response.143  Several peripherally restrictive KOP receptor agonists have been 
developed and undergone clinical trials as peripherally restricted KOP agonists for the treatment 
of dyspepsia, irritable bowel syndrome, and pancreatitis.  Due to lack of efficacy without causing 
CNS effects, these compounds failed clinical trials.98,99  However, tetrapeptides FE 200665 and 
FE 200666 are under clinical development and have been reported to have a greater therapeutic 
window than the previous compounds.146  KOP receptor modulation for the treatment of visceral 
pain is promising due to the successes of a number of behavioral assays.  Further development of 
KOP ligands with better pharmacological profiles will hopefully identify improved therapeutics 
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with reduced propensity for side effects such as constipation, respiratory depression, tolerance, 
and physical dependence. 
 
KOP Receptor Ligands in Depression 
KOP function is involved in stress-related conditions and KOP receptor antagonists have 
been reported to have antidepressant activity.99  The cAMP response element-binding protein 
(CREB) is a transcription factor that regulates gene expression, including the peptide precursor 
prodynorphin.147-150  Further investigation into this observation has shown that dynorphin and 
KOP receptor agonist result in aversive and depressive-like effects in humans and rodents.150-152  
Studies determined that increased levels of CREB in the nucleus accumbens of rodent models 
resulted in signs of depression and that stress also activated CREB in the nucleus 
accumbens.150,153,154  Inversely, decrease in CREB function lead to antidepressant-like effects 
comparable to those of known antidepressants.150,155  The depressive-like behavior resulting from 
elevated CREB levels were reversed by KOP antagonist norBNI, further implicating KOP 
receptors in depression.154 
The antidepressant-like effects of norBNI, GNTI (41), ANTI (42), and other KOP 
antagonists have been explored by a number of research groups which have confirmed each 
other’s findings into the antidepressant-like effects of KOP antagonists.155-158  Beardsley and 
coworkers expanded these findings by investigating the antidepressant-like effects of KOP 
antagonists norBNI and JDTic in Sprague-Dawley rats.135  Immobility, swimming, and climbing 
were measured in 5 second segments during the 5 minute forced swim test.  Desipramine, a 
tricyclic antidepressant, decreased immobility and increased climbing for all doses tested and 
increased swimming at dose 5.6 mg/kg compared to vehicle.  NorBNI decreased immobility and 
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increased swimming at doses of 1 and 10 mg/kg but did not affect climbing relative to vehicle.  
JDTic decreased immobility and increased swimming at doses 0.3, 1, and 3 mg/kg without 
affecting climbing compared to vehicle.  Retest of the forced swim test was performed one week 
after initial test and drug injection.  Desipramine and norBNI did not differ from vehicle in 
measurement of immobility, swimming or climbing.  High doses of JDTic (3 and 10 mg/kg) still 
showed positive effects by reducing immobility time.  KOP receptor antagonists norBNI and 
JDTic show similar profiles to SSRI antidepressants by decreasing immobility and increasing 
swimming time in the forced swim test. 
Correlation of KOP receptors and the modulation of the dopamine system in the brain 
cause concern with the potential use of KOP antagonists as antidepressants as the majority of 
drugs of abuse are associated with modulation of dopamine function.159,160  Therefore, 
investigations into the intracranial self-stimulation (ICSS) behavior and KOP antagonist ANTI 
were performed.161  It was found that ANTI doses eight-times higher than required for 
antidepressant-like effects in the forced swim test did not alter ICSS behavior.  Additionally, 
KOP antagonist effects on dopamine by direct administration of KOP antagonists into the 
nucleus accumbens are significantly less relative to cocaine and amphetamine.162  Currently, no 
evidence has been found reporting similarities in behavioral effects of KOP antagonists with 
those associated with drugs of abuse.150  Drawbacks to known KOP antagonists include their 
long duration of action and the limited number of studies published about the therapeutic 
potential of KOP antagonism for depression.150  Recently several chemical series have been 
identified that have lacked long-lasting inhibition in a diuresis assay, unlike previously known 
KOP antagonist.163  Identification and development of novel KOP receptor antagonists with 
 
23 
 
more drug-like pharmacodynamic and pharmacokinetic properties has the potential to further 
explore the therapeutic area of depression by utilizing a previously unexplored therapeutic target. 
 
KOP Receptor Ligands and Other Therapeutic Potential 
Additionally, KOP receptors have been linked to immunomodulation and neuroprotective 
effects.60  The therapeutic utility of opioid receptors and their potential immunomodulatory role 
is a relatively recent field.  KOP receptors have been recognized on cells from the immune 
system and human microglia cells have been identified to contain KOP receptor binding sites on 
the cell surface.164,165  KOP receptors also have been linked to activated T-cells due to the 
elucidation of KOP receptor expression on CD4+ and CD8+ cells.164,166  Future investigation 
into this area has the potential for novel therapeutic development. 
KOP receptors have been implicated to have a role in neuroprotection.167  Depending on 
the seizure model employed, KOP agonists have exhibited anticonvulsant effects in some 
models.167  Specifically, KOP agonist ethylketocyclazocine displayed naloxone-sensitive 
anticonvulsant activity in an electrically induced convulsion model of rats.167,168  The modulation 
of the KOP system after traumatic or ischemic injury has been reported in rat and rabbit 
models.167,169,170  In different animal models, KOP modulation has shown the ability decrease 
hippocampus neuronal damage resulting from ischemia, improve concussion-induced injury and 
forebrain ischemia, and improve motor recovery after spinal injury.167  However, to date, the 
neuroprotective effect of KOP receptors remains contradictory and controversial. 
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Drawbacks of Current KOP Ligands 
The lack of known ligands with KOP receptor activity, desirable biological effects, and 
suitable ADMET properties has limited the therapeutic utility of KOP receptors.  Known KOP 
agonists commonly cause sedation, dysphoria, and psychomimetic effects.96  Additionally, KOP 
antagonists such as norBNI, GNTI, and JDTic all share the pharmacological property of long 
duration of activity in vivo.171-177  Several hypotheses for the long duration of activity include 
being trapped in lipid membranes, biotransformation to long-lasting metabolites, and uncoupling 
of the KOP receptor signaling complexes.  In 2007, Bruchas and coworkers showed that KOP 
antagonists disrupt KOP receptor signaling through activation of c-Jun N-terminal Kinase (JNK) 
in a KOP receptor dependent mechanism.178  Investigations into new structural classes could lead 
to the identification of ligands that have more desirable properties for a marketed therapeutic.163  
One structural class to be investigated includes neoclerodane diterpenes, a subclass of the more 
broadly defined terpene class of natural products. 
 
Terpenes 
Neoclerodane diterpenes are members of the terpene class of natural products.  Terpenes 
provide interesting chemical targets for organic chemists and pharmacologists.  Their structural 
complexity and diversity, along with their unique pharmacological profiles results in attractive 
structural scaffolds for synthetic and biological investigation.  Terpenes are secondary 
metabolites and are consequently found in negligible concentrations in living organisms.179  
Many current therapeutic agents are terpenes including taxol as an anticancer drug and 
artemisinin as an antimalarial agent.8  Terpenes are derived from a common biosynthetic 
pathway originating with mevalonate and biosynthesized from units of isoprene, which have the 
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chemical formula C5H8.
179,180  The classification of terpenes is based on the varying number of 
isoprene units present in the carbon skeleton.179  Terpene classification includes hemiterpenes, 
monoterpenes, sesquiterpenes, diterpenes, sesterterpenes, and triterpenes, each consisting of one 
through six isoprene units.181  Additional terpene classifications include tetraterpenes, containing 
eight isoprene units, and polyterpenes composed of isoprene chains. The classification system is 
further divided into subclasses.179 
 
Figure 9: Structures of Selected Diterpene Natural Products 
 
Specifically focusing on diterpenes, over 50 different subclasses have been assigned 
based on biosynthetic ring construction inclucing labdanes, kauranes, gibberellins, taxanes, and 
beyeranes.  Many of these subclasses are comprised of secondary metabolites with biological 
activity including cardiovascular, anti-cancer, anti-inflammatory, analgesic, antimicrobial, and 
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antifeedant effects.181-183  Kaurane and pimarane-type diterpenes including kaurenoic acid (43) 
(Figure 9) and pimaradienoic acid (44) have been identified to have cardiovascular effects 
attributed to inhibition of extracellular Ca+2 influx.184  Kaurenoic acid has also been shown to 
have antimicrobial activity, anti-parasitic activity, and anti-inflammatory activity.184-186  A 
number of terpenoids from the labdane subclass have displayed anti-cancer activity including 
forskolin (45), isolated from Coleus forskholii.  Forskolin has been reported to decrease 
proliferation and induce apoptosis while also being associated with anti-hypertensive activity.180  
Taxol, isolated from Taxus brevifollia, is a member of the taxane subclass and is a currently 
available anticancer agent.  Tripterygium wilfordii Hook F. has been used for centuries in 
traditional Chinese medicine to treat rheumatoid arthritis, immune complex nephritis, and 
systemic lupus erythematosus.187,188  Diterpene triptolide (46) was identified from this extract 
and shown to have anti-inflammatory and immunosuppressive properties.187  Studies have shown 
that triptolide blocks gene transcription of several transcription factors including NF-B and AP-
1.188-190  A number of diterpenes are known for their antifeedant activity including miriamin (47) 
isolated from the eggs of Arion sp., a species of slug.191  The soft eggs are laid in clusters which 
were identified to contain diterpene miriamin that acts as a chemical deterrent.191   
Another well known subclass of diterpenes is the clerodane class.  Clerodanes are 
ubiquitous throughout nature and are found in a variety of plants, fungi, and microorganisms.192  
A natural product is regarded to be a clerodane if it contains four isoprene units and four 
contiguous stereocenters on a cis or trans decalin ring system (48).192  Approximately 25% of 
clerodanes contain the cis ring fusion and an example of this is the natural product columbin 
(49).192  Diterpenoid furanolactone 49 has been isolated from several plants including 
Sphenocentrum jollyanum Pierre (Menispermaceae) and Jateorhiza columba Miers 
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(Menispermacea).193,194  It is sold in a crude drug preparation called Calumbae Radix or 
Tinosporae Radix.193  Columbin itself has been shown to have dose dependent anti-inflammatory 
activity and chemopreventative activity against colorectal cancer.193-195  The other 75% of 
clerodanes contain the trans ring fusion resembling clerodin.  Clerodin (50) was orginially 
originally isolated from Clerodendrum infortunatum L. (Lamiaceae) and is an insect antifeedant 
with potential as a natural pesticide.196-198  Along with the relative configuration of the trans or 
cis junctions of the fused rings, clerodanes are further classified by their relative configuration at 
C-8 and C-9.192  This additional clarification results in four types of clerodane skeletons as 
defined with respect to configuration of ring fusion and substitution pattern at C-8 and C-9: 
trans-cis (TC), trans-trans (TT), cis-cis (CC) and cis-trans (CT).192  Clerodanes are further 
classified by their absolute stereochemistry.  Compounds that have the same absolute 
stereochemistry as clerodin are termed neoclerodanes and compounds that are enantiomers of 
clerodin are referred to as ent-neoclerodanes.199,200 
Another clerodane with unique biological activity is salvinorin A (51).  Salvinorin A is 
the active component of Salvia divinorum known for its hallucinogenic effects.137,201  Salvinorin 
A (51) is a tricyclic trans-cis neoclerodane diterpene containing seven chiral centers. 
Additionally, salvinorin A is oxidized relative to the clerodane scaffold which manifests as four 
carbonyls at C-1, C-17, C-18, and C-21. Two of the carbonyls are esters off of the C-2 and C-4 
positions of the decalin core, and the C-17 carbonyl is part of a -lactone ring system. 
Additionally, an oxygen bridge between C-15 and C-16 results in the formation of a furan ring 
extending off of C-12. Along with the functionality present on salvinorin A, C-8 has been shown 
to undergo epimerization readily in acidic or basic conditions. Despite the molecular complexity, 
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several total syntheses of salvinorin A have been accomplished and structural modifications have 
been completed.202-204 
The biological activity and structural complexity of natural products and neoclerodane 
diterpenes have driven their study in total synthesis efforts and pharmacological investigation 
into their biological and structure-activity relationship (SAR) studies. However, difficulties in 
conducting these studies result from the structural complexity, sensitivity to conditions of many 
typical organic reactions, potential problems in acquiring the natural product or plant material for 
extraction, and the unknown sites of action of neoclerodane diterpenes.205 The lack of precedent 
for chemical methodology required to transform neoclerodanes contributes to the limited number 
of SAR studies to date. Furthermore, developing reactions that are chemoselective for molecules 
that are often polyfunctionalized and contain multiple chiral centers is an extremely difficult 
undertaking. Determination of the molecular basis of activity through semi-synthetic means 
requires access to the natural product in substantial quantities, which can be difficult or 
impossible to obtain.  Additionally, the site of action of neoclerodane diterpenes is often 
unknown, increasing the difficulty in SAR development. Despite these challenges, several 
neoclerodane diterpenes, including salvinorin A, isolated from Salvia divinorum, have been 
investigated through total synthesis, semi-synthetic, and pharmacological studies. 
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CHAPTER II.  SALVINORIN A 
Salvinorin A 
Salvia divinorum L. Epling & Jativa (Lamiaceae) is a widely available psychoactive plant 
that has been used for hundreds of years in the traditional divination rituals of the Mazatec 
Indians of Oaxaca, Mexico due to its hallucinogenic effects.206  S. divinorum is a member of the 
sage family and is indigenous to Oaxaca, Mexico.206,207  In addition to its use in divination 
ceremonies, the Mazatec Indians also use S.divinorum for headaches, rheumatism, and panzón de 
barrego, a semimagical disease.207  S. divinorum is also known in the public eye for its notorious 
use as a recreational drug.208,209  Due to its hallucinogenic effects, several countries and states 
have schedule S. divinorum as a schedule I controlled substance.  The main active component of 
S. divinorum is neoclerodane diterpene salvinorin A (51).137,201,206,210  Salvinorin A rivals the 
potency of other classical hallucinogens such as lysergic acid diethylamide (LSD) (52) (Figure 
10) and 4-bromo-2,5-dimethoxyamphetamine (DOB) (53).137,201,206,210,211  However, unlike LSD 
and DOB, salvinorin A does not have activity at serotonin 5HT2A receptors.
210,212  In 2002, 
salvinorin A was identified as a potent and selective KOP receptor agonist.137  Salvinorin A is 
the first non-nitrogenous natural product having high affinity and efficacy at KOP receptors.137  
Its unique structure has little structural similarity to other known opioid receptor ligands in that it 
does not contain a basic nitrogen.  Morphine (19), cyclazocine (54), fentanyl (24), SNC 80 (55), 
U50,488 (36), 3FLB (56), and dynorphin A (34) are all known opioid ligands and all have a 
basic amino group, which was a stipulation for affinity at opioid receptors in traditional opioid 
pharmacology.213-217  It was accepted that the positively charged nitrogen of the ligand interacts 
with a highly conserved aspartate residue in TM III of the opioid receptor.215,218,219  Salvinorin A 
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lacks a basic amino group, which consequently led to reevaluation of the necessity of a basic 
nitrogen for opioid receptor affinity and efficacy.220 
 
Figure 10: Selected Classical Hallucinogens and KOP Receptor Ligands 
 
Salvinorin A KOP receptor Pharmacology 
In vitro Pharmacology 
In 2002, Roth and coworkers identified salvinorin A as the first non-nitrogenous, 
naturally occurring opioid receptor agonist.137  More specifically, salvinorin A was determined to 
be potent and selective for KOP receptors.  The molecular pharmacological profile of salvinorin 
A was examined through a large scale screening of at 51 molecular targets including human 
cloned GPCRs, ligand-gated ion channels, and transporters with the support of the NIMH 
Psychoactive Drug Screening Program.  Salvinorin A was found to only inhibit [3H]-
bremazocine-labeled KOP receptors and did not bind to cloned MOP or DOP receptors, 
identifying an opioid subtype specific ligand.  The functional properties of salvinorin A were 
then evaluated in a two model system.  Salvinorin A was evaluated for its ability to inhibit 
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forskolin-stimulated cAMP production in KOP receptor stably expressed HEK-293 cells and in 
situ in guinea pig caudate membranes.  In both systems, salvinorin A was identified as a potent 
KOP receptor agonist.  A more detailed report of the functional properties of salvinorin A was 
reported in 2004 by Chavkin et al.221  The ability of salvinorin A to inhibit forskolin-stimulated 
cAMP activity, intracellular calcium mobilization and potassium conductance were all evaluated.  
In all assays tested, salvinorin A was shown to be a potent and full agonist compared to known 
KOP receptor agonist U69,593.  KOP receptor subtypes have been suggested through ligand 
binding and physiological studies but have not been identified through gene coding.222-224  
Asnonoff and coworkers evaluated salvinorin A’s ability to selectively bind to KOP1 or KOP2 
receptors utilizing ligand-binding evidence.  Salvinorin A showed selective affinity at KOP1 
receptors and not at KOP2 receptors (Ki = 18.7 nM vs. Ki > 10,000).
87 
Wang and coworkers evaluated the pharmacological activity of salvinorin A in CHO cells 
and determined that salvinorin A had affinity and potency similar to U50,488 (Salvinorin A: Ki = 
7.9 nM, EC50 = 4.6 nM vs. U50,488: Ki = 11.0, EC50 = 2.2 nM).
225  Additionally, they evaluated 
salvinorin A’s ability to promote receptor internalization and down-regulation of KOP receptors.  
Previous studies have shown that activation of KOP receptors by U50,488, U69,593, and other 
KOP agonists down-regulate and internalize KOP receptors to variable extents.226-228  The 
resulting down-regulation and internalization of receptors is largely believed to play a role in 
tolerance.123,124,229  Using fluorescence flow cytometry, incubation of salvinorin A with cells 
expressing FLAG-hKOP receptors resulted in a dose-dependent reduction of cell surface 
fluorescence demonstrating internalization of the FLAG-hKOP receptors.   Salvinorin A is less 
potent than U50,488 for inducing internalization of KOP receptors (30 – 40% vs. 15%).87 
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In vivo Pharmacology 
Salvinorin A and Psychoactive Effects 
Traditionally, two methods of ingestion are reported: chewing whole leaves or crushing 
the leaves to extract juices which are then swallowed.210  Initial pharmacological investigations 
by Seibert determined that the active component of S. divinorum is deactivated in the 
gastrointestinal system and in tradition methods of ingestion the psychoactive effects have 
resulted from oral absorption.  Salvinorin A absorption through oral mucosa produced effects 
within 5 to 10 minutes that plateau at approximately an hour and decreased in the following 
hour.  Vaporization and inhalation of leaves caused effects within 30 seconds with peak effects 
occurring from 5 to 10 minutes and subsiding around 30 minutes.  Doses of 200 – 500 µg of pure 
salvinorin A produced effects that are behaviorally comparable to those of traditional ingestion 
methods making salvinorin A one of the potent naturally occurring hallucinogens to date. 
In 2011, Johnson and coworkers investigated the effects of salvinorin A in human 
subjects.230  Using a double-bind, placebo controlled study, 16 doses of salvinorin A were 
evaluated in ascending order with four placebo doses inserted into the sequence.  Salvinorin A 
was administered via vaporization and inhalation at doses ranging from 0.375 – 21 µg/kg.  
Subjective effects along with physiological effects were measure for one hour.  Time and dose-
dependent effects were observed with the maximal effects seen at 2 minutes, the first time point 
evaluated.  Using the Hallucinogen Rating Scale and the Mysticism Scale, salvinorin A 
administration resulted in dose-related increases on most subscales starting at the dose of 4.5 
µg/kg.  Over the range of doses tested, no significant effects on heart rate and blood pressure 
were detected along without any observation of resting or kinetic tremors.  These finding suggest 
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that salvinorin A has subjective hallucinogenic effects similar to other classical hallucinogens 
and is physiologically safe at the doses tested. 
Mendelson and coworkers investigated the sublingual administration of ascending doses 
of salvinorin A ranging from 0 – 4 mg in a placebo-controlled study.231  Subjective effects were 
measured by two Visual Analog Scales and the Subjective Drug Effects Questionnaire (SDEQ), 
Altered States of Consciousness Questionnaire (APZ-OAV), and Positive and Negative Affect 
Schedule (PANAS) two and four hours after drug administration.  Physiological effects 
including heart rate, blood pressure, O2 saturation, and body temperature were also measured.  
Blood and urine samples were collected for the highest dose (4 mg) and in two subjects at 1 mg 
dose that reported slight VAS intoxication effects.  For all doses tested, no significant difference 
in subjective effects and physiological effects were observed and blood and urine analysis found 
that most concentrations were below the limit of quantitation.   
Hooker and coworkers investigated the pharmacokinetic properties of salvinorin A in 
living brain concentrations by using positron emission spectroscopy (PET) in female baboons 
(Papio anubis).232  Through synthesis of a 11C-labeled salvinorin A derivative, use of PET, and 
intravenous administration, they found that salvinorin A rapidly entered the brain and reached 
maximum concentrations at approximately 40 seconds and had a half-life of 8 minutes.  The 
highest concentrations of salvinorin A were found in the cerebellum and the cortex and it is 
hypothesized that the high concentrations in these brain regions account for the hallucinogenic 
effects.  Kinetic analysis suggests two modes of metabolism and excretion occur through the 
biliary and renal systems.  These findings are consistent with the observed effects when smoking 
S. divinorum.  Based on the maximum brain concentration, they deduce that less than 10 µg of 
salvinorin A in the human brain is required to cause hallucinations.   
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Salvinorin A and Metabolism 
Schmidt et al. identified salvinorin B as a major metabolite of salvinorin A in ex vivo 
non-human primate studies.233  Salvinorin B concentrations in vivo were below the limit of 
detection suggesting salvinorin B is rapid cleared or accumulates in tissue or organs.233,234  A 
study in human volunteers by Pichini and coworkers found that based on a theoretically 
administered dose, only 0.8% of salvinorin A is excreted unchanged in urine when 0.58 mg of S. 
divinorum leaves are smoked.235 
Tsujikawa et al. further evaluated the metabolism of salvinorin A in rat plasma, 
specifically focusing on esterase metabolism.236  Four esterases are found in rat plasma including 
butyrylcholinesterase (BChE), acetylcholinesterase (AChE), arylesterase (ArE), and 
carboxylesterase (CES), and each could be responsible for salvinorin A metabolism.  To 
determine the role of each esterase, salvinorin A was incubated in rat plasma, with and without 
the addition of NaF, a known esterase inhibitor, and known selective esterase inhibitors.  
Analyses were complete using LC-MS/MS and several metabolites formed were thought to result 
from C-2 deacetylation.  To substantiate these findings, salvinorin A was incubated in the 
presence of NaF, which inhibited the formation of these metabolic products.  Additionally, 
BNPP, a CES inhibitor, and PMSF, a serine esterase inhibitor (CES is a serine esterase), were 
found to inhibit salvinorin A metabolism in a concentration-dependent manner.  Inhibitors of 
BChE, AChE, and ArE caused minimal degradation products of salvinorin A implicating CES as 
the esterase responsible for salvinorin A metabolism in rat plasma.  Tsujikwaka and coworkers 
also identified lactone hydrolysis by a calcium-dependent lactonase. 
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Teskin and coworkers investigated salvinorin A’s in vitro metabolism with ten CYP450 
isoforms and UGT2B7, the major enzyme involved in drug metabolism via glucuronidation.237-
240  Salvinorin A was separately incubated with each CYP450 for one hour at 50 µM 
concentration.237  A significant decrease in concentration was seen when salvinorin A was 
incubated with CYP2D6, CYP1A1, CYP2E1, and CYP2C18.  Further analysis of salvinorin A 
metabolism was performed by incubating salvinorin A with 5 µM concentrations of the CYP450 
isoforms active at higher concentrations.  The CYP450 isoforms also showed a statistically 
significant reduction of salvinorin A at 5 µM.  Salvinorin A was also incubated with UGT2B7 at 
concentrations of 5, 10, and 50 µM.  A statistically significant difference in metabolism was seen 
between the three doses relative to the control (51%, 18.1%, and 7%, respectively).  Comparing 
the percentages of metabolism at the different concentrations for CYP450 and UGT2B7 
metabolism, higher rates of metabolism were seen at lower doses suggesting saturable 
metabolism and Michaelis-Menten kinetics.  These studies suggest that salvinorin A may be a 
substrate for CYP2D6, CYP1A1, CYP2E1, CYP2C18, and UGT2B7. 
 
Salvinorin A and Toxicity 
The first study to investigate the potential toxicity associated with salvinorin A as a pure 
isolated compound was performed by Mowry and coworkers.241  Animal studies that explored 
the acute effects of salvinorin A in rats showed no statistically significant effect of rat heart rate 
and cardiac conduction.   However, pulse pressure did non-significantly increase after exposure.  
Additionally, salvinorin A did not cause changes in body temperature or galvanic skin response.  
The chronic effects of salvinorin A were measured in mice and concluded that after fourteen 
days of i.p. salvinorin A injections, no significant histologic changes were seen in the spleen, 
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blood, brain, liver, kidneys, and bone marrow at the doses tested.  Mowry concluded that 
salvinorin A had little physiologic effect and has relatively low toxicity. 
 
Salvinorin A and CNS Effects 
In 2007, Butelman and coworkers investigated the effects of salvinorin A in a prolactin 
neuroendocrine biomarker assay.242  Intravenous administration of salvinorin A and U69,593 
(0.0032, 0.01, 0.032, 0.056 mg/kg) resulted in dose-dependent and time-dependent increases in 
prolactin levels.  In male subjects, increases in prolactin levels were seen 5 minutes after 
salvinorin A injection.  At 90 minutes no dose was significantly different than vehicle prolactin 
levels.  U69,593 had a longer duration of action with increased prolactin levels still noticeable at 
the end of the 120 minute testing period.  Gonadally intact female monkeys have quantitatively 
greater salvinorin A effects.  Therefore, prolactin levels in gonadally intact female monkeys were 
also evaluated.  A dose of 0.0032 mg/kg causes only slight effect in males where as in females 
this dose caused larger prolactin elevations.  Subcutaneous administration of salvinorin A was 
investigated at 0.032 mg/kg.  Subcutaneous injection produced much lower prolactin levels and a 
slower onset with peak effects not occurring until the 60 minute time point.  Subcutaneous 
injection of salvinorin A (0.032 mg/kg) in females produced effects by 15 minutes and lasted 
until the 120 minute time point.  To test the role of KOP receptors in the effects of salvinorin A, 
nalmefene was utilized.  A low dose (0.01 mg/kg) of nalmefene antagonizes MOP receptors 
where a higher dose (0.1 mg/kg) antagonizes both MOP and KOP receptors.  Pretreatment of 
0.01 mg/kg nalmefene did not cause statistically significant changes in prolactin levels but a 
higher dose of 0.1 mg/kg antagonized the neuroendocrine effects of salvinorin A.  Pretreatment 
with ketanserin, a 5-HT2 antagonist showed no antagonism of salvinorin A.  Additionally, 
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Butelman et al. showed 98.4% homology between the rhesus monkey OPRK1 gene and human 
OPRK1 gene, which codes the KOP receptor. 
Butelman and coworkers were the first to investigate the fast onset and entry into the 
central nervous system and the unconditioned behavioral effects of salvinorin A in primates.243  
Behavioral scales were utilized that are known to measure the effects of centrally penetrating 
KOP receptor agonists.  Sedation, postural relaxation, facial relaxation, and ptosis were all 
measured.  Intravenous doses of 0.032 and 0.1 mg/kg salvinorin A in chaired subjects resulted in 
dose-dependent increases in sedation scores with statistical significance found at the 5, 15, and 
30 minute time points.  Using identical salvinorin A doses with subject in their home cage, 
salvinorin A caused dose-dependent effects on sedation and postural effects at the 5 and 15 
minute time points or at the 5, 15, and 30 minute time points, respectively.  Dose-dependent and 
time-dependent facial relaxation and ptosis were also seen following intravenous administration 
of salvinorin A.  The behavioral effects of salvinorin A were compared to known KOP agonist 
U69,593.  U69,593 also resulted in dose-dependent behavioral effects with a less defined time 
course and longer lasting effects.  Pretreatment of opioid antagonist nalmefene was given prior to 
salvinorin A injection and almost fully prevented the behavioral effects of salvinorin A.  
Additionally, nalmefene was given 11 minutes after salvinorin A injection to test the ability to 
reverse the behavioral effects of salvinorin A.  Nalmefene did cause rapid reversal of ongoing 
salvinorin A-induced facial relaxation and ptosis.  Pretreatment of CB1 antagonist rimonabant 
and serotonergic antagonist ketanserin were both ineffective at preventing salvinorin A-induced 
behavioral effects, further implicating KOP receptors in the modulation of salvinorin A’s 
behavioral effects in nonhuman primates. 
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Further investigations by Butelman and coworkers compared the behavioral effects of 
salvinorin A resulting from intravenous and subcutaneous administration.244  Unconditioned 
behavioral effects of facial relaxation and ptosis were measured and found that intravenous 
administration resulted in a more robust response and a faster onset than subcutaneous 
administration.  In fact, subcutaneous administration did not cause significant differences 
compared to vehicle in the measurement of facial relaxation.  Intravenous administration of 
salvinorin A and U69,593 resulted in dose-dependent ptosis in all subjects and the unconditioned 
behavioral effect was reversed by opioid antagonists quadazocine and naltrexone.  Peripherally 
restricted KOP agonist ICI204448 did not cause facial relaxation but did result in ptosis with 
much less potency that salvinorin A or U69,593.  This suggests that at high doses, ICI204448 
can result in centrally mediated effects.  Additionally, the serotonergic agonist psilocybin did not 
result in facial relaxation or ptosis at any dose tested. 
 
Salvinorin A and Drug Discrimination 
The first study to investigate salvinorin A’s discriminative effects in non-human primates 
was performed by Butelman and coworkers.245  Rhesus monkeys were previously trained to 
discriminate KOP agonist U69,593 from vehicle.  Administration of U69,593 in trained monkeys 
produced dose-dependent generalizations in all subjects.  Systemic subcutaneous administration 
of salvinorin A fully substituted for U69,593 in a dose-dependent manner.  Pretreatment with 
opioid antagonist quadazocine at an appropriate does of 0.32 mg/kg fully blocked the 
discriminative effects of salvinorin A and U69,593 in all test subjects.  In two of the three 
subjects, long acting KOP selective antagonist GNTI blocked the effects of salvinorin A.  A 
control experiment was performed using NMDA antagonist ketamine, which has been known to 
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produce psychomimetic effects or hallucinations in humans.  Ketamine was not generalized by 
the rhesus monkeys trained to discriminate U69,593, therefore further implicating salvinorin A’s 
mechanism of action as a selective KOP receptor agonist in non-human primates. 
Drug discrimination studies were extended to rat by Willmore-Fordham and 
coworkers.246  They found that salvinorin A fully substituted for U69,593 at doses of 1, 1.9, and 
3 mg/kg in behavioral response of appropriate drug lever selection without systematically 
decrease in the number of times the lever was pressed as does increased.  Pretreatment with KOP 
antagonist norBNI (10 mg/mL, 3 L, i.c.v.) one hour before salvinorin A administration blocked 
salvinorin A discriminative effects.  Co-administration of norBNI and salvinorin A resulted in 
the majority of vehicle lever responses. 
Further investigation by Baker and coworkers extended these findings in rats.247  Rats 
were trained to discriminate 0.13 mg/kg U69,593, 3.0 mg/kg U50,488, or 2.0 mg/kg salvinorin 
A; lower doses than previously evaluated.  In rats trained to discriminate U69,593, salvinorin A 
was found to result in a dose-dependent increase in drug-appropriate responding and full 
substitution for U69,593 at 1.0 mg/kg.  In U50,488 trained rats, salvinorin A once again resulted 
in U50,488-appropriate responding and fully substituted for U50,488 at 3.0 mg/kg.  In salvinorin 
A trained rats, U69,593 and U50,488 resulted in complete stimulus generalization. 
Discriminative hallucinogenic activity has been evaluated in rodents to a much greater 
extent than in nonhuman primates.  Li et al. extended these findings by evaluating hallucinogenic 
activity in nonhuman primates.248  Rhesus monkeys were trained to discriminate between 0.32 
mg/kg of 5-HT2A receptor agonist DOM and vehicle.  A number of known hallucinogens and 
drugs from other classes, including amphetamines, NMDA receptor antagonists, and D2/D3 
receptor agonists, were given to determine the discriminative stimulus effects of DOM.  Of 
 
40 
 
interest was that salvinorin A and U69,593 failed to substitute for DOM in monkeys.  This 
further illustrates that salvinorin A does not exert its hallucinogenic effects through 5-HT2A 
receptors. 
Butelman et al. showed that rhesus monkeys trained to discriminate salvinorin A 
generalized arylacetamide KOP receptor agonists U69,593 and U50,488, which had been 
previously shown in rats.244,247  Butelman also investigated structurally diverse KOP receptor 
agonist bremazocine, which was also generalized in these nonhuman primates.  Peripherally 
selective KOP receptor agonist ICI204,448 was only generalized in one of three subjects, further 
linking salvinorin A discriminative effects to central KOP agonist effects.  MOP agonist 
fentanyl, DOP agonist SNC80, 5-HT2 agonist psilocybin, and NMDA antagonist ketamine were 
also investigated and found not to be generalized at any dose in subjects trained to discriminate 
salvinorin A.  Opioid antagonist quadazocine (0.32 mg/kg) reversed the discriminative effects of 
salvinorin A for all salvinorin A doses and 5-HT2 antagonist ketanserin did not block the 
discriminative effects of salvinorin A. 
Killinger et al. expanded the evaluation of salvinorin A discriminative effects to another 
species; the Sprague-Dawley rat.249  Rats were trained to discriminate either serotonergic 
hallucinogen LSD or noncompetitive NMDA antagonist ketamine.  Salvinorin A did not 
substitute for LSD in LSD-trained rats or ketamine in ketamine-trained rats up to doses that 
significantly reduced responding. 
 
Salvinorin A and Antinociceptive Effects 
In 2005, Wang et al. investigated the antipruritic and antinociceptive activities of three 
non-arylacetamide KOP receptor agonists: TRK-820, 3FLB, and salvinorin A.225  Antiscratching 
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effects were measured in the compound 48/80-induced scratch assay and antinociceptive effects 
were measured using the acetic acid abdominal constriction test.  In the compound 48/80-
induced scratch assay TRK-820 was found to potently inhibit scratching while 3FLB showed no 
inhibition and salvinorin A produced very low activity.  Additionally, in the abdominal 
constriction assay, TRK-820 had potent antinociceptive effects, 3FLB showed no effect, and 
salvinorin A produced inconsistent and no dose-related effects. 
Conflicting results were published by McCurdy and coworkers in 2006 when they 
evaluated the effects of intraperitoneal injection of salvinorin A in the tail-flick test, hot-plate 
test, and the acetic acid abdominal constriction assay.250  They found that salvinorin A produced 
short-acting (peak effects at the 10 minute time-point) antinociceptive effects in mice in the tail-
flick test, hot-plate test, and the acetic acid abdominal constriction assay.  Furthermore, results in 
the tail-flick test showed pretreatment with norBNI inhibited the increased latencies.  They also 
hypothesize that the differences in antinociceptive effects compared to Wang and coworkers was 
a result of the time frame evaluated.  Wang and coworkers administered salvinorin A 20 minutes 
prior to measuring abdominal constrictions while McCurdy found salvinorin A’s peak effects are 
at 10 minutes and at 20 minutes the analgesic effect of salvinorin A were no longer present. 
Investigation by John and coworkers provided more evidence for the antinociceptive 
effects of salvinorin A.251  They found that intrathecal injection of salvinorin A caused a dose-
dependent antinociceptive effect in mice measured in the tail-flick test.  Tail-flick latencies were 
not altered by pretreatment of MOP receptor antagonist -FNA or DOP receptor agonist NTI, 
but the increase of tail-flick latencies were abolished by pretreatment of KOP antagonist 
norBNI.251 
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Ansonoff and coworkers investigated the antinociceptive and hypothermic effects of 
salvinorin A in wild-type and KOR-1 knock-out mice.87  Salvinorin A intracerebroventricular 
injection of 7.5 g showed significant antinociceptive effects at the 15 minute time-point of the 
tail-flick test in wild-type mice.  By 30 minutes, tail-flick latencies were not significantly 
different from vehicle.  A 50 g intracerebroventricular injection of salvinorin A was evaluated 
and antinociceptive effects were seen at the 15 minute time-point but significant drug effect was 
sustained until the 45 minute time-point in wild-type mice.  Significant hypothermia, measured 
by rectal body temperature, was not seen at salvinorin A dose of 7.5 g but was reported at a 
dose of 50 g, lasting at least 120 minutes in wild-type mice.  Neither dose-dependent 
antinociceptive nor hypothermic effects were seen in KOR-1 KO mice.  The analgesic and 
hypothermic efficacy of salvinorin A is consistent with other KOP agonists. 
 
Salvinorin A and Gastrointestinal Effects 
Limited research has been performed evaluating salvinorin A’s effects on gastrointestinal 
function.  Capasso et al. evaluated salvinorin A’s ability to inhibit enteric cholinergic 
transmission in the guinea-pig ileum.252  Ileum strips were subjected to electrical field 
stimulation (EFS) and the contractile responses were measured.  Exposing the ileum to salvinorin 
A or U50,488 resulted in partial dose-dependent decreases in amplitude of EFS-evoked 
contractions.  Inhibition of enteric cholinergic transmission by salvinorin A did not occur in the 
presence of opioid antagonist naloxone or KOP receptor antagonist norBNI.  EFS contraction 
inhibition was not affected by exogenous acetylcholine, further implicating salvinorin A’s effects 
through activation of prejunctional KOP receptors.  Additional work by Capasso et al. evaluated 
salvinorin A’s ability to reduce inflammation-induced hypermotility in mice.253  Small intestine 
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hypermotility and inflammation were induced with two administrations of croton oil.  Doses of 
salvinorin A tested ranged from 0.01 – 10 mg/kg.  Salvinorin A produced a dose-dependent 
decrease in intestinal motility starting at 3 and 0.3 mg/kg in control animals and croton-oil 
treated mice, respectively.  Interesting to note is the increase in sensitivity of salvinorin A in 
croton-oil treated mice.  U50,488 was also evaluated and showed a dose-dependent decrease in 
intestinal motility comparable in control and croton-oil treated mice.  The decreases in motility 
cause by salvinorin A and U50,488 were both antagonized by norBNI. 
 
Salvinorin A and Drug Abuse 
Morani et al. investigated salvinorin A’s ability to act like other KOP agonists and 
attenuate cocaine-induced drug-seeking in rats.254  Doses of 0.3 or 1.0 mg/kg salvinorin A via 
intraperitoneal administration were found to dose-dependently decrease cocaine-produced 
reinstatement after a 20 mg/kg intraperitoneal priming dose of cocaine.  At a dose of 0.3 mg/kg, 
salvinorin A did not reduce cocaine hyperactivity.  Additionally, salvinorin A doses of 0.3 and 
1.0 mg/kg did not significantly decrease sucrose self-administration. 
In 2008, Chartoff and coworkers investigated salvinorin A’s ability to modulate cocaine 
induced locomotor-stimulant effects and c-Fos expression in the dorsal striatum when salvinorin 
A was given chronically or acutely.255  Acute salvinorin A administration 5 minutes prior to 
cocaine injection significantly attenuated cocaine-stimulated locomotor activity in a 2 hour time 
frame to that of rats treated with vehicle or salvinorin A and saline.  Acute salvinorin A 
administration also blocked the locomotor effects of the dopamine receptor agonist SKF 82958.  
Chronic salvinorin A exposure showed an initial decrease in locomotor activity in the first 15 
minutes after drug administration but then significantly increased cocaine-stimulated locomotor 
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activity for the remainder of the 3 hour period measured relative to vehicle.  Also, previous 
salvinorin A administration showed the ability to potentiate the locomotor effects of cocaine 
compared to the rats administered vehicle and potentiated the effects of SKF 82958.  Previous 
repeat exposure to salvinorin A and the activity chamber increased the locomotor response to 
cocaine, while rats only exposed to salvinorin A, without exposure to the activity chamber did 
not potentiate the locomotor responses to cocaine relative to controls.  Cocaine has been shown 
to induce c-Fos in several brain regions including the dorsal striatum.  Stimulus-induced 
expression of c-Fos occurs from the activation of cAMP and/or Ca+2 second messengers.  Acute 
salvinorin A administration resulted in a decreased amount of c-Fos expression in the dorsal 
striatum but expression was increased when salvinorin A was given repeatedly in the activity 
chamber.  When salvinorin A was administered repeatedly in the home cage, c-Fos expression in 
the dorsal striatum was unaffected.  This study shows the ability of salvinorin A to modulate the 
locomotor effects of cocaine through mediation of dopamine neurotransmission in the dorsal 
striatum. 
 
Salvinorin A and Depression 
Selective KOP receptor ligands have shown the ability to cause changes in mood in 
humans and motivation behavior in animals.97,152,256  Therefore, Carlezon et al. investigated the 
ability of salvinorin A to cause depressive-like effects in rats using the behavioral models of the 
forced swim test and the intracranial self-stimulation (ICSS) test.97  Salvinorin A was found to 
dose-dependently increase immobility and decrease swimming behavior at doses between 0.25 
and 2.0 mg/kg.  No significant changes in climbing behavior were observed at any dose, and 
diving was not seen throughout the tests.  These behavioral effects are opposite to those seen 
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with SSRIs.97,257  To confirm the changes in immobility and swimming were due to salvinorin 
A’s depressive-like effects and not changes in locomotor activity, locomotor activity was 
measured in an open field following the same doses of salvinorin A given in the forced swim 
test.  No difference in locomotor activity was seen at any dose tested.  The ICSS behavioral 
assay delivers electricity-induced brain stimulation to an area of the brain associated with 
mediating reward.  In this experiment, electrodes were located in the medial forebrain bundle at 
the level of the lateral hypothalamus.  For doses of 0.5, 1.0, and 2.0 mg/kg, salvinorin A was 
found to dose-dependently increase ICSS thresholds.  This suggests that salvinorin A reduces the 
reward impact of the medial forebrain bundle, which reflects anhedonia and further indicates 
salvinorin A’s prodepressant-like effects.   Additionally, microdialysis studies showed that at a 
dose of 1.0 mg/kg, salvinorin A decreased extracellular dopamine concentrations in the nucleus 
accumbens without affecting 5-HT levels. 
Zhang and coworkers investigated the effects of salvinorin A on basal dopamine levels in 
the caudate putamen and the nucleus accumbens along with salvinorin A’s ability to cause 
locomotor changes and induce conditioned place preference or aversion in mice.258  Salvinorin A 
levels were explored at doses of 0.32, 1.0, and 3.2 mg/kg intraperitoneal.  Microdialysis studies 
showed a dose-dependent decrease of dopamine levels in the caudate putamen with significant 
decreases observed at doses of 1.0 and 3.2 mg/kg.  Pretreatment with norBNI blocked the effect 
on dopamine levels at salvinorin A’s highest given dose.  However, significant decreases in 
dopamine levels were not seen in the nucleus accumbens.  Conditioned place aversion and 
decreased locomotor activity were also seen at the same salvinorin A doses of 1.0 and 3.2 mg/kg.  
Pretreatment with norBNI attenuated the conditioned place aversion and decreased locomotor 
activity resulting from salvinorin A administration. 
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Further investigation of salvinorin A’s depressive-like effects was carried out by Ebner 
and coworkers.259  They evaluated the ability of salvinorin A to decrease dopamine levels in the 
core or shell of the nucleus accumbens and salvinorin A’s effect on intracranial self-stimulation 
and sucrose-reinforced responding.  The salvinorin A dose of 2.0 mg/kg via intraperitoneal 
administration was tested as it previously showed ability to increase ICSS threshold and 
immobility in the forced swim test.97  Salvinorin A was found to significantly decrease phasic 
dopamine release in the core and shell of the nucleus accumbens without influencing dopamine 
reuptake.259  ICSS behavioral testing showed that 2.0 mg/kg salvinorin A dose-dependently and 
time-dependently increased ICSS thresholds compared to vehicle.  This increase is attributed to a 
decrease in the rewarding impact of the medial forebrain bundle stimulation.  Changes in 
motivation following salvinorin A injection were additionally measured by progressive ratio 
responding for sucrose reward.  At 2.0 mg/kg, salvinorin A was found to lower breakpoints in 
progressive ratio responding.  Decreased responding for sucrose pellets is recognized as decrease 
in motivation. 
 
Salvinorin A and Sedation 
Fantegrossi et al. examined the sedative and/or ataxic properties of salvinorin A in the 
inverted screen test.260  All doses of salvinorin A significantly increased climbing time at the 5 
minute time point but did not produce dose-dependent effects on climbing behavior.  
Behaviorally equivalent doses of MOP agonist remifentanil (0.01 mg/kg) and KOP agonist 
U69,593 (1.0 mg/kg) compared to 2.0 mg/kg salvinorin A were evaluated and found to have 
similar effects in sedation and motor impairment relative to salvinorin A.  Motor incoordination 
of salvinorin A and U69,593 were significantly attenuated by pretreatment of norBNI but were 
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not altered by pretreatment of DOP antagonist naltrindole or low dose of opioid antagonist 
naloxone (0.1 mg/kg).  Motor effects of remifentanil were not modified by pretreatment of 
naltrindole or norBNI but were significantly reduced by naloxone.   
 
Salvinorin A and Cannabinoid Receptors 
Braida et al. evaluated the hallucinogenic and rewarding effects of salvinorin A in 
zebrafish by measuring swimming behavior and conditioned place preference.261  Additionally, 
they investigated the potential involvement of CB1 receptors with salvinorin A.  Low doses of 
salvinorin A (0.1 – 10 g/kg) were evaluated and zebrafish were injected intramuscularly into 
the caudal musculature.  Salvinorin A was found to modify normal swimming behavior in a 
biphasic manner.  Low doses of salvinorin A (0.1 and 0.2 g/kg) statistically accelerated 
swimming behavior while higher doses of 5 and 10 g /kg statistically decreased swimming 
behavior relative to vehicle.  Pretreatment of norBNI or CB1 antagonist rimonabant reversed 
swimming behavioral effects comparable to vehicle.  Low doses of salvinorin A (0.2 and 0.5 
g/kg) resulted in a statistical increase in time spent in the drug-associated compartment with 0.5 
g/kg dose having the greatest reinforcing effects.  Salvinorin A dose of 1.0 g/kg resulted in no 
effect relative to vehicle and a higher dose of 80 g/kg resulted in aversion.  Validation of the 
CCP test was completed by evaluating cocaine and KOP agonist spiradoline.  Cocaine increased 
the time spent in the drug-paired compartment while spiradoline decreased the time spent in the 
drug-paired compartment.  Pretreatment with norBNI or rimonabant reduced the time spent in 
the drug-paired compartment relative to salvinorin A. 
A follow-up study by Braida et al. investigated the involvement of the KOP receptor and 
endocannabinoid systems in Wistar rats by testing low doses of salvinorin A in the conditioned 
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place preference and intracerebroventricular self-administration paradigms.262  Subcutaneous 
administration of salvinorin A resulted in dose-dependent positive CPP response at dose 0.1 
g/kg – 40 g/kg, a neutral response at 80 g/kg and a negative CPP response at 160 g/kg 
relative to vehicle.  The CPP effect of salvinorin A was significantly blocked by pretreatment 
with norBNI or CB1 antagonist rimonabant.  Additionally, microdialysis showed that 40 g/kg of 
salvinorin A, the dose resulting maximum CPP response, significantly increased extracellular 
dopamine levels in the shell of the nucleus accumbens.  Results from intracerebroventricular 
self-administration studies found the same biphasic trend with lower and higher doses of 
salvinorin A.  Low doses of 0.1 and 0.5 g/infusion resulted in a significant increase in the 
number of drug-associated lever pressings and a dose of 1 g/infusion resulted in a significant 
decrease in the number of drug-associated lever pressings relative to vehicle.  Pretreatment with 
norBNI or rimonabant both statistically reduced the number of drug-associated lever pressing 
relative to salvinorin A alone. 
An additional study by Braida and coworkers investigated salvinorin A’s anxiolytic-like 
and antidepressant-like behavior in rodent models using the elevated plus maze, the forced swim 
test, and the tail suspension test.263  In the elevated plus maze test, salvinorin A was shown to 
cause significant differences relative to vehicle at doses ranging from 0.1 and 160 g/kg with no 
progressive dose-related increase in effect.  Salvinorin A’s anxiolytic-like effects were reversed 
by both KOP receptor antagonist norBNI and CB1 receptor antagonist AM251.  Results of the 
forced swim test contradicted those of Carlezon and coworkers who determine that 
intraperitoneal administration of salvinorin A caused pro-depressant-like effects in rats.97  Braida 
et al. tested subcutaneous lower doses of salvinorin A and found that at doses ranging from 0.001 
– 10 g/kg dose-dependently decreased immobility and increased swimming.  Additionally, 
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pretreatment with norBNI and AM251 reversed these effects.  The tail suspension test was 
performed on mice and doses between 0.001 – 1 g/kg resulted in a decrease in immobility and 
effects were reversed by pretreatment of norBNI and AM251.  These studies suggest both KOP 
receptors and CB1 receptors mediate the behavioral and rewarding effects of salvinorin A. 
Direct agonist activity of salvinorin A at CB1 receptors is improbable due to previous 
studies investigating salvinorin A’s binding affinity at these receptors.137,221  Therefore, 
Walentiny and coworkers evaluated salvinorin A in several in vitro and in vivo assays to screen 
for cannabinoid activity to more fully understand the endocannabinoid system’s role in the 
pharmacological effects of salvinorin A.264  Salvinorin A did not have affinity in cells transfected 
with human CB1 receptor when radiolabeled agonist or antagonist was used for displacement.  
Additionally, salvinorin A did not activate CB1 receptors in G protein and calcium flux 
functional assays or block the effects of CP55,940 in the [35S]GTPS assay, a characteristic of 
cannabinoid antagonists.  However, rimonabant antagonized U69,593 in a dose-dependent 
manner in the [35S]GTPS assay.  This in vitro data suggests that salvinorin A does not act 
directly at CB1 receptors or modulate its signaling cascade.  Four in vivo assays were performed 
measuring locomotor activity, tail flick, rectal temperature, and ring immobility.  THC was 
found to dose-dependently decrease spontaneous activity and body temperature, while causing 
dose-dependent antinociception and catalepsy.  Salvinorin A also resulted in a dose-dependent 
decrease in spontaneous activity and body temperature and dose-dependent antinociception and 
catalepsy.  Of note, salvinorin A altered body temperature and catalepsy to a lesser extent than 
THC.  Coadministration of KOP antagonist JDTic reversed the in vivo effects of salvinorin A but 
coadministration of rimonabant had no effect.  THC in vivo effects were attenuated by 
rimonabant; JDTic had no effect on locomotor suppression, antinociception, or catalepsy.  
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However, JDTic did antagonize THC’s hypothermic effects.  Additionally, salvinorin A failed to 
substitute at any dose in THC-trained mice.  These studies conclude that the effects of salvinorin 
A are not mediated by direct or indirect modulation of the endocannabinoid system.  It appears 
that the relationship between salvinorin A and the endocannabinoid system is a consequence of 
rimonabant’s ability to antagonize KOP receptors. 
 
Molecular Modeling Studies 
Opioid receptors are members of the membrane-bound GPCR superfamily and 
consequently their three-dimensional structures have not been elucidated by crystallography.  
The binding site of salvinorin A will not be certain until the co-crystal structure of salvinorin A 
and KOP is solved.95  However, several investigators have undertaken the task to understand its 
binding through molecular modeling, site-directed mutagenesis, and chimeric receptor 
studies.137,265-269  After identifying salvinorin A as a potent and selective KOP receptor agonist, 
Roth and coworkers performed molecular modeling studies in efforts to elucidate salvinorin A’s 
interactions with the KOP receptor.  They utilized a previous model of the KOP receptor with 
known agonist U69,593 as a starting point.137  Their modeling parameters proposed the furan 
ring of salvinorin A is directed towards TM1 with the furan oxygen interacting with Q115, the 4-
methoxycarbonyl is orientated towards TM5 and TM6 with the carbonyl oxygen hydrogen 
bonding with Y312, and the carbonyls of the C-2 acetate and lactone are interacting with Y313 
and Y139, respectively.  They also identified seven variable residues in the KOP receptor that 
are not conserved in the MOP or DOP receptors.  These variable amino acids result in different 
steric and electronic effects for KOP receptors comparable to MOP and DOP receptors in the 
region proposed for the salvinorin A binding site. 
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In 2005, Yan et al. examined salvinorin A binding to KOP receptors through molecular 
modeling, site-directed mutagenesis, radioligand binding and functional assay analysis of the 
mutated constructs, and cysteine-substitution mutagenesis.269  Through their molecular modeling 
predictions and mutant construct synthesis they found Y312A and Y312F mutants do not alter 
the affinity of salvinorin A for KOP receptors.  Therefore their model proposes little to no 
interaction with Y312.  The retained affinity of salvinorin A with the Y313F mutant but loss of 
affinity with the Y313A mutant suggests a hydrophobic interaction between the aromatic ring of 
tyrosine and the C-2 acetate.  Mutations of Y320A, Y320F, Y119A, and Y119F results in loss of 
affinity for salvinorin A suggesting hydrogen bond participation.  This model orientates the 
hydrogen bond interactions of Y320 and Y119 with the furanyl oxygen.  The proposed model 
also positions the C-4 methyl ester in close proximity to Ile294 and Glu297.  Cysteine-
substitution mutagenesis studies were performed with the hypothesis that if the cysteine mutation 
is in close proximity to the thiol of synthesized 2-thiosalvinorin B or the C-2 acetoxy of 
salvinorin A, then the affinity of the mutant with 2-thiosalvinorin B would be increased or 
maintained and the affinity with salvinorin A would likely decrease.  A C315S mutation was 
combined with cysteine substitutions of several key residues in the binding pocket.  Of specific 
interest was the C315S-Y313C double mutant.  The C315S-Y313C preserved the affinity of 2-
thiosavlinorin B but decreased affinity of salvinorin A further supporting the interaction of Y313 
with the C-2 acetoxy.  Additionally, Yan and coworkers synthesized salvinorin A affinity labels 
to covalently bind to the C315 anchoring residue.268  This study confirmed that a free cysteine is 
involved with or near the binding site of KOP with salvinorin A. 
In efforts to explain the binding interactions of KOP receptors with semi-synthetic 
salvinorin A derivatives that had meanwhile been synthesized, Kane and coworkers suggested a 
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new model utilizing chimeric and single-point mutant opioid receptors.266  While confirming the 
affinity of the chimeric receptors for their ability to bind diprenorphine, this study emphasized 
the importance of TM II, TMVII, and extracellular loop-2; with specific implications of Q115, 
Y119, Y313, and Y320.  This model predicts a vertical orientation of salvinorin A in the receptor 
binding site.  A follow up study also implicated I316 as an amino acid when mutated to alanine 
results in loss of salvinorin A affinity by interrupting a lipophilic -helical bundle in TM VII.265  
An additional publication by Vortherms et al. focuses on opioid receptor subtype 
selectively of salvinorin A and how the orientation of the transmembrane helices of MOP and 
DOP receptors prevent salvinorin A binding.267  KOP chimeric mutants with modifications in the 
TM2 and E2L retained affinity for naloxone but lost affinity for salvinorin A demonstrating the 
ligand binding pocket was still intact.  Site-mutations of nonconserved amino acids in helix 2 
implicated interest in V108 and V118, which resulted in a decrease of affinity for salvinorin A.  
Taking into consideration the loss in affinity of salvinorin A with V108 and V118 mutations, a 
modified receptor orientation was proposed.  The new model predicted that V108 and V118 
indirectly effect salvinorin A binding through the helical rotation of TM II and are major 
determinants of salvinorin A selectivity for KOP receptors. 
Molecular modeling studies hypothesize that the furan ring is involved in stabilization of 
salvinorin A in the KOP receptor active site.  Previous studies have shown that substitution of 
the furan ring is tolerated to retain affinity and efficacy at KOP receptors.  Additionally, past 
furan modifications have resulted in compounds with diverse pharmacology profiles.  Further 
structural modification of the 3-furan moiety will result in further understanding of structure 
activity relationships and the ideal interactions in the KOP receptor binding pocket.  
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Furthermore, these studies utilize an original scaffold in opioid pharmacology with the potential 
to develop new therapeutics with fewer side effects than traditional opioids. 
Through the identification of key amino acids involved in binding salvinorin A to the 
KOP receptor, models have predicted that the furan ring is involved in stabilization of salvinorin 
A in the KOP receptor active site.  Based on the information that if the furan ring is involved in 
stabilization of salvinorin A in the KOP receptor active site then modification of the furan ring 
will result in modulation of pharmacological activity along with a further understanding of 
structure activity relationships and the ideal interactions of salvinorin A in the KOP receptor 
binding pocket is proposed. 
 
Salvinorin A Structure Activity Relationship Studies 
Due to the activity of salvinorin A at KOP receptors, medicinal chemistry efforts have 
been performed to explore the SAR of salvinorin A.  Several reviews have been written 
summarizing past synthetic modifications and structure-activity relationships of salvinorin 
A.95,96,212,270  The SAR known at this time, not including furan modifications, is summarized in 
Figure 8.  Reduction or removal of the carbonyl at the C-1 position is tolerated and yet the 
introduction of an alkene at C-1 – C-10 showed antagonist activity.271-273  At the C-2 position, 
bioisosteric replacements of the ester functionality with amides, carbonates, and carbamates are 
tolerated.271,274-283 In general, small alkyl groups favor affinity at KOP receptors.  
Methoxymethyl and ethoxymethyl ethers at the C-2 position are among the most potent 
salvinorin A analogues reported to date.271  Aromatic groups at C-2 tend to favor affinity at MOP 
receptors with the example of the C-2 benzoyl ester named herkinorin.282  Herkinorin has 
interesting pharmacological properties in that activity changed from KOP to MOP opioid 
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receptors.  Modification of the C-4 position by reduction or hydrolysis reduces affinity at KOP 
receptors and replacement of the methyl ester with small alkyl groups is tolerated.271,284,285  
Alterations of the C-17 position by reduction or removal of the lactone is tolerated but 
subsequent methylation of the lactol resulted in decrease in affinity.281  Introduction of a C-8 – 
C-17 alkene was also tolerated.  Modifications to the furan ring will be discussed in depth. 
 
 Figure 11: Structure Activity Relationship Summary 
 
Furan Modifications 
Specific interest in derivation of salvinorin A continues to be focused around the furan 
ring due to the poor ADMET properties of furan.  The concern for hepatoxicity has resulted in 
the synthesis of a number of semi-synthetic derivatives and isolation of novel neoclerodanes 
from S. divinorum containing the core structure of salvinorin A with modified furan rings.286-289  
These derivatives focus on elucidating replacements for the furan ring and exploration of 
structure-activity relationships. 
Previous studies have shown that substitution of the furan ring is tolerated to retain 
affinity and efficacy at KOP receptors.286-289  Additionally, past furan modifications have 
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resulted in compounds with diverse pharmacological profiles.  Synthesis of semi-synthetic 
analogues of salvinorin A with modified furan substituents would be beneficial for the 
identification of compounds with therapeutic potential for the treatment of drug abuse and other 
disease states associated with KOP receptor modulation.  Modification of the furan ring utilizes 
an original scaffold in opioid pharmacology with the potential to develop new therapeutics with 
fewer side effects than traditional opioids. 
 
Figure 12: Compounds 59 – 74  
 
Past modification to the furan ring includes reduction of the furan ring to 
tetrahydrosalvinorin A (59) (Figure 12).281,289  Compound 59 was found to have reduced affinity 
for KOP receptors compared to salvinorin A.  Depending on the assay used, compound 59 had 
either 39-fold or 7-fold lower affinity than salvinorin A at KOP receptors.281,289  The C-13R 
epimer of 59 was separated by HPLC and retained high affinity for KOP receptors relative to 
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salvinorin A (Ki = 3.7 nM vs. Ki = 1.9 nM) but was 17-fold less efficacious than salvinorin 
A.281,289  This demonstrates that an aromatic may not be necessary for affinity at KOP 
receptors.289  However, complete removal of the furan ring resulted in a compound greater than 
1700-fold less active than salvinorin A at KOP receptors (60).287,289  Photoxidation of salvinorin 
A yielded natural products salvidivin A (61) and salvidivin B (62).289  -Hydroxybutenolide 61 
had antagonist activity at MOP and KOP receptors (Ke = 760 nM and Ke = 440 nM, 
respectively).289 
Treating salvinorin A with bromine in a mixture of DCM and MeOH at room temperature 
resulted in a mixture of trans (63) and cis (64) 2,5-dimethoxydihydrofuran isomers, which were 
separable by HPLC.289,290  Trans isomer 63 had an approximate 3-fold higher binding affinity at 
MOP receptors than the epimeric mixture (Ki = 3,190 nM vs. Ki >10,000 nM).  The cis (64) 
isomer had a 2-fold increase in affinity at KOP receptors compared to 63 or the epimeric mixture 
and had comparable affinity at MOP receptors to 63.  In the [35S]GTPS functional assay, 63 and 
64 were both weak nonselective antagonists at MOP, KOP, and DOP receptors.  Hydrogenation 
of 63 and 64 with 5% Rh/C in MeOH yielded the trans (65) and cis (66) 
dimethoxytetrahydrofuran derivatives, which were separated by HPLC.289  Compound 65 had a 
Ki = 25 nM and 66 had a Ki = 125 nM, 13-fold and 66-fold lower affinity for KOP receptors 
comparable to salvinorin A, respectively.  Additionally, reduction of the alkene in 63 changed 
the functional activity from an antagonist to an agonist (EC50 = 2,350 nM, Emax = 95% relative to 
U69,593).  As a mixture, the cis isomer 64 was selectively oxidized over the trans isomer (63) 
with KMnO4 in THF and H2O at -10°C to afford a mixture of the natural products salvinicin A 
(67) and salvinicin B (68).290,291  Diterpene 67 is a partial KOP agonist (Ki = 390 nM, EC50 = 4.1 
M, 80% relative to U50,488) and 68 is a MOP antagonist (KOP Ki = 700 M, MOP Ke = 1.9 
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M).291  Treatment of mixture of 65 and 66 with methanesulfonamide at 95°C in acetic acid 
afforded a mixture of the methanesulfonylpyrrole (69) and its C-8 epimer.287  Using this 
methodology, benzenesulfonamides 70 and 71 were synthesized.  N-sulfonylpyrroles 69, 70, and 
71 had reduced affinities and efficacies compared to salvinorin A but were found to be partial 
agonists compared to U50,488 and salvinorin A (Emax = 70%, 60%, 60%, respectively). 
 
Figure 13: Compounds 75 – 115   
 
Exposure of salvinorin A to bromine in DMF at 0°C gave way to dihydrofuran 72 as a 
mixture of C-15  and  isomers and the C-15  isomer was found to be stable.290  Treatment of 
salvinorin A with N-bromosuccinimide in acetonitrile or chloroform gave the 2-bromofuran 
product (73).286,289,290  Bromo analogue 73 was well-tolerated at KOP receptors and retained 
affinity relative to salvinorin A (Ki = 3.0 nM vs. Ki = 1.9 nM).
289  Additionally, compound 73 
was found to be a full agonist with an EC50 = 50 nM and Emax = 104% relative to U69,593.  The 
retained affinity and efficacy at KOP receptors observed with the introduction of a C-16 bromide 
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suggests that steric bulk is tolerated in the binding site of the furan ring.  Stille coupling of 73 to 
tributylvinyltin afforded the 2-vinylfuran product (74).286  Introduction of the vinyl group was 
also well-tolerated (Ki = 7.1 nM, EC50 = 4.6 nM, Emax = 120% relative to U50,488). 
A valuable intermediate that has been utilized to synthesize a number a furan modified 
analogues is the C-13 carboxylic acid (75) (Figure 13).  Carboxylic acid 75 is achieved by 
oxidative degradation of salvinorin A by NaIO4 and catalytic RuCl3·3H2O in a mixture of CCl4, 
CH3CN, and H2O.  Standard coupling conditions have been used to synthesize a number of esters 
and amides off the salvinorin A core (76 – 111).286,292  The C-13 methyl ester was prepared by 
treatment of 75 with (trimethylsilyl)diazomethane (TMSCHN2) (76).
286 Other alkyl esters were 
synthesized in the presence of EDCI, HOBt, and Et3N.
286,292  A large variety of amides were 
produced from 75 using appropriate amine, EDCI, HOBt, and in some cases with the addition of 
Et3N.
286,292  Additionally, carboxylic acid 75 was also reduced to the primary alcohol (112) with 
BH3·THF in THF at 55°C.  Alcohol 112 was alkylated with alkyl iodides in the presence of 
Ag2O to afford alkyl ethers (113, 114).
286  The primary alcohol was also acetylated (115) using 
acetic anhydride and Et3N.  Alkyl esters 76 – 78, and 83 had roughly 40- to 80-fold less affinity 
at KOP receptors while retaining functional activity as full agonists.286  Aryl esters 79 and 80 
showed no affinity at KOP, DOP, or MOP receptors.  In the amide derivative series, aromatic 
amide substitutions (87 – 99) were not tolerated at KOP receptors.286,292  Nonaromatic 
substitution with the cyclohexane (101) and cyclopentane (102) derivatives had affinity for KOP 
receptors but a decrease relative to salvinorin A with a greater than 10-fold and 5-fold loss, 
respectively.  Constricting cyclohexylamine 101 in to a piperidine (105) resulted in a 14-fold 
increase in affinity relative to 101 (Ki = 140 nM vs. Ki = 1,930 nM).  Further constriction of 105 
to pyrrolidine (106) produced a decrease in affinity (Ki = 1,210 nM), while bioisosteric 
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replacement to the morpholine (104) and thiomorpholine (107) did not further enhance affinity at 
KOP receptors but showed partial agonist activity (Ki = 230 nM, ED50 = 5110 nM, Emax = 85% 
relative to U50,488 and Ki = 160 nM, ED50 = 3780 nM, Emax = 57% relative to U50,488).  
Addition of a bromine in analogue 108 resulted in a decrease in affinity (Ki = 1,250 nM).  
Tetrahydrofuran amides (109, 110, 111) had weak to no affinity at KOP receptors, however, 
compound 109 showed selective low affinity at DOP receptors (DOP Ki = 3,090 nM).  Alcohol 
analogues (113 – 115) showed roughly a 200-fold loss in affinity relative to salvinorin A.286 
 
Figure 14: Compounds 116 – 133   
 
Carboxylic acid 75 also has been utilized to form the acid chloride and exposed to 
appropriate aryltributyl tin reagents under Stille conditions affording a variety of arylketones 
(116 – 120) (Figure 14).286  Arylketone 116 was reduced using sodium borohydride to yield the 
corresponding alcohol (121) as a mixture of C-13 epimers.  The majority of arylketone 
derivatives were reported to have no affinity at KOP receptors with only the 2-thiophene 117 and 
2-pyrazine 120 analogues retaining low nanomolar affinity and full agonist activity (Ki = 38 nM 
and 83 nM).286  Alcohol 121 was evaluated as full agonist with a Ki = 20 nM, EC50 = 35 nM, 
Emax = 111% relative to U50,488).  Carboxylic acid 75 was treated with either (2-
hydroxybenzyl)triphenyl- or (2-thiobenzyl)triphenyl phosphonium bromide in the presence of 
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CDMT and Et3N to afford the benzofuran (122) and benzothiophene (123).
292  Derivatives 122 
and 123 had little to no affinity at KOP receptors (Ki = 2,340 nM and Ki > 10,000 nM). 
The C-13 carboxylic acid 75 was also reacted with ethanolamine or L-serine methyl ester 
hydrochloride using standard amide coupling conditions followed by cyclization with bis(2-
methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor) to yield oxazolines 124 and 125.287,289  
Oxazoline 124 showed loss in affinity relative to salvinorin A (Ki = 300 nM).
289  Oxazoline 125 
was converted to oxazole 126 by treatment with bromotrichloromethane and DBU.287  A variety 
of oxadiazoles (127 – 133) have been synthesized by treating carboxylic acid 75 with appropriate 
amidoximes in the presence of EDCI and HOBt followed by heating in toluene and HPLC 
purification.286,287,289,292,293  Additionally, Simpson and coworkers reported that oxadiazole 127 
results in a 29-fold loss in affinity relative to salvinorin A (Ki = 56 nM) and is a functional 
antagonist at both KOP and MOP receptors (KOP: Ke = 360 nM MOP: Ke = 430 nM).
289  
However oxadiazoles 127 – 133 were synthesized by Béguin and coworkers and all were found 
to have no appreciable binding at KOP receptors.286 
Additionally, carboxylic acid 75 has been transformed to the C-13 aldehyde through the 
thioester intermediate (134) (Figure 15).  Carboxylic acid 75 was treated with 2-chloro-4,6-
methoxy-1,3,5-triazine (CDMT) and N-methyl morpholine (NMM) followed by the addition of 
ethanethiol.  Thioester 134 was then reduced with triethylsilane and Pd/C to afford the aldehyde 
(135). 286,292  B-allyl-(10S)-(trimethylsilyl)-9-borabicyclo[3.3.2]decane (prepared in situ from 
commercially available 9-[(1R,2R)-pseudoephedrinyl]-(10S)-(trimethylsilyl)-9-borabicyclo 
[3.3.2]decane and allylmagnesium bromide) achieved the asymmetric allylation (136) of the C-
13 aldehyde (135).292  To determine the stereochemistry of the allylic alcohol product, the 
Mosher ester (137) was prepared with oxalyl chloride and (R)-(+)--methoxy--
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trifluoromethylphenylacetic acid.  Allylic alcohol 136 was acylated with acryloyl chloride in the 
presence of Et3N and DMAP, and the subsequent ester was subjected to ring closing metathesis 
using 2nd generation Grubb’s catalyst to afford the 5,6-dihydro-2H-pyran-2-one product (138).  
Unfortunately, these modifications lead to a drastic decrease in affinity at KOP receptors (Ki = 
8,060 nM).292 
 
Figure 15: Compounds 134 – 145  
 
Using Seyferth-Gillbert homologation conditions aldehyde 135 was converted to the 
terminal alkyne (139).293  Alkyne product 139 was coupled with various azides under copper(I)-
catalyzed click reaction conditions to afford 1,4-disubstituted-1,2,3-triazoles (140 – 143).293  The 
pivalyl triazole 143 was treated with 1N NaOH and reacetylated to give a mixture of C-8 epimers 
and the N-unsubstituted triazoles (144, 145).  All triazoles synthesized resulted in loss of affinity 
at KOP receptors (Ki > 1,000 nM). 
The Diels-Alder reaction has been performed on salvinorin A using the furan ring as the 
4π diene.294  Very reactive/electron-poor dienophiles such as diethyl acetylenedicarboxylate, 
dimethyl acetylene dicarboxylate, and 4,4,4-trifluoro-2-butynoate were cyclized using traditional 
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heating methods or microwave radiation yielding derivatives 146 – 149 (Figure 16), 
respectively.  Additionally, 150 was synthesized from generating benzyne from 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate and cesium fluoride in CH3CN but the relative 
configuration is unable to be determined.  Salvinorin A was also heated with 3,6-epoxy-3,6-
dihydrotribenzocycloheptatrienone or 3,6-epoxy-3-methyl-3,6-dihydrotribenzocycloheptatrien-
one in toluene to afford 151 and 152, respectively.294  Cycloadduct 151 was identified as a 
mixture of exo and endo while 152 was a single compound.  Bicycles 146 – 150 were exposed to 
Fe2(CO)9 in toluene and heat to undergo reductive elimination of water to yield aromatic 
compounds 153 – 157.  Cyclic analogues 146 and 147 had reduced but still appreciable affinity 
but reduced efficacy at KOP receptors relative to salvinorin A (Ki = 120 nM, ED50 = 2150 nM, 
Emax = 90% and Ki = 60 nM, ED50 = 980 nM, Emax = 100% relative to U50,488 in efficacy 
assay).  Introduction of the methyl group to trienone analogue 151 altered KOP receptor affinity 
45-fold with further investigations pending to rationalize this observation (Ki > 13,000 nM vs. Ki 
= 290 nM).  Non-heterocyclic aromatic rings of 153 – 157 had reduced affinity at KOP receptors 
relative to salvinorin A. 
In addition to the large variety of replacements for the furan ring, the stereochemistry of 
C-12 has been inverted (158).286  Heating salvinorin A in 5% aqueous KOH afforded the diacid 
and then the free hydroxyl at C-2 was reacetylated with Ac2O and pyridine.  Refluxing in acetic 
acid promoted cleavage at C-1 and lactonization to afford the inverted center at C-12, and 
subsequent methylation of the acid at C-4 using TMSCHN2 provided 12-epi salvinorin A (158).  
The binding of affinity of epi-salvinorin A was 16-fold less than the natural epimer but 
interestingly showed partial agonist effects at KOP receptors (EC50 = 84 nM, Emax = 67% relative 
to U50,488).286 
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Figure 16: Compound 146 – 158  
 
A number of salvinorin A derivatives have been made, largely focusing at the C-2 and the 
C-13 position.96,212,270  Further investigations into salvinorin A derivatives with modified furan 
substituents will results in the identification of novel compounds with unique pharmacological 
profiles, shown with previous furan modifications.286,287,289,290,292  Continued exploration of 
salvinorin A derivatives with modified furan moieties with strategic introduction of steric bulk 
and hydrogen bonding interactions will lead to further understanding of the structure activity 
relationships of salvinorin A. 
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CHAPTER III.  RATIONALE AND SPECIFIC AIMS  
Salvinorin A has shown great therapeutic potential, but optimization is required for 
human use as a KOP receptor agonist due to several drawbacks.  These drawbacks include 
hallucinogenic and dysphoric effects along with its poor pharmacokinetic properties including 
ADMET (absorption, disposition, metabolism, excretion, and toxicity) properties.  Desirable 
ADMET properties are essential for the development of therapeutic agents.  Natural products, 
such as salvinorin A, often have excellent potency and selectivity for a specific biological target 
but have unsatisfactory ADMET properties.  Assessment of ADMET properties has recently 
been incorporated early into the drug discovery process and assists to direct the project to 
derivatives with a greater chance of clinical success.  Elimination of poor ADMET 
characteristics in a natural product or any drug candidate is essential for a drug development 
campaign.  ADMET properties are often modified through semi- or total synthesis. 
 
Figure 17: Diterpenes with Associated Toxicity  
 
Salvinorin A has several ADMET properties that need to be addressed to fully utilize 
salvinorin A’s therapeutic potential.  Salvinorin A has been shown to have hallucinogenic and 
dysphoric effects in human and animal models that need to be modulated to develop a 
therapeutic agent.  Additionally, furan containing natural products have been linked to 
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hepatotoxicity.295-297  Inspection of the structure of salvinorin A suggests that the furan ring of 
salvinorin A is a potential metabolic problem.292  Furan-containing natural products have 
historically shown limited therapeutic utility due to their potential for bioactivation and 
consequent hepatoxicity.295-297  Previous metabolic studies on teucrin A (57) (Figure 17), a 
structurally similar neoclerodane diterpene from Teucrium chamaedrys L., has been shown to be 
metabolized by CYP450s to afford a highly reactive enedial intermediate which forms stable 
peptide conjugates leading to hepatoxicity.298-300  Aflatoxin B1 (58), a difurano-containing 
natural product produced by an Aspergillus species, is also known to have associated toxicity.301  
Aflatoxin B1 is thought to undergo bioactivation by CYP450s to a comparable enedial 
intermediate resulting in hepatic carcinogenic effects.301  Salvinorin A shares a common toxic 
feature with these other furan-containing natural products not ideal for medicinal use.96  One way 
to circumvent the potential toxicity associated with salvinorin A would be to identify analogues 
with modified furan substituents.  Preferably, semi-synthetic modifications to the furan ring 
would introduce structural replacements with little to no potential for toxicity while still retaining 
activity and affinity at KOP receptors.  These modifications would be beneficial for the 
identification of compounds with therapeutic potential for the treatment of drug abuse and other 
disease states associated with KOP receptor modulation. 
Salvinorin A is a highly lipophilic molecule that has poor solubility in aqueous solution.  
Aqueous solubility is a requirement for pharmacological testing therefore a vehicle is used.  The 
vehicle chosen has the ability to alter bioavailability and increase or decrease the toxicity 
associated with the drug.302  Detergents, solvents, or vegetables oils are commonly used vehicles 
with Tween-20 and Tween-80 as the most common detergents, DMSO and ethanol as the most 
common solvents, and emulphor-620 as the most common vegetable vehicle utilized.302  Vehicle 
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formulations for salvinorin A are various and range from Tween-80:ethanol:saline (1:1:8) to 
DMSO:H2O (3:1).
244,259  Current available vehicles for salvinorin A administration have 
drawbacks associated with them largely associated to the use of ethanol or DMSO.270  Ethanol 
potentiates the effects of opioid receptors potentially obscuring biological results and DMSO has 
been shown to modulate the potency of other opioids, such as morphine, following acute or 
chronic administration.303  Identification of a different vehicle for salvinorin A would be useful 
for simplifying pharmacological data analysis. 
Salvinorin A has also been shown by Teskin and coworkers to be a P-glycoprotein (P-gp) 
substrate but not a P-gp inhibitor.237  Using the P-gp ATPase assay, 5 µM and 10 µM 
concentrations of salvinorin A significantly increased P-gp-mediated ATPase activity in a 
concentration-dependent manner suggesting that salvinorin A is a P-gp substrate.  Salvinorin A is 
a highly lipophilic molecule that has been shown to rapidly cross the blood brain barrier in PET 
imaging studies.232  Teskin and coworkers use MDCK-MDR1 cells to determine salvinorin A’s 
permeability across cell membranes expressing P-gp.237  MDCK-MDR1 cells form a highly 
confluent monolayer which is used as model of transepithelial transport and is able to predict 
brain uptake.  Secretory transport of salvinorin A was higher than absorptive transport further 
associating salvinorin A with P-gp.  P-gp activity could also contribute to salvinorin A’s short 
duration of action.  Better understanding the role P-gp plays in mediating the effects of salvinorin 
A would lead to analogues with greater therapeutic potential.99 
Salvinorin A is a biologically active neoclerodane diterpene that produces potent 
hallucinogenic effects.  Unlike classical hallucinogens, salvinorin A does not act at 5-HT2 
receptors but was identified as the first naturally occurring potent and selective KOP receptor 
agonist not containing a basic nitrogen.137  The unprecedented neoclerodane diterpene activity at 
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a subclass of opioid receptors has lead to investigations aimed to further the understanding of 
structure-activity relationships and pharmacology of salvinorin A.  Initial studies have shown 
that modification to salvinorin A’s scaffold resulted in the identification of compounds that are 
tolerated at opioid receptors and had altered pharmacological profiles.  Continued structural 
modification of salvinorin A will identify new analogues with diverse biological activity and 
more desirable pharmacological properties.  The following specific aims are proposed to increase 
our knowledge of the chemistry and pharmacology of salvinorin A.   
 
Specific Aim #1: Prepare and evaluate C-13 salvinorin A analogues with reduced potential 
for hepatoxicity.  
The furan ring of salvinorin A is a concern due to its potential for hepatoxicity.  The 
metabolism of the furan ring in structurally similar neoclerodane diterpenes has been linked to 
hepatoxicity.  Modifications of the furan ring present in salvinorin A will further elucidate the 
importance the furan ring plays in binding and activity at opioid receptors while identifying 
compounds with a more desirable pharmacological profile.  A series of amide, amine, ketone, 
and oxime derivatives will be synthesized as structural replacements to the furan ring in attempts 
to limit potential toxicity and improve pharmacokinetic properties.  Additionally, the strategic 
addition of steric bulk and investigation into key hydrogen bonding interactions at the binding 
site of salvinorin A at KOP receptors will result in further elucidation of its KOP receptor 
binding site.  These modifications are intended to show that alteration of the furan ring of 
salvinorin A is tolerated for KOP receptor binding and modifications at this position have the 
potential to modulate opioid subtype selectivity.   
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Specific Aim #2:  Investigate Captisol® as a method to improve the solubility of salvinorin 
A in aqueous solution.   
Neoclerodanes such as salvinorin A have poor solubility in aqueous media due to their 
lipophilic nature, which causes difficulty in in vitro and in vivo pharmacological investigations.  
Current vehicles used to improve the solubility of salvinorin A and related analogues in water or 
saline include either DMSO or ethanol.  Both DMSO and ethanol have been associated with 
opioid mediated effects making their use in opioid receptor pharmacology less than 
ideal.270,304,305  Investigation into the potential use of Captisol® as a vehicle for salvinorin A 
delivery will be investigated.  -Cyclodextrins, such as Captisol®, have been successfully 
utilized as a vehicle for the delivery of diterpene taxol and have the potential to assist in 
solubilizing neoclerodane diterpenes such as salvinorin A.306,307 
Completion of these specific aims is intended to improve the pharmacological profile of 
salvinorin A through structural modifications and formulation.  Synthetic modifications are 
intended to exploit salvinorin A as a lead molecule.  These modifications are intended to improve 
the pharmacokinetic properties of salvinorin A with the focus to increase metabolic stability.  
Rational design of salvinorin A derivatives will identify novel and biologically relevant 
salvinorin A analogues with the potential to be used as opioid receptor probes.  Investigation into 
a novel vehicle for neoclerodane administration also will be completed.  These studies will focus 
on enhancing the solubility of salvinorin A while taking into consideration the drawbacks of 
current vehicles.  The results of these studies will be discussed herein. 
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CHAPTER IV. RESULTS AND DISCUSSION 
Introduction 
In efforts to further elucidate the pharmacophore and structure-activity relationships of 
salvinorin A at opioid receptors, furan modified salvinorin A analogues were synthesized.  
Compounds were intended to limit the potential hepatoxicity associated with the furan ring and 
to investigate the structural requirements for activity at this position.  Several series were 
synthesized replacing the furan ring including amide, amine, ketone, and oxime derivatives 
(Figure 18).  Initially, a series of amide derivatives were synthesized replacing the furan ring.  
Incorporation of the amide was an attempt to retain a potential hydrogen bond interaction of the 
furan ring by replacement with the carbonyl, to identify a new interaction in the binding pocket 
with the various amide substituents, and to increase water solubility of the analogues.  Reduction 
of the amide was investigated to determine the importance of the carbonyl in hydrogen bonding, 
the effect of introducing a basic amine, and as a potential solution to improve water solubility.  A 
series of ketone derivatives were also synthesized based on similar rationale to the amide series.  
The intention was to identify a more desirable hydrogen bond interaction with the carbonyl and 
its KOP receptor binding site while accessing another interaction reliant on the ketone 
substituent.  Initially, phenyl ketone derivatives were synthesized that included substitutions at 
the ortho, meta, and para positions with the electron donating and hydrogen bond accepting 
methoxy group and the electron donating and hydrogen bond donating hydroxyl group.  These 
derivatives were proposed to investigate the hydrogen bonding, electronic, and steric effects of 
phenyl substitutions.   
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Figure 18: Design Rationale 
 
Additionally, several of the ketone derivatives showed promise as intermediates for other 
desired analogues of significant importance.  For example, a ketone alkene derivative showed 
potential to achieve the 2-furanyl analogue of salvinorin A, which is of great interest to elucidate 
the ideal positioning of the oxygen of the furan ring and its requirement for activity at KOP 
receptors.  The 2-hydroxyphenyl ketone analogue had the promise to be an intermediate for a 
benzisoxazole derivative, which is highly sought after to further understand the steric restraints 
and hydrophobic nature of the furan binding pocket by the introduction of a benzene ring while 
retaining the oxygen position as the furan ring.  Synthesis of the benzisoxazole analogue then 
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lead to the use of ketone derivatives to synthesize several oxime derivatives to further investigate 
the structural requirements to modulate subtype selectively at opioid receptor. 
Analogues were then evaluated for affinity at the different opioid receptor subtypes using 
radioligand displacement assays.  Compounds that displayed high affinity, a Ki value of 
approximately 150 nM or lower, were then further evaluated for efficacy at the specified opioid 
receptor subtype.  Included herein is the synthesis of analogues along with the in vitro 
pharmacological results of select compounds.   
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Scheme 1: Synthesis of Amide Derivatives. Reagents and Conditions: a) NaIO4, RuCl3·3H2O, 
CH3CN/CCl4/H2O; b) NR2, EDCI, HOBt, Et3N, CH2Cl2 
 
Amide derivatives were synthesized through carboxylic acid 75.  As previously reported, 
salvinorin A was reacted with NaIO4 and a catalytic amount of RuCl3·3H2O in 
CH3CN/H2O/CCl4 (2:2:3) to afford carboxylic acid 75 in 74% yield.
290  Carboxylic acid 75 was 
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then used to synthesize a series of amide derivatives by addition of the appropriate aniline or 
alkylamine, EDCI, HOBt, and Et3N in anhydrous CH2Cl2 at room temperature for 24 hours (89, 
100 – 102, 159 – 161).292  Yields of all amide derivatives synthesized ranged from 21 – 45%. 
 
 
Scheme 2: Synthesis of Amine Derivatives. Reagents and Conditions: a) CDMT, NMM, EtSH, CH2Cl2; b) Pd/C, 
Et3SiH, CH2Cl2; c) HNR2, NaBH(OAc)3, DCE 
 
Amines were synthesized utilizing reductive amination conditions once the C-13 
aldehyde was in hand.  Reductive amination was used to circumvent difficulties and degradation 
products resulting from the functionality of the salvinorin A core.  To synthesize the desired 
aldehyde, carboxylic acid 75 was exposed to CDMT and N-methylmorpholine in anhydrous THF 
followed by the addition of ethanethiol at room temperature for 48 hours to afford thioester 134 
in 88% yield.286,292  Thioester 134 was then reacted with 10% palladium on carbon and Et3SiH in 
anhydrous CH2Cl2 and stirred at room temperature over night to yield aldehyde 135 in 82% 
yield.292  Aldehyde 135 was then exposed to the appropriate amine, sodium 
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triacetoxyborohydride, in 1,2-dichloroethane and stirred at room temperature overnight.  Desired 
amines 162 – 165 were achieved ranging from 12 – 70% yield.   
 
 
Scheme 3: Synthesis of Ketone Derivatives. Reagents and Conditions: a) CDMT, NMM, HSPh, CH2Cl2; b) 
RB(OH)2,CuTC, Pd(dba)2, PEt3, THF 
 
A series of ketone derivatives were also synthesized.  Many different methodologies of 
carbon-carbon bond forming reactions are known in scientific literature.  However, many of 
these methods are not amenable to substrates with high functionality along with acid and base 
sensitivity of salvinorin A.  Asymmetric allylation of aldehyde 135 was achieved in 50% yield 
with B-allyl-(10S)-(trimethylsilyl)-9-borabicyclo[3.3.2]decane (prepared in situ from 9-[(1R,2R)-
pseudoephedrinyl]-(10S)-(trimethylsilyl)-9-borabicyclo[3.3.2]-decane and allylmagnesium 
bromide).292  Attempts to perform Grignard reactions using aldehyde 135 were met with limited 
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success due to poor solubility of 135 in THF and ether at low temperatures resulting in low 
yields (0 – 20%).308  Béguin and coworkers were able to synthesize several ketone derivatives 
through in situ formation of the acid chloride followed by coupling stannanes via Stille coupling 
in low to moderate yields (7 – 57%).286  This procedure is also limited by the commercial 
availability and toxicity of stannane reagents.  
 
 
Scheme 4: Synthesis of 2-Furanyl Salvinorin A. Reagents and Conditions: a) SeO2, 
bromobenzene, reflux 
 
The structural complexity of salvinorin A limits traditional approaches to chemical 
transformations to be performed on salvinorin A.294  To overcome these challenges, investigation 
into the Liebeskind-Srogl reaction was investigated.  The Liebeskind-Srogl reaction is a 
palladium catalyzed cross-coupling reaction between a thiophenol ester and boronic acid 
requiring a stoichometric amount of copper (I) additive.309,310  The Liebeskind-Srogl reaction 
occurs at neutral pH and room temperature and had previously been utilized on base sensitive 
substrates.311,312  Additionally, an increasing number of boronic acid are commercially available, 
which further contributes to the convenience of analogue development.  With promising 
credentials, the thiophenol ester at the C-13 position was synthesized using the same CDMT and 
N-methylmorpholine previously developed with substitution of ethanethiol for thiophenol.  
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Thioester 166 was synthesized in 47% yield.  Using bis(dibenzylideneacetone)palladium (0), 
copper (I) thiophene carboxylate, and triethyl phosphate in anhydrous THF, coupling of thioester 
166 and desired boronic acids synthesized ketone derivatives 116, 117, 119, 167 – 187 in 23 – 
87% yields.311     
The 2-furanyl analogue of salvinorin A was of great interest to elucidate the ideal 
positioning of the oxygen of the furan ring and its requirement for activity at KOP receptors.  To 
access this compound, ketone analogue 184 was refluxed with Se2O in bromobenzene.
313  The 
initial thought was to isolate the dicarbonyl and use previously developed conditions to cyclize to 
the 2-furan in a two-step procedure.314  Fortuitously, cyclization also occurred under oxidative 
conditions to afford analogue 185 in 18% yield from 184. 
 
 
Scheme 5: Synthesis of Benzisoxazole Derivative. Reagents and Conditions: a) hydroxylamine hydrochloride, 
pyridine, MeOH; b) DIPEA, MsCl, isopropyl acetate, 55°C 
 
A benzisoxazole analogue of salvinorin A was also desired to further understand the 
steric restraints and hydrophobic nature of the furan binding pocket by the introduction of a 
benzene ring while retaining the oxygen position as the furan ring.  This was achieved by 
dissolving ketone derivative 170 in MeOH followed by the addition of hydroxylamine 
hydrochloride and pyridine under gentle reflux.  Both the E and Z hydroxylamines were formed 
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and the Z hydroxylamine was isolated in 41% yield and utilized.  Hydroxylamine 186 was 
mesylated using methanesulfonyl chloride and diisopropylethylamine in isopropyl acetate at 
55°C, which cyclized in situ to yield the benzisoxazole 187 in 35% yield. 
After knowing how the benzisoxazole altered affinity at KOP receptors, several oxime 
derivatives were synthesized to further investigate the potential to modulate subtype selectively 
at opioid receptors.  Ketone derivatives 119, 177, and 117 were chosen due to their affinity at 
KOP and MOP receptors in effort to identify structure requirements of opioid subtype selectivity.  
Oxime derivatives were synthesized using the previously mentioned conditions of 
hydroxylamine hydrochloride and pyridine under gentle reflux in MeOH.  Both the E and Z 
hydroxylamines 188 – 190 were formed in yields ranging from 53 – 69%.  Receptor binding 
studies were performed as a mixture of E and Z isomers.  
 
 
Scheme 6: Synthesis of Oxime Derivatives. Reagents and Conditions: a) H2NOH·HCl, pyridine, MeOH, 
65°C 
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Affinity and Activity Studies 
Amide Affinity 
Based on the hypothesis that retention of the hydrogen bonding interaction could be 
maintained by the carbonyl and that the phenyl substituent would be able to participate in 
hydrophobic interactions comparable to the aromatic furan ring of salvinorin A, aniline 
derivative 90 was synthesized.  This modification was not tolerated and affinity at KOP opioid 
receptors was lost (Ki > 10,000 nM) (Table 1).  In efforts to limit the free rotation of the phenyl 
ring, the conformationally constrained indoline derivative 100 was synthesized but did not 
enhance affinity at opioid receptors (Ki > 10,000 nM).  Several other aromatic amides were 
synthesized, including those with hydrogen bond accepting groups, which were not tolerated for 
affinity in the amide series.292  Explorations of non-aromatic amides were then pursued based on 
the hypothesis that the aromatic ring was responsible in the loss of affinity.  Initially, the 
cyclohexylamide (101) and cyclopentylamide (102) were synthesized to find that these saturated 
systems resulted in a greater than a 10-fold and 5-fold increase in affinity at KOP receptors 
relative to amide 90 (Ki = 1,930 ± 220 nM and Ki = 4,060 ± 280 nM vs. Ki > 10,000 nM).  With 
the resulting increase in affinity for cyclohexylamide 101 and cyclopentylamide 102 derivatives, 
additional analogues were synthesized to evaluate non-aromatic substitutions.  Piperidine and 
pyrrolidine amides were synthesized as contracted analogues and were found to have increased 
affinity of 14-fold and 1.6-fold compared to the cyclohexylamide 101, respectively (Ki = 140 ± 
10 nM and Ki = 1,210 ± 80 nM vs. Ki = 1,930 ± 220 nM).  Due to the increase in affinity seen 
with the piperidine derivative, bioisosteric replacements of the piperidine ring were explored.  
Substitution of piperazine (159) and N-methylpiperazine (160) resulted in loss of affinity at KOP 
receptors while introduction of either a morpholine or a thiomorpholine ring were well tolerated 
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but did not increase affinity at KOP receptors (Ki = 230 ± 20 nM and Ki = 160 ± 10 nM, 
respectively).  Anilide 161 was synthesized based on the success of Frankowski and coworkers 
with the identification of N-alkyl-octahydroisoquinolin-1-one-8-carboxamides as a nonbasic 
KOP opioid receptor ligand.315  Several of their most promising analogues contained a 4-chloro-
3-trifluoromethylphenyl moiety, which was incorporated into salvinorin A analogue 161.  This 
modification did not significantly increase affinity relative to other aromatic amide derivatives 
(Ki = 3,600 ± 300 nM).  The affinity of this agent was not similar to the N-alkyl-
octahydroisoquinolin-1-one-8-carboxamides synthesized by Frankowski and coworkers 
suggesting that their analogues are not binding in an identical manner to the neoclerodanes.   
 
Table 1 Opioid receptor binding affinity for amide 
and amine derivatives 
 Ki ± SD, nM 
Cmpd 
[3H]DAMGO 
(MOP) 
[3H]DADLE 
(DOP) 
[3H]U69,593 
(KOP) 
51a 1370 ± 130 >10,000 7.4 ± 0.7 
90a  >2,800 >4,700 >10,000 
100a >2,800 >4,700 >10,000 
101a >2,800 >4,700 1,930 ± 220 
102a >2,800 >4,700 4,060 ± 280 
159a >10,000 >10,000 >10,000 
160a >10,000 >10,000 >10,000 
161b >10,000 >10,000 3600 ± 300 
162a >2,800 >4,700 410 ± 50 
163a >3,400 >5,200 510 ± 40  
164a >3,000 >5,000 300 ± 20 
165a >3,000 >5,000 560 ± 30 
51 = Salvinorin A 
a Receptor binding was performed in CHO cells 
which express the human MOP, DOP or KOP 
receptors. All results are n = 3. 
b Results are n = 1, with sextuplet determinations and 
are based on inhibition of the 3H-ligand by 1 µM of 
the test compound 
 
 
79 
 
Amine Affinity 
The effects of removing the carbonyl of the amide were investigated by reductive 
amination of aldehyde 135.  Selected amine derivatives were synthesized based on the affinities 
of their amide equivalent.  First to be synthesized was aniline derivative 162.  Unexpectedly, 162 
had a 25-fold increase in affinity evaluated against anilinoamide deriviate 90 (162: Ki = 410 ± 50 
nM vs. 90: Ki >10,000 nM) (Table 1).  Efforts to increase the affinity of the amine were explored 
by modulating the basicity of the amine by introducing a fluorine in the para and meta position 
of the aromatic ring (163, 164).  Introduction of the fluorine substituent did not lead to 
significant changes in affinity (Ki = 510 ± 40 nM and Ki = 300 ± 20 nM, respectively).  
Additionally, the reduced morpholine amide (165) was synthesized to find a 2-fold loss of 
affinity (Ki = 560 ± 30 nM vs. Ki = 230 ± 20 nM).  No further amine derivatives were 
synthesized due to the lack of high affinity for KOP receptors. 
 
Ketone Affinity 
With a similar hypothesis as the amide series ketone derivatives were synthesized with 
the expectations to retain a hydrogen bond interaction with the KOP receptor through the 
carbonyl of the ketone as well as maintain an aromatic interaction comparable to the furan ring 
of salvinorin A.  Investigations started by synthesis of the phenyl ketone derivative in efforts to 
retain hydrogen bond accepting interaction through the carbonyl and hydrophobic interaction 
through the phenyl ring.  Analogue 119 had roughly a 10-fold decrease in binding affinity at 
KOP receptors relative to salvinorin A (Ki = 68 ± 3 nM vs. Ki = 7.4 ± 0.7 nM) (Table 2).  The 
difference in affinity between phenyl ketone analogue 119 and phenyl amide 90 is not readily 
apparent (Ki = 68 ± 3 nM vs. Ki > 10,000 nM) but could be due to the different electronic 
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characteristics of the carbonyl, different positioning of the phenyl ring in each derivative as a 
result as the sp2 character of the amide bond, or size constraints of the KOP receptor binding  
 
Table 2 Opioid receptor binding affinity for ketone 
derivatives  
 Ki ± SD, nM 
Cmpd 
[3H]DAMGO 
(MOP) 
[3H]DADLE 
(DOP) 
[3H]U69,593 
(KOP) 
51 a 1370 ± 130 > 10,000 7.4 ± 0.7 
119 a 1,490 ± 160 > 5,200 68 ± 3 
167 a > 14,000 > 5,200 1,070 ± 80 
168 a 3,090 ± 260 > 5,200 290 ± 10 
169 a > 3,400 > 5,200 > 10,000 
170 a 3,600 ± 40 > 5,000 500 ± 20 
171 a > 2,700 > 5,200 110 ± 5  
172 a > 3,000 > 5,000 8,470 ± 900 
173 6000 ± 700 a > 10,000b 1010 ± 50 a 
174b 4100 ± 150 > 10,000 2800 ± 150 
175 12300 ± 1300 b > 5,000b 40 ± 1 a 
176b 3650 ± 360 > 5,000 220 ± 10 a 
177 4800 ± 400 a 2800 ± 200 b 9700 ± 800 b 
178  3400 ± 150 a 4000 ± 350 b 2500 ± 300 b 
116 a > 3,200 > 5,000 81 ± 4 
179a > 2,700 > 5,200 150 ± 10 
117 a > 8,600 > 5,000 36 ± 2 
180a 2,530 ± 250 > 5,000 31 ± 3 
181c > 2,500 ND d > 8,700 
182a > 7,700 > 5,000 9,210 ± 680 
183b 3500 ± 300 > 5,000 1500 ± 1800 
184a > 1,700 > 5,000 320 ± 20 
a Receptor binding was performed in CHO cells which 
express the human MOP, DOP or KOP receptors. All results 
are n = 3. 
b Results are n = 1, with sextuplet determinations and are 
based on inhibition of the 3H-ligand by 1 µM of the test 
compound 
c Receptor binding was performed in CHO cells which 
express the human MOP or KOP receptors. Results are n = 
1. 
d ND = Not Determined 
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pocket exploited through the additional presence of the nitrogen.  Phenylketone 119 was 
previously synthesized by Béguin and coworkers, however in their hands 119 had a Ki > 1,000 
nM.286 
Focusing on our affinity results and the ability of 119 to retain less than 100 nM affinity 
at KOP receptors and the potential of this scaffold to have greater metabolic stability than furan 
containing salvinorin A, investigations into substitutions at the ortho, meta, and para positions 
were completed with the electron donating and hydrogen bond accepting methoxy group (167 – 
169) and the electron donating and hydrogen bond donating hydroxyl group (170 – 172).  These 
substitutions were not tolerated at the ortho or para positions.  Meta substitution of the methoxy 
group (168) and the hydroxyl group (171) resulted in affinity of 290 ± 10 nM and 110 ± 5 nM, 
respectively.  Therefore, further exploration of meta substituted phenyl ketones were continued.  
Specific interest was to synthesize a carboxamide derivative due to the past successes of 
Wentland and coworkers who unexpectedly identified high affinity at opioid receptors when the 
8-position hydroxyl of cyclazocine (54) (Figure 10) was substituted with a carboxamido 
group.316,317  Hoping an observation in past opioid pharmacology held true in the ketone series of 
compounds as well, carboxamido analogue 175 was synthesized.  Carboxamide (175) had a Ki 
value of 40 ± 1 nM.  The addition of a cyano moiety in the meta position of the phenyl ring (176) 
decreased affinity relative to 119 (176: Ki = 220 ± 10
 nM vs. 119: Ki = 68 ± 3 nM).  Further 
exploration of substation at the meta position with the addition of electron donating groups such 
as trifluoromethoxy (177) and trifluoromethyl (178) resulted in a substantial loss in affinity at 
KOP receptors indicating that the decrease in electron density of the phenyl ring is not tolerated 
(177: Ki = 9700 ± 800 nM and 178: Ki = 2500 ± 300 nM).  
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Additionally, the effects of introducing heteroaromatic groups as replacements for the 
phenyl ring were investigated.  Introduction of the 2-furan (116) and 3-furan (179) ketone probed 
the optimal interaction with the furan ring and the binding pocket.  Bioisosteric substitution of 
the phenyl ketone with the 2-thiophene (117) and 3-thiophene (180) was well tolerated and 
increased affinity at KOP receptors comparable to the phenyl ketone derivative (117: Ki = 36 ± 2 
nM, 180: Ki = 31 ± 3 nM vs. 119: Ki = 68 ± 3 nM).  Béguin et al. had also previously synthesized 
116 and 117 and reported a Ki > 1,000 nM for 116 and similar affinity with our results for 117 
(Ki = 38 ± 10 nM).
286  With our successful introduction of heteroaromatic substituents, the size 
tolerated at the C-13 position was examined through synthesis of the 2-benzofuran (181), 2-
benzothiophene (182), and 3-benzothiophene (183) analogues.  The introduction of steric bulk 
associated with the additional aromatic ring was not tolerated at KOP receptors (182: Ki = 9,210 
± 680 nM and 183: Ki = 1500 ± 1800 nM).  Alkene 184 was also synthesized to investigate the 
scope of the Liebeskind-Srogl reaction and to probe the requirement of an aromatic ketone 
substituent for affinity at KOP receptors.  Alkene 184 showed 44-fold loss in affinity relative to 
salvinorin A (Ki = 320 ± 20 nM).   
Table 3 Opioid receptor binding for furan derivatives 
 Ki ± SD, nM 
Cmpd 
[3H]DAMGO 
(MOP) 
[3H]DADLE 
(DOP) 
[3H]U69,593 
(KOP) 
51a 1370 ± 130 > 10,000 7.4 ± 0.7 
185b 1400 ± 3 b > 10,000 b 8.7 ± 0.4 a 
187b 470 ± 20 a > 10,000 450 ± 220 b 
188b > 10,000 > 10,000 1740 ± 5 
189b 1300 ± 10 1700 ± 4 > 10,000 
190b 230 ± 5 670 ± 10 44 ± 0.3 
a Receptor binding was performed in CHO cells 
which express the human MOP, DOP or KOP 
receptors. All results are n = 3. 
b Results are n = 1, with sextuplet determinations and 
are based on inhibition of the 3H-ligand by 1 µM of 
the test compound 
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Additional Affinity Studies 
The ideal positioning of a possible hydrogen bond with the oxygen in the furan ring of 
salvinorin A and the KOP receptor was investigated by changing the position of the oxygen in 
the furan ring (185) (Table 3).  Radioligand binding studies indicate that 185 has a Ki = 8.7 ± 0.4 
nM affinity at KOP receptors (Table 3), which is comparable to the affinity of salvinorin A at 
KOP receptors.  Further investigations into this compound are currently underway. 
Benzisoxazole 187 was synthesized in efforts to probe the steric limitations of the KOP 
opioid receptor binding site and it was found that 187 lost affinity at KOP receptors while 
increasing affinity at MOP receptors relative to salvinorin A (Ki = 470 ± 20 nM).  These finding 
suggest that 187 is either binding to a different binding site or that the introduction of steric bulk 
at this position is not well tolerated at KOP receptors.  However, the MOP receptor binding site 
is able to accommodate the introduction the hydrophobic aromatic ring present in derivative 187.  
The hypothesis that KOP receptors cannot tolerate steric bulk when introduced at this manner is 
also seen with some of the ketone analogues (181 – 183).   
With the increase in affinity observed for analogue 187 at MOP receptors, studies were 
completed to determine the effects of introducing an oxime at the ketone position (188 – 190).  
Thus, to determine if the introduction of an oxime could modulate opioid receptor subtype 
selectivity, several oxime derivatives were synthesized.  Preliminary affinity studies of 188 
identified that the introduction of an oxime in this compound resulted in loss of affinity for both 
KOP and MOP receptors compared to its ketone derivative while 189 increased affinity 4-fold 
relative to its ketone equivalent.  Oxime 190 retained affinity at KOP receptors and increased 
affinity at MOP receptors relative to its corresponding ketone analogue 117 (190: KOP: Ki = 44 
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± 0.30 nM and MOP: Ki = 230 ± 4 nM vs. 117: KOP Ki = 36 ± 2 nM and MOP: Ki > 8,600 nM).  
Pharmacological evaluation of the separated E and Z isomers is currently ongoing.   
 
Selected Efficacy Results 
Efficacy studies were completed using the [35S]GTPS assay and the fluorometric 
imaging plate reader (FLIPR) assay.  The [35S]GTPS assay measures efficacy by measuring G 
protein activation followed by ligand binding to the GPCR.318  Efficacy is measured by 
analyzing of the binding of non-hydrolyzable [35S]GTPS to G subunits.318  The FLIPR assay 
utilizes chimeric G proteins to measure changes in intracellular calcium with fluorescent calcium 
sensitive dyes.319  Human G16 is one of the most promiscuous G proteins in relation to its 
number of GPCRs interactions.  Upon agonist binding, G16 stimulates phospholipase Cβ 
activation through the Gq pathway resulting in calcium mobilization, which is then measured 
with fluorescent calcium sensitive dyes using the flourometric imaging plate reader.319,320  
Opioid receptors are intrinsically Gi-coupled therefore each opioid receptor is cotransfected with 
G16 in CHO cells to stimulate the Gq pathway.320  
In the GTPS assay, phenyl ketone 119 shows a promising pharmacological profile as a partial 
agonist but results in a significant decrease in activity relative to salvinorin A  (ED50 = 2,280 ± 
550 nM, Emax = 74 ± 6% relative to U50,488) (Table 4).  Analogue 176 also was shown to be a 
partial agonist with significant loss in activity relative to salvinorin A at KOP receptors in the 
FLIPR assay (ED50 = 1100 ± 380 nM, Emax = 78 ± 5% relative to U69,593) (Table 5).  
Derivatives 116, 117, 175 and 180 are full agonists in the GTPS assay with significant loss in 
activity relative to salvinorin A with the most potent analogue being 175 which has an 18-fold 
loss in efficacy relative to salvinorin A.  In the FLIPR assay, cyanoketone analogue 175 showed 
 
85 
 
a 12-fold loss in activity relative to salvinorin A in the FLIPR assay (175: ED50 = 75.4 ± 21 nM, 
Emax = 97 ± 2% vs. 51: ED50 = 6.11 ± 0.04 nM, Emax = 97 ± 5%, relative to U69,593).  Of all 
derivatives tested for activity, the most promising analogue was 2-furanyl salvinorin A (185) 
which had an EC50 of 138 ± 11 nM and an Emax of 104 ± 2% relative to U50,488 in the GTPS 
assay and an EC50 = 12.2 ± 4.4 nM and an Emax = 97 ± 8% relative to U69,593 in the FLIPR 
assay.  Analogue 185 identifies the potential to synthesize compounds with varying connectivity 
relative to salvinorin A while still retaining high affinity and efficacy.   
 
Table 4 Opioid receptor activity 
measured in the [35S]GTPS assay 
Cmpd 
KOP  
ED50 ± SD
a 
KOP  
Emax ± SD
b 
51 40 ± 6 124 ± 6 
119 2,280 ± 550 74 ± 6 
116 2,860 ± 700 94 ± 8 
117 1,630 ± 230 95 ± 4 
175 730 ± 90 92 ± 4 
180 620 ± 50 88 ± 2 
185 140 ± 10 104 ± 2 
aED50 = Effective dose for 50% 
maximal response.  
bEmax is % which compound 
stimulates binding compared to (-)-
U50,488 (500 nM) at KOP receptors. 
n  = 3 
 
The initial binding model proposed by Roth and coworkers of the KOP receptor binding 
site and salvinorin A has continued to be revised.137  The exact interactions of salvinorin A and 
the KOP receptor still is not known due to the lack of KOP receptor-salvinorin A co-crystal 
structure.  Elucidation of the interactions of salvinorin A and the KOP receptor have been 
attempted through molecular modeling, site-directed mutagenesis, chimeric receptor synthesis, 
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and SAR studies.267-269  Furan analogues synthesized through these studies have assisted in 
explaining how the furan substituent of salvinorin A influences affinity and activity at the KOP 
receptor binding site.  Focusing on the furan interactions with the KOP receptor binding site, 
 
Table 5 Opioid receptor activity measured 
in the FLIPR assay 
Cmpd 
KOP  
ED50 ± SD
a 
KOP  
Emax ± SD
b% 
U69,593 c 12.5 ± 5.4 100 
51d 6.11 ± 0.04 97 ± 5 
175c 75.4 ± 21 97 ± 2 
176c 1100 ± 380 78 ± 5 
185c 12.2 ± 4.4 97 ± 8 
aED50 = Effective dose for 50% maximal 
response.  
bEmax is % which compound stimulates 
binding compared to (-)-U69,593 at KOP 
receptors. 
cN = 3 
dN = 2 
 
Yan and et al. identified the importance of Y320 and Y119 by site-directed mutagenesis of 
Y320A, Y320F, Y119A, and Y119F that resulted in loss of affinity.269  Due to the loss of affinity 
of these substitutions it was hypothesized that Y320 and Y119 were stabilizing the furan ring of 
salvinorin A through hydrogen bonding interactions with the furanyl oxygen.  However, a 
computational model proposed by Singh and coworkers implicated that a direct hydrogen bond 
was not formed with the furanyl oxygen.321  2-Furanyl salvinorin A (175) was able to retain 
affinity at KOP receptors relative to salvinorin A, which supports Singh and coworkers findings 
that the furan ring of salvinorin A interacts with KOP receptors through hydrophobic interactions 
and not a hydrogen bond (175: Ki = 8.7± nM vs. 51: Ki = 7.4 ± 0.7 nM).  Moving the furanyl 
oxygen did not alter affinity and activity at KOP receptors implicating that the oxygen does not 
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directly interact with the KOP receptor binding site.  This identifies a new scaffold for 
modification in the efforts to further elucidate the KOP receptor binding site and more 
efficacious salvinorin A analogues.  Additionally, the loss in affinity seen with the majority of 
ketone analogues shows the importance in the positioning of the aromatic group.  Homologation 
through introduction of the carbonyl functionality generally decreases affinity relative to 
salvinorin A, which could result from the change in connectivity from the salvinorin A core and 
the aromatic substituent.  These observations further corroborate that the furan ring is acting 
through aromatic interactions and not directly through hydrogen bonding.  Additional ligand 
based models are required to further understand salvinorin A binding at KOP receptors.   
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Salvinorin A and Solubility 
 As a neoclerodane diterpene, salvinorin A is highly lipophilic and consequently has poor 
solubility in aqueous solvents.  To assist in solubility, vehicles are utilized, which have the 
potential to modulate bioavailability and toxicity.302  Therefore, choice of vehicle can alter the 
biological data of an assay, especially if the vehicle causes measurable effects.  Currently, a 
number of vehicle formulations ranging from Tween-80:ethanol:saline (1:1:8) to DMSO:H2O 
(3:1) are used to solubilize salvinorin A.244,259  Use of these vehicles is less than ideal due to the 
known effects of DMSO and ethanol in analgesia.270,304,305  DMSO, being an amphipathic 
molecule, is efficient for use as a solvent for compounds with poor water solubility.322  However, 
DMSO causes a number of effects on its own and can lead to incorrect data interpretation.  
Specifically of interest in opioid receptor pharmacology is the ability of DMSO at high doses of 
i.v. or i.p. administration to cause in significant analgesia in both the hot-plate and tail flick tests 
in both local and systemic manners.304  Additionally, ethanol has been showed to potentiate the 
inhibitory effects of endogenous opioids at concentrations as low as 0.1%.305  Ethanol also 
appears to enhance the action of endogenous opioids by inhibiting substance P release.305  
Identification of a new vehicle to assist in salvinorin A solubility is needed without potential 
pharmacological interactions at opioid receptors.  A new vehicle could also lead to the 
deconvolution pharmacological findings.  Therefore, investigation in to the potential use of 
Captisol® as a vehicle for salvinorin A was completed. 
Captisol® is a modified -cyclodextrin (-CD) known also as (SBE)7m--CD.  SBE refers 
to sulfobutyl ether substitutions variably substituted at the 2-, 3-, and 6- position of -CD while 7 
refers to the average degree of subsitution.323  -Cyclodextrins are cyclic oligosaccharides linked 
through 1,4 glycosidic bonds into a macrocycle resulting in a cone-like structure.324  They have a 
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hydrophobic interior that encapsulates lipophilic drugs and a hydrophilic exterior that increases 
aqueous solubility through the formation of inclusion complexes through non-covalent 
interactions.324-326  Complexation of the cyclodextrin and the drug molecule is a dynamic process 
that results in rapid and quantitative release, which is not a limiting factor.326  Cylcodextrins have 
shown considerable potential as a drug carrying agents and the ability to assist with dosage 
formulation.325  However, the use of -CD itself is limited due to its solubility problems along 
with associated renal toxicity.327  As a result, many -CD derivatives have been synthesized with 
improved aqueous solubility and toxicity profiles.  Two of the most pharmacologically relevant 
derivatives meeting the standards for high quality and safety are (SBE)7m--CD (Captisol®) and 
hydroxypropyl--CD (HP).327-332 
-CD derivatives have been investigated as a solubilizing agent for paclitaxel due to side-
effects cause by its formulation with Cremophor EL®.307,324  Successful formulation was found to 
include paclitaxel with RAME--CD (randomly methylated).324  Paclitaxel is a diterpene which 
has poor aqueous solubility, P-gp efflux, and cytochrome P450 metabolism, like salvinorin A.306  
Testosterone has also been evaluated with (SBE)7m--CD and HP--CD to act as a solubilizing 
and an osmotic pump agent.323  Testosterone was chosen as a model drug due to its poor water 
solubility and (SBE)7m--CD was found to increase the solubility approximately 70% greater 
than HP--CD.  Prednisolone, another poorly water-soluble drug, has also been formulated with 
(SBE)7m--CD and showed controlled and complete drug release.333  Melphalan, carmustine, and 
etomidate have all been effectively formulated with Captisol®.327,334  With the successes of 
Captisol® as a solubilizing agent for a number of known therapeutics along with poorly water-
soluble compounds, we investigated its ability to assist in salvinorin A solubility.   
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In preliminary studies, an excess of salvinorin A was added to solutions of Captisol® at 
concentration of 0.5, 1.0, 1.5, 2.0 and 2.5 M in sterile water.  Excess salvinorin A was added into 
duplicate 2 mL screw cap vials which contained approximately 1 mL of the Captisol® solution.  
The vials were sonicated for 72 hours and then set at room temperature for 24 hours.  Vials were 
then centrifuged at 7700 rpm for 10 minutes and the supernatant was passed through 0.45 µm 
nylon non-sterile Fisherbrand® syringe filters and immediately analyzed by HPLC without 
diluting (column: Phenomenex Luna C18 (250 × 4.5 mm, 5 µm); mobile phase: 60% 
CH3CN:40% H2O; flow rate: 5.00 mL/min; injection volume: 100 µL).  Wavelengths 209.4 nm 
and 214.06 nm were both evaluated.    
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Figure 19: (A) Calibration Curve of Salvinorin A; (B) Effect of Concentration of Captisol® on Solubility of 
Salvinorin A  
 
The amount of salvinorin A was calculated from the peak area of the salvinorin A 
standard curve under the same HPLC conditions as described (Figure 19).  The solubility of 
salvinorin significantly increased with increasing concentrations of Captisol®.  The effects of 
different concentrations of Captisol® on the solubility of salvinorin A are summarized in Table 6 
as fold increased relative to salvinorin A in sterile water.  The solubility of salvinorin A was 
 
91 
 
highest with the greatest concentration of Captisol®.  Use of 2.5 M Captisol® was found to 
increase the aqueous solubility of salvinorin A approximately 50-fold. 
 
Table 6 Increase in Solubility of Salvinorin A with varying amounts of 
Captisol® 
Captisol® 
(M) 
Salvinorin A (mg/mL ± SD) Fold Increase 
209.4 nm 214.06 nm 209.4 nm 214.06 nm 
0.25 0.504 ± 0.0287 0.510 ± 0.0291 39 59 
0.206 0.406 ± 0.0135 0.406 ± 0.0186 32 47 
0.151 0.326 ± 0.0312 0.324 ± 0.0291 25 37 
0.102 0.245 ± 0.0108 0.239 ± 0.0130 19  28 
0.0500 0.101 ± 0.0212 0.0973 ± 0.0223 8.0 11 
 
Increasing concentrations of Captisol® in sterile water increased the solubility of 
salvinorin A, which identifies a new vehicle for salvinorin A delivery.  One of the most used 
formulations to assist with salvinorin A solubility in in vivo studies is the mixture of Tween-
80:ethanol:saline (1:1:8).  This vehicle cocktail still uses ethanol, which is unsatisfactory given 
its known opioid effects.305  Even with the use of ethanol, only 0.2 mg/mL of salvinorin A is able 
to be solubilized in solution.308  By using Captisol® we were able to successfully solubilized 0.5 
mg/mL of salvinorin A in sterile water with the potential to limit the negative effects of currently 
known vehicles.  Thus, we have identified Captisol® as a solubilizing agent to assist in the 
pharmacological evaluation of salvinorin A and salvinorin A derivatives.  
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CHAPTER V. CONCLUSIONS 
Furan derivatives of salvinorin A were synthesized to further elucidate the 
pharmacophore of salvinorin A while identifying analogues with more desirable pharmacological 
properties.  The focus of compounds synthesized was specifically to minimize the potential for 
hepatoxicity while establishing structural requirements for affinity and activity.  Several series of 
analogues were synthesized through rational design that replaced the furan ring with amide, 
amine, ketone, and oxime substituents.  The intentions in the amide and ketone series were to 
retain hydrogen bond potential with the carbonyl, possible introduction of additional interactions 
in the binding pocket of KOP receptors due to the new substituent, and to improve the 
pharmacological characteristics of the analogues by enhancing toxicity profiles and water 
solubility.  Amines synthesized were to reveal the importance of the carbonyl, investigate the 
effects of introducing a basic amine, and to improve water solubility.  Lastly, several oxime 
analogues were synthesized to further investigate the structural requirements to modulate 
subtype selectivity at opioid receptors.  A summary of the affinity and efficacy trends identified 
is summarized in Figure 20. 
Investigations into amide and amine derivatives concluded that aliphatic amide analogues 
had greater affinity at opioid receptors compared to the aromatic amide derivatives.  
Additionally, aromatic amines had improved affinity relative to the parent amide but aliphatic 
amines appeared to have comparable affinity to the corresponding amide.  Ketone analogues 
were synthesized utilizing a high yielding method to prepare arylketones via palladium mediated 
coupling of the appropriate boronic acid and a thioester.  Exploration of the ketone series 
identified phenylketone 119 as having < 100 nM affinity at KOP receptors.  Based on this 
finding, studies were carried out to determine the effects of hydrogen bonding, electronic effects, 
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and steric effects of phenyl substitution at the ortho, meta, and para positions.  Several 
substitutions at the meta position were found to retain affinity relative to phenylketone 119.  
Introduction of a carboxamido or cyano substituent resulted in analogues with KOP receptor 
affinity of 40 ± 1 nM and 220 ± 10 nM, respectively.   The introduction of the electron 
withdrawing groups trifluoromethoxy and trifluoromethyl were not tolerated.  Substituent 
modifications on the phenyl ring resulted in compounds with altered affinity and selectivity at 
opioid receptors.  Ketone and amide replacements generally decreased affinity and efficacy 
relative to salvinorin A. 
 
 
Figure 20: Affinity and Efficacy Relationships Established Through These Studies 
 
Heteroaromatic groups were substituted for the phenyl ring and were found to be 
tolerated.  The introduction in size of the ketone substituent generally decreased affinity at KOP 
receptors.  A trend relating to the introduction of steric bulk and increased affinity of MOP 
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receptors was observed.   Depending on the substituent introduced, it appears that increased size 
resulted in improved affinity at MOP receptors.  The trend of introducing steric bulk and 
increasing MOP receptor affinity was observed with the introduction of a benzisoxazole moiety, 
which increased affinity at MOP receptors relative to salvinorin A.  The benzisoxazole derivative 
leads one to believe that steric bulk at this position is not tolerated at KOP receptors but MOP 
receptors are better able to accommodate the bulk with a potential explanation being additional 
hydrophobic interactions.  Additionally, the 2-furanyl salvinorin A (185) analogue was able to 
maintain affinity and activity at KOP receptors relative to salvinorin A.  Proposed molecular 
modeling studies implicate the importance of the furan ring of salvinorin A through interaction 
with specific tyrosine residues through either hydrogen bonding or aromatic interactions.267-269,321  
The retention of affinity and activity observed with 2-furanyl salvinorin A (185) supports that the 
furan ring is interacting at the KOP receptor through aromatic interactions and not directly 
through hydrogen bonding.  The development of additional ligand based models will further 
elucidate the interaction of the furan ring of salvinorin A at KOP receptors.  Throughout this 
work, several furan derivatives have been identified that retain affinity at KOP receptors and 
others in which affinity has been observed at MOP receptors.  Analogues without a furan ring 
have a decreased potential for hepatoxicity compared to salvinorin A, which increases potential 
for the development of a therapeutic agent.   
Studies were also completed to evaluate Captisol® as a vehicle for salvinorin A 
administration.  Results are summarized in Figure 21.  Increasing concentrations of Captisol® 
increased the solubilized amount of salvinorin A in solution.  The concentration of salvinorin A 
in 2.5 M Captisol® was able to reach the concentration of 0.5 mg/mL, the highest concentration 
of salvinorin A in aqueous solution to date.  The use of Captisol® as a delivery agent for 
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salvinorin A and derivatives has the potential to deconvolute data analysis by eliminating the use 
of DMSO or ethanol. 
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  Figure 21: Summary of Salvinorin A Solubility Results 
 
These studies have helped to further elucidate the structure-activity relationships and 
pharmacophore of salvinorin A.  Information from these studies will help to direct future 
exploration of the salvinorin A scaffold and determine how it interacts at opioid receptors.  
Specific emphasis was made to improve the pharmacological profile of salvinorin A analogues to 
increase the potential to lead to identification of novel opioid therapeutics.  Moving forward, 
interest includes the elucidation of structure-activity relationships for 2-furanyl substituents and 
analogue development of compounds with both C-2 and C-12 substitutions to increase potency. 
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CHAPTER VI. EXPERIMENTALS 
Unless otherwise indicated, all reagents were purchased from commercial suppliers and were 
used without further purification.  Melting points were determined on a Thomas-Hoover 
capillary melting apparatus.  NMR spectra were recorded on a Bruker DRX-400 with qnp probe 
or a Bruker AV-500 with cryoprobe using  values in ppm (TMS as internal standard) and J (Hz) 
assignments of 1H resonance coupling.  High resolution mass spectrometry data were collected 
on either a LCT Premier (Waters Corp., Milford, MA) time of flight mass spectrometer or an 
Agilent 6890 N gas chromatograph in conjunction with a quarto Micro GC mass spectrometer 
(Micromass Ltd, Manchester UK).  Thin-layer chromatography (TLC) was performed on 0.25 
mm plates Analtech GHLF silica gel plates using ethyl acetate/n-hexanes, in 1:1 ratio as the 
solvent system unless otherwise noted. Spots on TLC were visualized by uv (254 or 365 nm), if 
applicable, and phosphomolybdic acid in ethanol.  Column chromatography was performed with 
Silica Gel (32 – 63 µ particle size) from Bodman Industries (Atlanta, GA).  Analytical HPLC 
was carried out on an Agilent 1100 Series Capillary HPLC system with diode array detection at 
209.4 nm on an Agilent Eclipse XDB-C18 column (250  10 mm, 5 µm) with isocratic elution in 
60% CH3CN/40% H2O at a flow rate of 5.0 mL/min unless otherwise noted, or on a Phenomenex 
Luna column (250 × 4.5 mm, 5 µm) with isocratic elution in 60% CH3CN/40% H2O unless 
otherwise noted.  The systematic name for salvinorin A (1) is (2S,4aR,6aR,7R,9S,10aS,10bR)-
methyl 9-acetoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-benzo[f]iso-
chromene-7-carboxylate.  Salvinorin A was isolated from S. divinorum as previously 
described.276 
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General Procedure A 
A solution of 51(1 equiv), appropriate amine (1.5 equiv), EDCI (2.5 equiv), HOBt (2.5 equiv) 
and Et3N (10 equiv) in 20 mL DCM was stirred at room temperature overnight.  An additional 15 
mL of DCM was added and then reaction mixture was then washed with saturated aqueous 
NaHCO3 (3 × 15 mL), H2O (3 × 15 mL), brine (15 mL), and dried over anhydrous Na2SO4.  The 
solvent was evaporated in vacuo and the resulting residue purified by flash column 
chromatography on silica gel using mixtures of EtOAc/n-hexanes and triturated in EtOAc/n-
hexanes to afford desired product. 
 
General Procedure B 
To an oven dried round bottom flask under argon was added 51 (1 equiv), CDMT (3 equiv), N-
methylmorpholine (6 equiv) was stirred in anhydrous THF.  After 1 hour, appropriate thiol (3 
equiv) was added and reaction stirred at room temperature for 48 hours.  The reaction was 
quenched with H2O (25 mL) and extracted with Et2O (3 × 30 mL).  The combined Et2O portion 
was washed with saturated aqueous NaHCO3 (3 × 20 mL), 2N HCl (3 × 20 mL), brine (3 × 20 
mL), and dried over anhydrous Na2SO4.  The solvent was evaporated in vacuo and the resulting 
residue purified by flash column chromatography on silica gel using mixtures of EtOAc/n-
hexanes and triturated in EtOAc/n-hexanes to afford desired product.   
 
General Procedure C 
A solution of 135 (1 equiv), appropriate amine (1.05 equiv), and sodium triacetoxyborohydride 
(2.2 equiv) in 1,2-dichloroethane was stirred at room temperature overnight.  The reaction 
mixture was then quenched with NaHCO3 (10 mL) and extracted with DCM (3 × 15 mL).  The 
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combined DCM extracts were washed with saturated aqueous NaHCO3 (3 × 15 mL), brine (3 × 
15 mL) and dried over anhydrous Na2SO4.  The solvent was evaporated in vacuo and the 
resulting residue purified by flash column chromatography on silica gel using mixtures of 
EtOAc/n-hexanes and triturated in EtOAc/n-hexanes to afford desired product.   
 
General Procedure D 
A solution of 119 (1 equiv), appropriate boronic acid (3 equiv), copper(I) thiophene-2-
carboxylate (1.5 equiv), and bis(dibenzylideneacetone)palladium(0) (5 mol%) in anhydrous THF 
under argon was stirred at room temperature.  To the stirring solution, triethyl phosphite (20 mol 
%) was added.  The reaction mixture was stirred at room temperature and monitored by TLC 
until complete.  Reactions were typically complete in 2 – 5 hours.  The mixture was then washed 
with saturated aqueous NaHCO3 (3 × 15 mL), brine (15 mL) and dried over anhydrous Na2SO4.  
The solvent was evaporated in vacuo and the resulting residue purified by flash column 
chromatography on silica gel using mixtures of EtOAc/n-hexanes and triturated in EtOAc/n-
hexanes to afford desired product.   
 
General Procedure E 
Appropriate ketone derivative (1 equiv) was dissolved in MeOH followed by the addition of 
hydroxylamine hydrochloride (2 equiv) and pyridine (10 equiv).  Reaction mixture was heated to 
a gentle reflux and monitored by TLC.  Upon completion, reaction was cooled to room 
temperature and solvent evaporated.  The crude product was dissolved in 20 mL EtOAc and 
washed with aqueous 2 N HCl (3 × 10 mL), brine (15 mL), and dried over anhydrous Na2SO4.  
The solvent was evaporated in vacuo and the resulting residue purified by flash column 
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chromatography on silica gel using mixtures of EtOAc/n-hexanes and triturated in EtOAc/n-
hexanes to afford desired product. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetoxy-7-(methoxycarbonyl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-2-carboxylic acid (75). 
A solution of 51 (Salvinorin A; 2.00 g, 4.62 mmol, 1 equiv) in CCl4:CH3CN:H2O (2:2:3, 70 mL) 
was stirred at room temperature.  To the stirring solution, NaIO4 (11.88 g, 55.4 mmol, 12 equiv) 
was added followed by a catalytic amount of RuCl3·3H2O.  The mixture was stirred for 3 hours 
and then filtered through a pad of Celite.  The Celite was washed thoroughly with EtOAc and the 
organic layer was collected.  The organic layer was washed with saturated aqueous NaHCO3 (3 × 
50 mL) and the aqueous layer collected.  And then the aqueous layer was acidified to pH 2 with 
2N HCl and extracted with EtOAc (3 × 100 mL).  The organic layer was then washed with H2O 
(3 × 30 mL), brine (3 × 30 mL), and dried over anhydrous Na2SO4.  The solvent was evaporated 
in vacuo to yield a a white solid, mp 245 – 248 °C; which was used without further purification. 
1H NMR (500 MHz, CDCl3)  6.31 (s, 1H), 5.34 – 5.27 (m, 1H), 5.01 (dd, J = 6.7, 10.5 Hz, 1H), 
3.72 (d, J = 6.7 Hz, 3H), 2.84 (dd, J = 5.6, 11.2 Hz, 1H), 2.57 (dd, J = 6.7, 13.5 Hz, 1H), 2.36 (s, 
1H), 2.30 (td, J = 7.0, 12.4 Hz, 2H), 2.20 (s, 3H), 2.18 – 2.08 (m, 2H), 1.80 – 1.73 (m, 1H), 1.70 
– 1.58 (m, 2H), 1.50 (dd, J = 10.7, 13.4 Hz, 1H), 1.37 (s, 3H), 1.08 (s, 3H). 13C NMR (126 MHz, 
CDCl3)  202.21, 172.91, 171.92, 171.25, 170.54, 75.84, 73.63, 63.68, 53.24, 52.20, 50.31, 
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42.22, 38.76, 37.83, 35.46, 30.76, 20.92, 18.30, 16.48, 15.78. HRMS(m/z): [M-H] calcd for 
C20H25O9, 409.1499; found, 409.1455. HPLC tR = 2.024 min; purity = 96.20%. 
 
 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(phenyl-
carbamoyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (90). 
Compound 90 was synthesized from 75 using Procedure A and aniline to afford 0.189 g 
(47.4%) as a white solid, mp 136 – 140 ºC; 1H NMR (500 MHz, CDCl3)  8.14 (s, 1H), 7.54 (dd, 
J = 1.0, 8.6 Hz, 2H), 7.38 – 7.31 (m, 2H), 7.18 – 7.13 (m, 1H), 5.18 (dd, J = 8.2, 11.9 Hz, 1H), 
5.03 (dd, J = 6.1, 11.0 Hz, 1H), 3.72 (s, 3H), 2.77 (ddd, J = 5.3, 13.1, 16.8 Hz, 2H), 2.36 – 2.25 
(m, 2H), 2.19 (d, J = 9.4 Hz, 4H), 2.15 – 2.03 (m, 2H), 1.82 – 1.74 (m, 1H), 1.72 – 1.60 (m, 2H), 
1.60 – 1.51 (m, 1H), 1.42 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3)  201.62, 171.68, 
170.29, 169.85, 167.32, 136.77, 129.27, 125.16, 120.18, 76.01, 74.84, 63.96, 53.49, 52.15, 51.21, 
42.00, 39.18, 37.92, 35.52, 30.87, 20.73, 18.19, 16.44, 15.59. HRMS (m/z): [M+Na] calcd for 
C26H31NO8Na, 508.1948; found, 508.1970. HPLC tR = 5.568 min; purity = 98.23%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(indoline-1-carbonyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (100). 
Compound 100 was synthesized from 75 using Procedure A and indoline to afford 0.086 g 
(34.1%) as a white solid, mp 146 – 149 ºC; 1H NMR (500 MHz, CDCl3)  8.21 – 8.16 (m, 1H), 
7.22 (t, J = 7.0 Hz, 2H), 7.11 – 7.04 (m, 1H), 5.22 (t, J = 7.8 Hz, 1H), 5.19 – 5.11 (m, 1H), 4.34 
– 4.26 (m, 1H), 4.08 – 4.00 (m, J = 7.3, 9.5 Hz, 1H), 3.73 (s, 3H), 3.23 (t, J = 8.5 Hz, 2H), 2.77 
(dd, J = 6.1, 10.7 Hz, 1H), 2.54 (dd, J = 8.3, 13.5 Hz, 1H), 2.43 (dd, J = 3.2, 11.6 Hz, 1H), 2.33 – 
2.26 (m, 2H), 2.16 (s, 3H), 2.11 (dd, J = 3.2, 13.9 Hz, 1H), 1.92 (dd, J = 7.3, 13.5 Hz, 1H), 1.75 
(dd, J = 3.1, 12.9 Hz, 1H), 1.72 – 1.54 (m, 3H), 1.42 (d, J = 8.4 Hz, 3H), 1.07 (s, 3H). 13C NMR 
(126 MHz, CDCl3)  202.44, 171.81, 171.30, 169.98, 166.93, 142.42, 131.61, 127.76, 124.92, 
124.88, 117.53, 75.12, 73.58, 64.74, 53.33, 52.12, 49.15, 47.75, 42.15, 37.83, 37.50, 35.28, 
30.80, 28.21, 20.74, 18.31, 17.17, 16.12. HRMS (m/z): [M+H] calcd for C28H34NO8, 512.2285; 
found, 512.2294. HPLC tR = 6.680 min; purity = 98.00%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(cyclohexylcarbamoyl)-6a,10b-dimethyl 
-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (101). 
Compound 101 was synthesized from 75 using Procedure A and cyclohexylamine to afford 
0.053 g (21.0%) as a white solid, mp 141 – 145 ºC; 1H NMR (500 MHz, CDCl3)  6.26 (d, J = 
8.3, 1H), 5.16 (dd, J = 8.0, 12.1, 1H), 4.86 (dd, J = 6.1, 10.8, 1H), 3.81 – 3.69 (m, 4H), 2.77 – 
2.66 (m, 2H), 2.35 – 2.20 (m, 2H), 2.17 (d, J = 3.8, 4H), 2.13 – 2.06 (m, 1H), 2.06 – 2.00 (m, 
1H), 1.88 (t, J = 15.0, 2H), 1.81 – 1.69 (m, 4H), 1.66 – 1.47 (m, 4H), 1.44 – 1.22 (m, 7H), 1.10 
(d, J = 8.9, 3H). 13C NMR (126 MHz, CDCl3)  201.56, 171.68, 170.65, 169.80, 168.32, 76.01, 
74.83, 64.07, 53.54, 52.09, 51.11, 48.38, 42.01, 39.35, 37.98, 35.46, 33.17, 32.99, 30.92, 25.50, 
24.99, 24.97, 20.69, 18.20, 16.41, 15.65. HRMS (m/z): [M+H] calcd for C26H38NO8, 492.2598; 
found, 492.2597. HPLC tR = 5.793 min; purity = 98.29%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(cyclopentylcarbamoyl)-6a,10b-dimeth-
yl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (102). 
Compound 102 was synthesized from 75 using Procedure A and cyclopentylamine to afford 
0.058 g (24.4%) as a white solid, mp 188 – 190 ºC; 1H NMR (500 MHz, CDCl3)  6.30 (d, J = 
7.6 Hz, 1H), 5.16 (dd, J = 7.9, 12.1 Hz, 1H), 4.86 (dd, J = 6.1, 10.8 Hz, 1H), 4.19 (dd, J = 7.2, 
14.4 Hz, 1H), 3.72 (s, 3H), 2.77 – 2.66 (m, 2H), 2.35 – 2.20 (m, 2H), 2.17 (s, 4H), 2.10 (dd, J = 
3.2, 14.0 Hz, 1H), 2.00 (m, 3H), 1.78 (d, J = 13.1 Hz, 1H), 1.73 – 1.49 (m, 7H), 1.44 – 1.30 (m, 
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5H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3)  201.55, 171.69, 170.63, 169.82, 168.82, 76.03, 
74.84, 64.12, 53.59, 52.12, 51.17, 51.14, 42.03, 39.34, 38.01, 35.48, 33.15, 33.05, 30.94, 23.88, 
23.87, 20.71, 18.22, 16.43, 15.64. HRMS (m/z): [M+H] calcd for C25H36NO8, 478.2441; found, 
478.2422. HPLC tR = 5.098 min; purity = 95.33%. 
 
 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(piperazine 
-1-carbonyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (159). 
Compound 159 was synthesized from 75 using Procedure A and piperazine to afford 0.105 g 
(44.9%) as a white solid, mp 180 – 183 ºC;  1H NMR (500 MHz, CDCl3) δ 5.23 (t, J = 7.7 Hz, 
1H), 5.20 – 5.11 (m, 1H), 3.72 (s, 4H), 3.55 (s, 1H), 3.46 (d, J = 35.7 Hz, 2H), 2.87 (s, 2H), 2.81 
– 2.72 (m, 1H), 2.44 – 2.25 (m, 5H), 2.17 (s, 3H), 2.11 – 2.03 (m, 1H), 1.88 (dd, J = 7.2, 13.7 
Hz, 1H), 1.78 – 1.53 (m, 6H), 1.38 (d, J = 3.9 Hz, 3H), 1.06 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 202.49, 171.89, 171.45, 170.06, 167.45, 75.18, 71.45, 64.80, 53.44, 52.19, 49.14, 
47.16, 46.53, 45.95, 43.82, 42.20, 37.89, 35.27, 30.89, 20.82, 18.36, 17.30, 16.21. HRMS (m/z): 
[M+H] calcd for C24H35N2O8, 479.2393; found 479.2405. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-2-(4-methylpiperazine-
1-carbonyl)-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (160). 
Compound 160 was synthesized from 75 using Procedure A and N-methyl piperazine to afford 
0.083 g (34.9%) as a white solid, mp 124 – 127 ºC;  1H NMR (500 MHz, CDCl3) δ 5.22 (t, J = 
7.7 Hz, 1H), 5.19 – 5.12 (m, 1H), 3.72 (s, 4H), 3.59 (s, 1H), 3.49 (d, J = 29.0 Hz, 2H), 2.76 (dd, 
J = 5.4, 11.4 Hz, 1H), 2.50 – 2.26 (m, 11H), 2.16 (d, J = 5.4 Hz, 3H), 2.10 – 2.03 (m, 1H), 1.89 
(dd, J = 7.3, 13.6 Hz, 1H), 1.74 (d, J = 12.8 Hz, 1H), 1.70 – 1.52 (m, 3H), 1.37 (s, 3H), 1.06 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 202.40, 171.82, 171.34, 169.96, 167.28, 75.10, 71.44, 
64.75, 55.15, 54.62, 53.39, 52.11, 49.10, 46.07, 45.79, 42.63, 42.13, 37.84, 37.80, 35.22, 30.84, 
20.75, 18.29, 17.26, 16.15. HRMS (m/z): [M+H] calcd for C25H37N2O8, 493.2550; found 
493.2570. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(4-chloro-3-(trifluoromethyl)phenyl-
carbamoyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate (161). 
Compound 161 was synthesized from 75 using Procedure A and 4-chloro-3-
(trifluoromethyl)aniline to afford 0.074 g (41.5%) isolated as a white solid, mp = 141 – 144 °C; 
1H NMR (500 MHz, CDCl3)  8.40 (s, 1H), 7.89 (d, J = 2.5 Hz, 1H), 7.78 (dd, J = 2.6, 8.7 Hz, 
1H), 7.47 (d, J = 8.7 Hz, 1H), 5.17 (dd, J = 8.1, 11.9 Hz, 1H), 5.04 (dd, J = 6.0, 11.3 Hz, 1H), 
3.72 (s, 3H), 2.80 (dd, J = 6.0, 13.9 Hz, 1H), 2.74 (dd, J = 4.4, 12.4 Hz, 1H), 2.36 – 2.28 (m, 
2H), 2.17 (s, 4H), 2.15 – 2.04 (m, 2H), 1.84 – 1.78 (m, 1H), 1.71 – 1.51 (m, 3H), 1.42 (s, 3H), 
1.11 (s, 3H). 13C NMR (126 MHz, CDCl3)  201.42, 171.45, 169.97, 169.75, 167.58, 135.63, 
132.14, 128.92 (q, 2JCF = 31.6 Hz), 127.70 (d, 
3JCF = 1.7 Hz), 124.02, 122.43 (q, JCF = 273.5 Hz), 
119.04 (q, 3JCF = 5.5 Hz), 75.87, 74.74, 63.82, 53.47, 52.03, 51.28, 41.90, 39.07, 37.84, 35.41, 
30.76, 20.57, 18.08, 16.33, 15.32.  HRMS (m/z): [M+NH4] calcd for C27H33ClF3N2O8, 605.1878; 
found 605.1899.  HPLC tR = 14.957 min; purity = 99.08%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(ethylthiocarbonyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (134). 
Compound 134 was synthesized from 51 using Procedure B and ethanethiol to afford 1.130 g 
(88.0% yield) as a white solid, mp 187 – 191 °C; 1H NMR (500 MHz, CDCl3)  5.18 – 5.11 (m, 
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1H), 4.97 (dd, J = 7.2, 9.7 Hz, 1H), 3.72 (s, 3H), 2.90 (q, J = 7.4 Hz, 2H), 2.73 (dd, J = 5.4, 11.4 
Hz, 1H), 2.62 (dd, J = 7.2, 13.7 Hz, 1H), 2.35 – 2.26 (m, 2H), 2.18 (s, 3H), 2.17 – 2.10 (m, 2H), 
2.10 – 2.02 (m, 1H), 1.81 – 1.73 (m, 1H), 1.70 – 1.62 (m, 1H), 1.62 – 1.51 (m, 2H), 1.37 (s, 3H), 
1.27 (td, J = 2.3, 7.3 Hz, 3H), 1.08 (s, 3H). 13C NMR (126 MHz, CDCl3)  201.81, 199.44, 
171.72, 170.08, 170.04, 80.41, 75.01, 64.42, 53.54, 52.24, 50.57, 42.13, 39.54, 37.96, 35.59, 
30.85, 23.23, 20.81, 18.33, 16.36, 16.09, 14.54.  HRMS(m/z): [M +Na] calcd for C22H30O8SNa, 
477.1559; found, 477.1536. HPLC tR = 26.93 min; purity = 98.31%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-formyl-6a,10b-dimethyl-4,10-dioxo-
dodecahydro-1H-benzo[f]isochromene-7-carboxylate (135). 
A solution of 134 (0.700 g, 1.54 mmol), triethylsilane (0.737 mL, 4.62 mmol), and 10% 
palladium on carbon (32.7 mg, 0.31 mmol) were added to 20 mL DCM under argon and stirred 
at room temperature overnight.  Upon completion, the reaction mixture was filtered through 
Celite and the solvent was removed under reduced pressure.  The crude solid was triturated using 
EtOAc/n-hexanes (1:25) (40 mL) and collected by filtration and dried to afford 0.498 mg (81.9% 
yield) of 135 as a white solid, mp 194 – 197 °C; 1H NMR (500 MHz, CDCl3)  9.68 (s, 1H), 5.16 
(dd, J = 8.6, 11.6 Hz, 1H), 4.89 (dd, J = 7.2, 9.8 Hz, 1H), 3.73 (s, 3H), 2.75 (dd, J = 5.2, 11.6 Hz, 
1H), 2.52 (dd, J = 7.1, 13.7 Hz, 1H), 2.36 – 2.24 (m, 2H), 2.18 (s, 3H), 2.16 – 2.07 (m, 1H), 1.96 
(dd, J = 3.1, 11.8 Hz, 1H), 1.78 (dt, J = 3.1, 13.4 Hz, 1H), 1.72 – 1.50 (m, 4H), 1.39 (s, 3H), 1.09 
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(s, 3H). 13C NMR (126 MHz, CDCl3)  201.91, 197.98, 171.69, 170.36, 170.11, 79.71, 75.05, 
64.50, 53.52, 52.24, 50.98, 42.16, 37.93, 36.64, 35.39, 30.82, 20.80, 18.35, 16.41, 16.37; HRMS 
(m/z): [M+H] calcd for C20H27O8, 395.1706; found, 395.1712. HPLC tR = 7.561 min; purity = 
95.63%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-((phenyl-
amino)methyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (162). 
Compound 162 was synthesized from 135 using Procedure B and aniline to afford 0.199 g 
(69.9%) as a white solid, mp 113 – 116 ˚C; 1H NMR (500 MHz, CDCl3)  7.23 – 7.16 (m, 2H), 
6.75 (t, J = 7.3 Hz, 1H), 6.61 (dt, J = 4.1, 8.2 Hz, 2H), 5.21 – 5.08 (m, 1H), 4.73 (d, J = 3.0 Hz, 
1H), 4.07 (s, 1H), 3.73 (s, 3H), 3.44 (d, J = 13.5 Hz, 1H), 3.18 (dd, J = 6.4, 13.7 Hz, 1H), 2.80 – 
2.68 (m, 1H), 2.35 – 2.25 (m, 3H), 2.19 (d, J = 2.3 Hz, 3H), 2.17 – 2.11 (m, 2H), 2.02 – 1.94 (m, 
1H), 1.82 – 1.73 (m, 1H), 1.68 – 1.49 (m, 2H), 1.43 (d, J = 12.4 Hz, 1H), 1.38 (d, J = 6.2 Hz, 
3H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3)  202.35, 171.76, 171.50, 170.26, 147.63, 
129.62, 118.38, 113.41, 76.52, 75.29, 64.20, 53.70, 52.23, 51.40, 48.97, 42.28, 39.92, 38.30, 
35.22, 30.89, 20.82, 18.32, 16.54, 15.47.  HRMS (m/z): [M+H] calcd for C26H34NO7, 472.2335; 
found, 472.2346. HPLC tR = 6.676 min; purity = 99.24%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((4-fluorophenylamino)methyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (163). 
Compound 163 was synthesized from 135 using Procedure B and 4-fluoroaniline aniline to 
afford 0.105 g (46.4%) as a white solid, mp 120 – 123 ˚C; 1H NMR (500 MHz, CDCl3)  6.93 – 
6.87 (m, 2H), 6.57 – 6.52 (m, 2H), 5.16 – 5.09 (m, 1H), 4.71 (d, J = 3.0 Hz, 1H), 3.96 (s, 1H), 
3.72 (s, 3H), 3.37 (d, J = 11.9 Hz, 1H), 3.13 (dd, J = 6.8, 13.6 Hz, 1H), 2.78 – 2.69 (m, 1H), 2.35 
– 2.25 (m, 3H), 2.20 – 2.11 (m, 5H), 2.01 – 1.95 (m, 1H), 1.79 (d, J = 13.1 Hz, 1H), 1.67 – 1.50 
(m, 3H), 1.38 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz, CDCl3)  202.30, 171.73, 171.37, 
170.26, 156.43 (d, JCF = 263.05 Hz), 143.96 (d, 
4JCF = 1.76 Hz), 116.05 (2C, d, 
2JCF = 22.37 Hz) 
114.44 (2C, d, 3JCF = 7.46 Hz), 76.38, 75.31, 64.29, 53.77, 52.22, 51.48, 49.87, 42.31, 40.03, 
38.34, 35.26, 30.93, 20.80, 18.35, 16.54, 15.47.  HRMS (m/z): [M+H] calcd for C26H33NO7F, 
490.2241; found, 490.2236. HPLC tR = 7.333 min; purity = > 99.99%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((3-fluorophenylamino)methyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (164). 
Compound 164 was synthesized from 135 using Procedure B and 3-fluoroaniline aniline to 
afford 0.034 g (15.2%) as a white solid, mp 118 – 121˚C; 1H NMR (500 MHz, CDCl3)  7.11 
(dd, J = 8.2, 14.9, 1H), 6.42 (dd, J = 7.3, 9.4 Hz, 1H), 6.37 (dd, J = 1.6, 8.1 Hz, 1H), 6.29 (dt, J = 
2.3, 11.4 Hz, 1H), 5.16 – 5.08 (m, 1H), 4.71 (d, J = 3.0 Hz, 1H), 4.20 (s, 1H), 3.73 (s, 3H), 3.37 
(s, 1H), 3.17 (s, 1H), 2.78 – 2.67 (m, 1H), 2.34 – 2.25 (m, 3H), 2.21 – 2.09 (m, 5H), 2.01 – 1.94 
(m, 1H), 1.79 (d, J = 13.1 Hz, 1H), 1.69 – 1.48 (m, 3H), 1.38 (s, 3H), 1.10 (s, 3H). 13C NMR 
(126 MHz, CDCl3)  202.28, 171.73, 171.28, 170.24, 164.26 (d, JCF = 243.49 Hz), 149.45 (d, 
3JCF = 10.52 Hz), 130.71 (d, 
3JCF = 10.18 Hz), 109.15 (d, 
4JCF = 2.24 Hz), 104.84 (d, 
2JCF = 21.54 
Hz), 100.19 (d, 2JCF = 25.32 Hz), 76.29, 75.29, 64.26, 53.76, 52.22, 51.49, 48.98, 42.30, 40.01, 
38.32, 35.27, 30.93, 20.80, 18.34, 16.55, 15.47.  HRMS (m/z): [M+H] calcd for C26H33NO7F, 
490.2241; found, 490.2234. HPLC tR = 7.642 min; purity = > 99.99%. 
 
 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-2-(morpholinomethyl)-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (165). 
Compound 165 was synthesized from 135 using Procedure B and morpholine to afford 0.047 g 
(11.9 %) as a white solid, mp 193 – 195; 1H NMR (500 MHz, CDCl3)  5.17 – 5.09 (m, 1H), 
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4.68 – 4.59 (m, 1H), 3.70 (d, J = 2.4 Hz, 3H), 3.67 (t, J = 4.7 Hz, 4H), 2.77 – 2.65 (m, 1H), 2.57 
– 2.40 (m, 6H), 2.34 – 2.23 (m, 2H), 2.22 – 2.14 (m, 4H), 2.14 – 2.07 (m, 2H), 1.95 – 1.88 (m, 
1H), 1.74 (dd, J = 3.0, 10.1 Hz, 1H), 1.65 – 1.49 (m, 3H), 1.34 (d, J = 6.4 Hz, 3H), 1.06 (s, 3H). 
13C NMR (126 MHz, CDCl3)  202.29, 171.79, 171.49, 170.28, 76.46, 75.21, 67.15, 64.35, 
63.60, 54.75, 53.71, 52.22, 51.44, 42.23, 40.80, 38.32, 35.14, 30.93, 20.85, 18.34, 16.55, 15.36.  
HRMS (m/z): [M+H] calcd for C24H36NO8, 466.2441; found, 466.2449. HPLC tR = 3.838 min; 
purity = 95.61%. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(phenyl-
thiocarbonyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (166). 
Compound 166 was synthesized from 51 using Procedure B and thiophenol to afford 0.335 g 
(47.6%) as a white solid, mp 136 – 140 ºC; 1H NMR (500 MHz, CDCl3)  7.47 – 7.38 (m, 5H), 
5.14 (dd, J = 8.6, 11.6 Hz, 1H), 5.09 (dd, J = 7.2, 9.6 Hz, 1H), 3.72 (s, 3H), 2.74 (dd, J = 5.2, 
11.6 Hz, 1H), 2.65 (dd, J = 7.2, 13.7 Hz, 1H), 2.37 – 2.22 (m, 2H), 2.22 – 2.10 (m, 6H), 1.84 – 
1.74 (m, 1H), 1.74 – 1.50 (m, 3H), 1.39 (s, 3H), 1.09 (s, 3H).  13C NMR (126 MHz, CDCl3)  
201.80, 197.76, 171.71, 170.01, 169.87, 134.91, 130.09, 129.62, 126.07, 80.51, 75.03, 64.39, 
53.56, 52.21, 50.64, 42.17, 39.52, 37.96, 35.68, 30.89, 20.77, 18.38, 16.38, 16.20.  HRMS (m/z): 
[M+H] calcd for C26H31O8S, 503.1740; found 503.1720.  HPLC tR = 8.507 min; purity = 
>99.99%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-benzoyl-6a,10b-dimethyl-4,10-dioxo-
dodecahydro-1H-benzo[f]isochromene-7-carboxylate (119). 
Compound 119 was synthesized from compound 166 using Procedure D and phenyl  boronic 
acid to afford 0.221 g (82.4%) isolated as an off-white solid, mp = 164 – 167 °C.  1H NMR (500 
MHz, CDCl3)  7.93 – 7.86 (m, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.48 (t, J = 7.8 Hz, 2H), 5.85 (t, J 
= 8.3 Hz, 1H), 5.13 – 5.03 (m, 1H), 3.69 (s, 3H), 2.74 – 2.58 (m, 2H), 2.25 (dd, J = 6.8, 13.5 Hz, 
2H), 2.18 – 2.06 (m, 6H), 1.78 – 1.48 (m, 4H), 1.44 (s, 3H), 1.06 (s, 3H). 13C NMR (126 MHz, 
CDCl3)  202.20, 195.39, 171.79, 171.15, 170.06, 134.58, 133.66, 129.32, 129.15, 75.46, 75.06, 
65.03, 53.46, 52.19, 49.53, 42.20, 38.44, 37.93, 35.78, 30.90, 20.80, 18.47, 16.97, 16.22.  HRMS 
(m/z): [M+Na] calcd for C26H30O8Na, 493.1838; found 493.1819.  HPLC tR = 6.003 min; purity 
= 95.36%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2-methoxybenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (167). 
Compound 167 was synthesized from compound 166  using Procedure D and 2-methoxyphenyl 
boronic acid to afford 0.082 g (66.2%) isolated as a white solid, mp = 186 – 188 °C.  1H NMR 
(500 MHz, CDCl3)  7.79 (dd, J = 1.8, 7.8 Hz, 1H), 7.56 – 7.47 (m, 1H), 7.07 – 6.99 (m, 1H), 
6.96 (d, J = 8.2 Hz, 1H), 5.89 (t, J = 8.1 Hz, 1H), 5.10 – 5.02 (m, 1H), 3.92 (s, 3H), 3.69 (s, 3H), 
2.75 – 2.63 (m, 2H), 2.30 – 2.19 (m, 2H), 2.16 – 2.06 (m, 6H), 1.72 (dt, J = 3.2, 13.3 Hz, 1H), 
1.68 – 1.46 (m, 3H), 1.40 (s, 3H), 1.05 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.11, 197.37, 
171.83, 171.72, 169.99, 159.03, 135.43, 131.80, 124.34, 121.47, 112.15, 79.32, 75.08, 65.20, 
55.96, 53.51, 52.16, 49.69, 42.24, 38.20, 38.08, 35.76, 30.96, 20.84, 18.51, 16.90, 16.26.  HRMS 
(m/z): [M+NH4] calcd for C27H36O9N, 518.2390; found 518.2369.  HPLC tR = 6.040 min; purity 
= >99.99% 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-methoxybenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (168). 
Compound 168 was synthesized from compound 166 using Procedure D and 3-methoxyphenyl 
boronic acid to afford 0.093 g (60.9%) isolated as a white solid, mp = 162 – 164 °C.  1H NMR 
(500 MHz, CDCl3)  7.48 – 7.43 (m, 2H), 7.40 (dd, J = 5.8, 10.3 Hz, 1H), 7.16 (ddd, J = 1.1, 
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2.6, 8.1 Hz, 1H), 5.86 (t, J = 8.3 Hz, 1H), 5.16 – 5.06 (m, 1H), 3.86 (s, 3H), 3.72 (s, 3H), 2.77 – 
2.61 (m, 2H), 2.28 (dd, J = 7.1, 13.5 Hz, 2H), 2.20 – 2.09 (m, 6H), 1.80 – 1.73 (m, 1H), 1.67 (dt, 
J = 8.0, 14.9 Hz, 1H), 1.62 – 1.52 (m, 2H), 1.46 (s, 3H), 1.08 (s, 3H).  13C NMR (126 MHz, 
CDCl3)  202.16, 195.34, 171.78, 171.14, 170.04, 160.31, 134.96, 130.32, 121.55, 121.08, 
113.35, 75.51, 75.04, 65.02, 55.72, 53.45, 52.18, 49.49, 42.19, 38.59, 37.92, 35.79, 30.89, 20.80, 
18.46, 16.93, 16.21. HRMS (m/z): [M+H] calcd for C27H33O9, 501.2125; found 501.2112.  HPLC 
tR = 6.217 min; purity = 99.03%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(4-methoxybenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (169). 
Compound 169 was synthesized from compound 166 using Procedure D and 4-methoxyphenyl 
boronic acid to afford 0.069 g (50.7%) isolated as a white solid, mp = 117 – 120 °C.  1H NMR 
(500 MHz, CDCl3)  7.90 – 7.85 (m, 2H), 6.97 – 6.91 (m, 2H), 5.81 (t, J = 8.2 Hz, 1H), 5.14 – 
5.01 (m, 1H), 3.87 (d, J = 7.1 Hz, 3H), 3.69 (s, 3H), 2.74 – 2.65 (m, 1H), 2.62 (dd, J = 8.7, 13.6 
Hz, 1H), 2.25 (dd, J = 6.7, 13.8 Hz, 2H), 2.20 – 2.05 (m, 6H), 1.75 – 1.47 (m, 4H), 1.43 (s, 3H), 
1.05 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.25, 193.81, 171.82, 171.36, 170.07, 164.65, 
131.56, 126.54, 114.55, 75.19, 75.08, 65.08, 55.81, 53.45, 52.18, 49.37, 42.21, 38.59, 37.93, 
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35.73, 30.90, 20.81, 18.47, 17.08, 16.20.  HRMS (m/z): [M+NH4] calcd for C27H36O9N, 
518.2390; found 518.2379.  HPLC tR = 6.247 min; purity = 96.68%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2-hydroxybenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (170). 
Compound 170 was synthesized from compound 166 using Procedure D and 2-hydroxybenzene 
boronic acid to afford 0.090 g (44.0%) isolated as a white solid, mp = 200 – 203 °C.  1H NMR 
(500 MHz, CDCl3)  11.73 (s, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 
8.5 Hz, 1H), 6.95 (t, J = 7.6 Hz, 1H), 5.92 (t, J = 8.4 Hz, 1H), 5.10 (t, J = 10.0 Hz, 1H), 3.72 (s, 
3H), 2.72 (dd, J = 8.7, 13.8 Hz, 2H), 2.28 (dd, J = 6.8, 13.4 Hz, 2H), 2.23 – 2.09 (m, 6H), 1.84 – 
1.56 (m, 4H), 1.47 (s, 3H), 1.09 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.20, 200.58, 171.74, 
170.98, 170.06, 163.70, 137.98, 129.64, 119.97, 119.25, 116.55, 75.08, 74.43, 64.96, 53.46, 
52.22, 49.49, 42.23, 38.94, 37.93, 35.83, 30.88, 20.79, 18.49, 16.82, 16.22.  HRMS (m/z): [M - 
H] calcd for C26H29O9, 485.1812; found 485.1808.  HPLC tR = 6.986 min; purity = 96.16%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-hydroxybenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (171). 
Compound 171 was synthesized from compound 166 using Procedure D and 3-hydroxyphenyl 
boronic acid to afford 0.033 g (28.9%) isolated as a white solid, mp = 131 – 135 °C.  1H NMR 
(500 MHz, CDCl3)  7.23 (t, J = 7.9 Hz, 1H), 7.16 – 7.12 (m, 1H), 7.10 (d, J = 7.8 Hz, 1H), 6.96 
(s, 1H), 6.92 (dd, J = 1.9, 8.1 Hz, 1H), 5.78 (dd, J = 6.9, 10.2 Hz, 1H), 5.17 (dd, J = 8.0, 12.1 Hz, 
1H), 3.73 (d, J = 2.0, 3H), 3.00 – 2.89 (m, 2H), 2.82 (dd, J = 10.3, 13.4 Hz, 1H), 2.37 – 2.25 (m, 
2H), 2.21 (s, 3H), 2.19 – 2.09 (m, 2H), 1.84 (d, J = 9.8 Hz, 1H), 1.78 – 1.62 (m, 3H), 1.48 (s, 
3H), 1.07 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.84, 196.51, 172.04, 171.73, 171.59, 
157.11, 133.45, 130.47, 122.70, 120.61, 114.06, 76.42, 75.37, 63.95, 52.94, 52.19, 48.83, 42.71, 
38.75, 37.79, 35.85, 30.81, 21.00, 18.82, 17.22, 16.13.  HRMS (m/z): [M-H] calcd for C26H29O9, 
485.1812; found 485.1801.  HPLC tR = 4.286 min; purity = 99.66%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(4-hydroxybenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (172). 
Compound 172 was synthesized from compound 166 using Procedure D and 4-hydroxyphenyl 
boronic acid to afford 0.092 g (68.0%) isolated as a white solid, mp = 232 – 236 °C.  1H NMR 
(500 MHz, CDCl3)  7.82 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.16 (s, 1H), 5.80 (t, J = 
8.3 Hz, 1H), 5.13 – 5.08 (m, 1H), 3.72 (s, 3H), 2.72 (d, J = 7.7 Hz, 1H), 2.62 (dd, J = 8.7, 13.6 
Hz, 1H), 2.30 (d, J = 10.7 Hz, 2H), 2.20 (s, 1H), 2.17 (s, 5H), 1.79 – 1.52 (m, 4H), 1.45 (s, 3H), 
1.08 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.27, 193.59, 171.80, 171.60, 170.41, 161.34, 
131.84, 126.60, 116.09, 77.44, 75.25, 65.01, 53.45, 52.21, 49.43, 42.25, 38.48, 37.94, 35.71, 
30.88, 20.85, 18.46, 17.06, 16.23.  HRMS (m/z): M-H] calcd for C26H29O9, 485.1812; found 
485.1783.  HPLC tR = 4.624 min; purity = 95.63%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2-(cyanomethoxy)benzoyl)-6a,10b-di-
methyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (173). 
Compound 173 was synthesized from compound 166 using Procedure D and 2-
cyanomethoxyphenyl boronic acid to afford 0.149 g (47.1%) isolated as a light yellow solid, mp 
= 110 – 113 °C.  1H NMR (500 MHz, CDCl3)  7.71 (dd, J = 1.7, 7.7 Hz, 1H), 7.61 – 7.55 (m, 
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1H), 7.21 (t, J = 7.2 Hz, 1H), 7.06 (d, J = 8.2 Hz, 1H), 5.68 (dd, J = 7.7, 8.8 Hz, 1H), 5.16 – 5.09 
(m, 1H), 4.90 (q, J = 15.8 Hz, 2H), 3.72 (s, 3H), 2.74 (dd, J = 5.5, 11.4 Hz, 1H), 2.64 (dd, J = 
7.7, 13.6 Hz, 1H), 2.34 – 2.25 (m, 2H), 2.19 (s, 1H), 2.16 (s, 3H), 2.12 (dt, J = 4.6, 14.4 Hz, 2H), 
1.76 (d, J = 13.0 Hz, 1H), 1.72 – 1.53 (m, 3H), 1.43 (s, 3H), 1.08 (s, 3H).  13C NMR (126 MHz, 
CDCl3)  202.21, 197.63, 171.80, 171.05, 170.09, 155.31, 134.90, 131.67, 126.48, 124.00, 
114.69, 113.40, 79.36, 75.13, 64.81, 54.59, 53.49, 52.18, 50.06, 42.25, 38.04, 38.03, 35.69, 
30.93, 20.83, 18.44, 16.65, 16.35.  HRMS (m/z): [M+Na] calcd for C28H31NO9Na, 548.1897; 
found 548.165.  HPLC tR = 11.818 min; purity = 98.62% using 50 CH3CN:50 H2O as the mobile 
phase. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(4-chloro-3-(trifluoromethyl)benzoyl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (174). 
Compound 174 was synthesized from compound 166 using Procedure D and 4-chloro-3-
(trifluoromethyl)benzene boronic acid to afford 0.059 g (33.3%) isolated as a gray solid, mp = 
109 – 112 °C.  1H NMR (500 MHz, CDCl3)  8.29 (d, J = 2.0 Hz, 1H), 8.03 (dd, J = 2.1, 8.4 Hz, 
1H), 7.66 (d, J = 8.4 Hz, 1H), 5.77 (t, J = 8.2 Hz, 1H), 5.18 – 5.11 (m, 1H), 3.72 (s, 3H), 2.79 – 
2.70 (m, 1H), 2.58 (dd, J = 8.0, 13.7 Hz, 1H), 2.35 – 2.26 (m, 2H), 2.21 (s, 1H), 2.16 (s, 3H), 
2.14 – 2.08 (m, 2H), 1.81 – 1.52 (m, 4H), 1.47 (s, 3H), 1.09 (s, 3H). 13C NMR (126 MHz, 
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CDCl3)  201.92, 192.99, 171.52, 170.27, 169.90, 138.69 (d, 3JCF = 1.3 Hz), 133.01, 132.34, 
132.23, 129.62 (q, 2JCF = 32.3 Hz), 128.39 (q, 
3JCF = 5.2 Hz), 122.20 (q, JCF = 273.7 Hz), 75.42, 
74.85, 64.62, 53.28, 52.02, 49.73, 41.97, 37.69, 37.45, 35.50, 30.68, 20.59, 18.20, 16.65, 16.09.  
HRMS (m/z): [M+NH4] calcd for C27H32O8F3ClN, 590.1769; found 590.1783.  HPLC tR = 
17.187 min; purity = 95.64%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-carbamoylbenzoyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (175). 
Compound 175 was synthesized from compound 166 using Procedure D and 3-
aminocarbonylphenyl boronic acid to afford 0.062 g (37.8%) isolated as a white solid, mp = 148 
– 152 °C.  1H NMR (500 MHz, CDCl3)  8.30 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.02 (d, J = 7.9 
Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 6.52 – 6.31 (m, 1H), 5.88 (t, J = 8.4 Hz, 1H), 5.84 – 5.65 (m, 
1H), 5.18 – 5.11 (m, 1H), 3.72 (s, 3H), 2.82 – 2.73 (m, 1H), 2.65 (dd, J = 8.4, 13.6 Hz, 1H), 2.28 
(dd, J = 7.3, 13.3 Hz, 3H), 2.20 – 2.09 (m, 5H), 1.78 (d, J = 13.0 Hz, 1H), 1.75 – 1.54 (m, 3H), 
1.47 (s, 3H), 1.09 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.32, 194.95, 171.81, 170.95, 
170.22, 168.05, 134.59, 133.96, 133.38, 132.26, 129.75, 127.79, 75.66, 75.18, 64.74, 53.40, 
52.20, 49.71, 42.24, 38.11, 37.91, 35.78, 30.90, 20.82, 18.49, 16.87, 16.27.  HRMS (m/z): 
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[M+Na] calcd for C27H31NO9Na, 536.1897; found 536.1901.  HPLC tR = 3.465 min; purity = 
96.22% using 40 CH3CN:60 H2O as the mobile phase. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-cyanobenzoyl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (176). 
Compound 176 was synthesized from compound 166 using Procedure D and 3-
cyanophenylboronic acid to afford 0.055 g (43.9%) isolated as a white solid, mp = 124 – 127 °C. 
1H NMR (500 MHz, CDCl3)  8.25 (t, J = 1.4 Hz, 1H), 8.18 – 8.14 (m, 1H), 7.92 – 7.88 (m, 1H), 
7.66 (t, J = 7.8 Hz, 1H), 5.79 (t, J = 8.3 Hz, 1H), 5.18 – 5.10 (m, 1H), 3.72 (s, 3H), 2.80 – 2.71 
(m, 1H), 2.58 (dd, J = 7.9, 13.7 Hz, 1H), 2.35 – 2.26 (m, 2H), 2.21 (s, 1H), 2.20 – 2.08 (m, 5H), 
1.82 – 1.52 (m, 4H), 1.48 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz, CDCl3)  202.11, 193.43, 
171.71, 170.42, 170.09, 137.18, 134.85, 133.13, 132.96, 130.28, 117.76, 113.99, 75.65, 75.05, 
64.78, 53.49, 52.22, 50.01, 42.18, 37.90, 37.64, 35.72, 30.88, 20.80, 18.41, 16.77, 16.30.  HRMS 
(m/z): [M-H] calcd for C27H28NO8, 494.1815; found 494.1806.  HPLC tR = 6.510 min; purity = 
95.94%. 
 
 
120 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(3-(tri-
fluoromethoxy)benzoyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (177). 
Compound 177 was synthesized from compound 166 using Procedure D and 3-
(trifluoromethoxy)-phenylboronic acid to afford 0.038 g (24.3%) isolated as a white solid, mp = 
92 – 94 °C.  1H NMR (500 MHz, CDCl3)  7.86 – 7.80 (m, 2H), 7.56 (t, J = 8.0 Hz, 1H), 7.48 (d, 
J = 7.2 Hz, 1H), 5.81 (t, J = 8.3 Hz, 1H), 5.16 – 5.09 (m, 1H), 3.72 (s, 3H), 2.78 – 2.69 (m, 1H), 
2.62 (dd, J = 8.3, 13.6 Hz, 1H), 2.29 (dd, J = 7.2, 13.5 Hz, 2H), 2.19 (s, 1H), 2.18 – 2.09 (m, 
5H), 1.77 (d, J = 13.2 Hz, 1H), 1.71 – 1.53 (m, 3H), 1.47 (s, 3H), 1.09 (s, 3H).  13C NMR (126 
MHz, CDCl3)  202.15, 193.97, 171.75, 170.72, 170.07, 150.00 (q 3JCF = 1.97), 135.62, 130.91, 
127.43, 126.77, 121.56, 120.56 (q JCF = 258.18 ), 75.62, 75.06, 64.91, 53.48, 52.21, 49.77, 42.19, 
38.03, 37.91, 35.76, 30.89, 20.79, 18.44, 16.88, 16.27.  HRMS (m/z): [M+Na] calcd for 
C27H29F3O9Na, 577.1661; found 577.1621.  HPLC tR = 15.925 min; purity = 97.74%.  
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(3-(tri-
fluoromethyl)benzoyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (178). 
Compound 178 was synthesized from compound 166 using Procedure D and 3-
(trifluoromethyl)phenyl boronic acid to afford 0.044 g (38.8%) isolated as an off-white solid, mp 
= 94 – 97 °C.  1H NMR (500 MHz, CDCl3)  8.23 (s, 1H), 8.10 (d, J = 7.9 Hz, 1H), 7.88 (d, J = 
7.8 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 5.84 (t, J = 8.3 Hz, 1H), 5.16 – 5.10 (m, 1H), 3.72 (s, 3H), 
2.79 – 2.70 (m, 1H), 2.61 (dd, J = 8.2, 13.6 Hz, 1H), 2.29 (dd, J = 7.5, 13.5 Hz, 2H), 2.20 (s, 
1H), 2.19 – 2.08 (m, 5H), 1.77 (d, J = 13.2 Hz, 1H), 1.75 – 1.53 (m, 3H), 1.48 (s, 3H), 1.09 (s, 
3H).  13C NMR (126 MHz, CDCl3)  202.15, 194.16, 171.74, 170.66, 170.08, 134.49, 132.33, 
132.05 (q, 2JCF =33.11 Hz), 130.87 (q, 
3JCF = 3.41 Hz), 129.97, 126.18 (q, 
3JCF = 3.84 Hz), 
123.63 (q, JCF = 272.85 Hz), 75.56, 75.06, 64.91, 53.49, 52.22, 49.84, 42.20, 37.92, 37.86, 35.75, 
30.90, 20.80, 18.44, 16.90, 16.28.  HRMS (m/z): [M+Na] calcd for C27H29F3O8Na, 561.1712; 
found 561.1670.  HPLC tR = 5.799 min; purity = 95.0% as determined using a Phenomenex Luna 
column (250 × 4.5 mm, 5 µm). 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-2-carbonyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (116). 
Compound 116 was synthesized from compound 166 using Procedure D and 2-furanylboronic 
acid to afford 0.109 g (84.6%) isolated as a white solid, mp = 207 – 209 °C.  1H NMR (500 
MHz, CDCl3)  7.64 (dd, J = 0.7, 1.7 Hz, 1H), 7.35 (dd, J = 0.7, 3.7 Hz, 1H), 6.57 (dd, J = 1.7, 
3.7 Hz, 1H), 5.60 (t, J = 8.4 Hz, 1H), 5.14 – 5.06 (m, 1H), 3.70 (s, 3H), 2.76 – 2.66 (m, 1H), 2.62 
(dd, J = 8.0, 13.6 Hz, 1H), 2.26 (dd, J = 7.1, 13.5 Hz, 2H), 2.19 – 2.06 (m, 6H), 1.74 (d, J = 13.2 
Hz, 1H), 1.70 – 1.49 (m, 3H), 1.42 (s, 3H), 1.06 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.11, 
184.26, 171.78, 170.92, 170.09, 150.12, 148.06, 120.56, 113.14, 76.23, 75.10, 64.85, 53.52, 
52.20, 49.89, 42.22, 38.27, 37.97, 35.69, 30.91, 20.81, 18.43, 16.67, 16.28. HRMS (m/z): [M+H] 
calcd for C24H29O9, 461.1812; found 461.1796.  HPLC tR = 13.29 min; purity = 97.83% using 40 
CH3CN:60 H2O as the mobile phase. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-3-carbonyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (179). 
Compound 179 was synthesized from compound 166 using Procedure D and furan-3-boronic 
acid to afford 0.106 g (67.5%) isolated as a white solid, mp = 159 – 161 °C.  1H NMR (500 
MHz, CDCl3)  8.20 (dd, J = 0.8, 1.3 Hz, 1H), 7.44 (dd, J = 1.4, 1.9 Hz, 1H), 6.79 (dd, J = 0.8, 
1.9 Hz, 1H), 5.28 (t, J = 8.0 Hz, 1H), 5.17 – 5.07 (m, 1H), 3.69 (s, 3H), 2.71 (dd, J = 5.4, 11.4 
Hz, 1H), 2.54 (dd, J = 7.8, 13.8 Hz, 1H), 2.33 – 2.23 (m, 2H), 2.18 (s, 1H), 2.14 (s, 3H), 2.10 – 
2.01 (m, 2H), 1.79 – 1.70 (m, 2H), 1.69 – 1.58 (m, 1H), 1.55 – 1.47 (m, 1H), 1.40 (s, 3H), 1.06 
(s, 3H).  13C NMR (126 MHz, CDCl3)  202.05, 191.00, 171.77, 170.83, 170.06, 149.28, 144.44, 
124.23, 109.43, 78.51, 75.08, 64.82, 53.52, 52.19, 50.08, 42.18, 38.25, 37.92, 35.57, 30.90, 
20.80, 18.40, 16.97, 16.32.  HRMS (m/z): [M+H] calcd for C24H29O9, 461.1812; found 461.1796.  
HPLC tR = 5.105 min; purity = 99.67%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(thiophene-
2-carbonyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (117). 
Compound 117 was synthesized from compound 166 using Procedure D and 2-thiophene 
boronic acid to afford 0.036 g (36.4%) isolated as an off-white solid, mp = 188 – 190 °C.  1H 
NMR (500 MHz, CDCl3)  7.83 (dd, J = 1.1, 3.9 Hz, 1H), 7.75 (dd, J = 1.1, 4.9 Hz, 1H), 7.18 
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(dd, J = 3.9, 4.9 Hz, 1H), 5.61 (t, J = 8.2 Hz, 1H), 5.17 – 5.08 (m, 1H), 3.72 (s, 3H), 2.77 – 2.68 
(m, 1H), 2.63 (dd, J = 8.1, 13.7 Hz, 1H), 2.29 (dd, J = 7.6, 13.5 Hz, 2H), 2.23 – 2.07 (m, 6H), 
1.72 (ddd, J = 9.4, 20.0, 39.3 Hz, 3H), 1.57 (d, J = 11.7 Hz, 1H), 1.45 (s, 3H), 1.08 (s, 3H).  13C 
NMR (126 MHz, CDCl3)  202.13, 188.51, 171.78, 170.85, 170.06, 140.23, 136.00, 134.26, 
128.92, 77.03, 75.10, 64.86, 53.50, 52.20, 49.82, 42.21, 38.68, 37.93, 35.72, 30.90, 20.80, 18.43, 
16.92, 16.28.  HRMS (m/z): [M+Na] calcd for C24H28O8SNa, 499.1403; found 499.1380.  HPLC 
tR = 5.733 min; purity = 96.12%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(thiophene-
3-carbonyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (180). 
Compound 180 was synthesized from compound 166 using Procedure D and 3-thiophene 
boronic acid to afford 0.081 g (74.3%) isolated as an off-white solid, mp = 170 – 173 °C.  1H 
NMR (500 MHz, CDCl3)  8.20 (dd, J = 1.2, 2.8 Hz, 1H), 7.56 (dd, J = 1.2, 5.1 Hz, 1H), 7.37 
(dd, J = 2.9, 5.1 Hz, 1H), 5.60 (t, J = 8.1 Hz, 1H), 5.17 – 5.08 (m, 1H), 3.72 (s, 3H), 2.78 – 2.67 
(m, 1H), 2.61 (dd, J = 8.3, 13.7 Hz, 1H), 2.29 (dd, J = 7.5, 13.5 Hz, 2H), 2.20 (s, 1H), 2.19 – 
2.06 (m, 5H), 1.71 (ddd, J = 12.5, 22.2, 34.2 Hz, 3H), 1.59 – 1.49 (m, 1H), 1.45 (s, 3H), 1.08 (s, 
3H).  13C NMR (126 MHz, CDCl3)  202.17, 189.63, 171.78, 171.01, 170.06, 138.44, 134.68, 
127.63, 127.21, 77.09, 75.08, 64.96, 53.49, 52.19, 49.71, 42.20, 38.30, 37.92, 35.69, 30.90, 
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20.81, 18.44, 17.05, 16.27.  HRMS (m/z): [M+Na] calcd for C24H28O8SNa, 499.1403; found 
499.1393.  HPLC tR = 5.657 min; purity = 99.78%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(benzofuran-2-carbonyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (181). 
Compound 181 was synthesized from compound 166 using Procedure D and 2-benzofuranyl 
boronic acid to afford 0.090 g (77.2%) isolated as a white solid, mp = 228 – 232 °C.  1H NMR 
(500 MHz, CDCl3)  7.74 (d, J = 7.8 Hz, 1H), 7.71 (d, J = 0.9 Hz, 1H), 7.60 (dd, J = 0.8, 8.5 Hz, 
1H), 7.55 – 7.50 (m, 1H), 7.38 – 7.31 (m, 1H), 5.75 (t, J = 8.3 Hz, 1H), 5.16 – 5.08 (m, 1H), 3.72 
(s, 3H), 2.77 – 2.67 (m, 2H), 2.29 (dd, J = 7.5, 13.5 Hz, 2H), 2.25 – 2.18 (m, 2H), 2.18 – 2.11 
(m, 4H), 1.81 – 1.60 (m, 4H), 1.48 (s, 3H), 1.10 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.15, 
186.33, 171.78, 170.86, 170.04, 156.20, 149.86, 129.49, 126.98, 124.56, 123.93, 116.49, 112.90, 
76.49, 75.07, 64.86, 53.49, 52.20, 49.92, 42.22, 38.22, 37.95, 35.77, 30.92, 20.80, 18.45, 16.78, 
16.29.  HRMS (m/z): [M+Na] calcd for C28H30O9Na, 533.1788; found 533.1797.  HPLC tR = 
7.558 min; purity = 99.33%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(benzo[b]thiophene-2-carbonyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (182). 
Compound 182 was synthesized from compound 166 using Procedure D and thianaphthene-2-
boronic acid to afford 0.095 g (78.8%) isolated as a white solid, mp = 127 – 130 °C.  1H NMR 
(500 MHz, CDCl3)  8.10 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.54 – 7.46 
(m, 1H), 7.46 – 7.40 (m, 1H), 5.74 (t, J = 8.2 Hz, 1H), 5.19 – 5.09 (m, 1H), 3.72 (s, 3H), 2.79 – 
2.71 (m, 1H), 2.67 (dd, J = 8.1, 13.7 Hz, 1H), 2.34 – 2.25 (m, 2H), 2.25 – 2.18 (m, 2H), 2.17 – 
2.08 (m, 4H), 1.85 – 1.73 (m, 2H), 1.73 – 1.63 (m, 1H), 1.63 – 1.53 (m, 1H), 1.48 (s, 3H), 1.09 
(s, 3H).  13C NMR (126 MHz, CDCl3)  202.22, 190.04, 171.79, 170.84, 170.01, 143.20, 139.72, 
139.13, 131.67, 128.45, 126.81, 125.56, 123.11, 76.90, 75.08, 64.83, 53.46, 52.19, 49.81, 42.21, 
38.59, 37.90, 35.75, 30.91, 20.79, 18.44, 16.98, 16.29.  HRMS (m/z): [M+Na] calcd for 
C28H30O8SNa, 549.1559; found 549.1573.  HPLC tR = 9.577 min; purity = 98.44%. 
 
 
 
127 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(benzo[b]thiophene-3-carbonyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (183). 
Compound 183 was synthesized from compound 166 using Procedure D and 1-benzothiphen-3-
yl boronic acid to afford 0.065g (23.3%) isolated as an off-white solid, mp = 133 – 136 °C.  1H 
NMR (500 MHz, CDCl3)  8.72 (d, J = 7.9 Hz, 1H), 8.43 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.56 
– 7.50 (m, 1H), 7.46 (dd, J = 4.1, 11.1 Hz, 1H), 5.77 (t, J = 8.2 Hz, 1H), 5.18 – 5.08 (m, 1H), 
3.72 (s, 3H), 2.77 – 2.70 (m, 1H), 2.65 (dd, J = 8.3, 13.7 Hz, 1H), 2.29 (dd, J = 7.2, 13.5 Hz, 
2H), 2.26 – 2.18 (m, 2H), 2.13 (d, J = 16.9 Hz, 4H), 1.84 – 1.53 (m, 4H), 1.47 (s, 3H), 1.09 (s, 
3H).  13C NMR (126 MHz, CDCl3)  202.27, 190.09, 171.80, 171.13, 170.04, 139.79, 139.45, 
136.99, 131.61, 126.46, 126.16, 125.67, 122.57, 76.76, 75.12, 64.94, 53.50, 52.19, 49.68, 42.23, 
38.51, 37.97, 35.68, 30.91, 20.79, 18.46, 17.06, 16.26.  HRMS (m/z): [M+H] calcd for 
C28H31O8S, 527.1740; found 527.1742.  HPLC tR = 6.64 min; purity = 96.84%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((E)-but-2-enoyl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (184). 
Compound 184 was synthesized from compound 166 using Procedure D and cis-1-propen-1-
ylboronic acid to afford 0.195 g (72.7%) isolated as a white solid, mp = 153 – 155 °C.  1H NMR 
(500 MHz, CDCl3)  6.48 (dq, J = 7.3, 11.4 Hz, 1H), 6.33 (dd, J = 1.7, 11.4 Hz, 1H), 5.19 – 5.11 
(m, 1H), 4.92 (dd, J = 7.4, 9.3 Hz, 1H), 3.72 (s, 3H), 2.73 (dd, J = 5.8, 11.1 Hz, 1H), 2.52 (dd, J 
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= 7.4, 13.7 Hz, 1H), 2.33 – 2.25 (m, 2H), 2.17 (dd, J = 2.0, 7.0 Hz, 7H), 2.10 (dd, J = 3.4, 14.3 
Hz, 1H), 2.00 (dd, J = 3.2, 11.8 Hz, 1H), 1.76 (dd, J = 3.3, 13.3 Hz, 1H), 1.65 (dd, J = 12.6, 27.3 
Hz, 1H), 1.59 – 1.48 (m, 2H), 1.38 (s, 3H), 1.08 (s, 3H).  13C NMR (126 MHz, CDCl3)  201.98, 
196.49, 171.76, 170.83, 170.10, 149.06, 122.82, 79.95, 75.10, 64.78, 53.60, 52.20, 50.37, 42.21, 
38.05, 37.94, 35.56, 30.91, 20.81, 18.40, 16.76, 16.43, 16.35.  HRMS (m/z): [M+Na] calcd for 
C23H30O8Na, 457.1838; found 457.1859.  HPLC tR = 15.253 min; purity = 95.43% using 40 
CH3CN:60 H2O as the mobile phase. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-2-yl)-6a,10b-dimethyl-4,10-di-
oxododecahydro-1H-benzo[f]isochromene-7-carboxylate (185). 
Alkene 184 (0.108 g, 0.249 mmol) was dissolved in bromobenzene (15 mL) followed by the 
addition of selenium (IV) oxide (0.083 g, 0.746 mmol).  Reaction mixture was heated at 160°C 
and monitored by TLC.  The solvent was evaporated in vacuo and the resulting residue purified 
by flash column chromatography on silica gel using mixtures of EtOAc/n-hexanes and triturated 
in EtOAc/n-hexanes to yield 0.195 g (18.1%) of 185 as a white solid, mp 198 – 200 ºC; 1H NMR 
(500 MHz, CDCl3)  7.39 (dd, J = 0.8, 1.7 Hz, 1H), 6.36 – 6.31 (m, 2H), 5.52 (dd, J = 5.6, 11.6 
Hz, 1H), 5.18 – 5.11 (m, 1H), 3.73 (s, 3H), 2.81 – 2.72 (m, 1H), 2.45 (dd, J = 5.6, 13.6 Hz, 1H), 
2.36 – 2.27 (m, 2H), 2.23 (s, 1H), 2.20 – 2.12 (m, 5H), 1.93 – 1.85 (m, 1H), 1.83 – 1.76 (m, 1H), 
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1.71 – 1.59 (m, 2H), 1.44 (s, 3H), 1.11 (s, 3H).  13C NMR (126 MHz, CDCl3)  202.17, 171.79, 
171.07, 170.20, 151.41, 143.38, 110.66, 109.27, 75.27, 72.01, 64.30, 53.78, 52.21, 51.25, 42.33, 
40.52, 38.36, 35.51, 30.95, 20.79, 18.36, 16.53, 15.28.  HRMS (m/z): [M+Na] calcd for 
C23H28O8Na, 455.1682; found, 455.1695.  HPLC tR = 24.103 min; purity = 97.44% using 40 
CH3CN:60 H2O as the mobile phase. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((Z)-(hydroxyimino)(2-hydroxyphenyl) 
methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate 
(186). 
Compound 186 was synthesized from 170 using Procedure E to afford 0.095 g (41.0%) as a 
white solid, mp 156 – 160 ºC; 1H NMR (500 MHz, CDCl3)  10.38 (s, 1H), 9.22 (s, 1H), 7.31 – 
7.23 (m, 1H), 7.15 – 7.09 (m, 1H), 6.94 (d, J = 7.3 Hz, 1H), 6.84 (t, J = 7.6 Hz, 1H), 6.02 (dd, J 
= 5.8, 12.2 Hz, 1H), 5.23 (t, J = 10.0 Hz, 1H), 3.75 (s, 3H), 2.97 – 2.86 (m, 1H), 2.49 (dd, J = 
5.9, 13.2 Hz, 1H), 2.40 – 2.24 (m, 2H), 2.24 – 2.08 (m, 5H), 1.95 (d, J = 9.0 Hz, 1H), 1.75 (d, J = 
13.0 Hz, 1H), 1.56 (tt, J = 12.8, 25.2 Hz, 3H), 1.43 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz, 
CDCl3)  201.98, 172.01, 171.35, 170.96, 157.69, 157.02, 131.42, 127.76, 119.76, 117.77, 
116.12, 75.44, 71.90, 63.32, 53.06, 52.23, 51.58, 42.08, 38.08, 37.65, 35.80, 30.80, 20.97, 18.36, 
16.67, 15.02. HRMS (m/z): [M+Na] calcd for C26H31NO9Na, 524.1897; found, 524.1919.  HPLC 
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tR = 11.12 min; purity = 99.43% as determined on a Phenomenex Luna column (250 × 4.5 mm, 5 
µm) using 40 CH3CN:60 H2O as the mobile phase. 
 
OO
O
CO2Me
H H
AcO
O
N
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(benzo[d]isoxazol-3-yl)-6a,10b-dimethyl 
-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (187). 
Oxime 186 (0.101 g, 0.202 mmol) was dissolved in isopropyl acetate (10 mL) and cooled to 0°C 
under an argon atmosphere.  Diisopropylethylamine (0.042 mL, 0.242 mmol) was added 
followed by dropwise addition of methanesulfonyl chloride (0.047 mL, 0.606 mmol).  The 
reaction was maintained at 0°C for 30 minutes.  Another 1.2 equivalents of 
diisopropylethylamine (0.042 mL, 0.242 mmol) was added and reaction was heated to 55°C and 
monitored by TLC.  Upon completion, reaction was cooled to room temperature and quenched 
with 2N HCl.  EtOAc (10 mL) was added and organic layer was collected.  Organic layer was 
washed with saturated aqueous NaHCO3 (3 × 15 mL), brine (15 mL) and dried (Na2SO4).  The 
solvent was evaporated in vacuo and the resulting residue purified by flash column 
chromatography on silica gel using mixtures of EtOAc/n-hexanes and triturated in EtOAc/n-
hexanes to afford desired product in 0.037 g (37.7%) as a white solid, mp = 114 – 117°C; 1H 
NMR (500 MHz, CDCl3)  7.84 (d, J = 8.0 Hz, 1H), 7.62 – 7.56 (m, 2H), 7.35 (ddd, J = 2.0, 5.9, 
8.0 Hz, 1H), 6.02 (dd, J = 6.4, 9.6 Hz, 1H), 5.18 (dd, J = 8.7, 11.4 Hz, 1H), 3.73 (s, 3H), 2.83 – 
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2.72 (m, 2H), 2.35 – 2.29 (m, 3H), 2.27 – 2.09 (m, 6H), 1.79 (dt, J = 3.1, 13.3 Hz, 1H), 1.77 – 
1.65 (m, 1H), 1.65 – 1.57 (m, 2H), 1.54 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3)  
202.05, 171.79, 170.81, 170.01, 163.98, 157.41, 130.65, 124.29, 122.40, 119.86, 110.30, 75.11, 
71.74, 64.48, 53.63, 52.20, 51.00, 42.20, 40.18, 38.08, 35.73, 30.96, 20.79, 18.39, 16.51, 16.46.  
HRMS (m/z): [M+Na] calcd for C26H29NO8Na, 506.1791; found, 506.1762.  HPLC tR = 11.12 
min; purity = 99.67%.  
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((hydroxyimino)(phenyl)methyl)-6a,10b 
-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (188). 
Compound 188 was synthesized from 119 using Procedure E to afford 0.140 g (65.0%) as a 
white solid, mp 158 – 162 ºC; 1H NMR (500 MHz, CDCl3)  9.48 (s, 1H), 7.84 (s, 1H), 7.57 – 
7.40 (m, 9H), 7.40 – 7.32 (m, 1H), 5.95 (dd, J = 5.7, 12.3, 1H), 5.51 – 5.44 (m, 1H), 5.34 (dd, J = 
5.6, 11.6 Hz, 1H), 5.17 – 5.07 (m, 1H), 3.77 (s, 4H), 3.70 (s, 2H), 2.79 (dd, J = 5.6, 11.4 Hz, 
1H), 2.73 – 2.65 (m, 2H), 2.38 – 2.21 (m, 9H), 2.17 (s, 2H), 2.10 – 2.02 (m, 2H), 1.95 (d, J = 
11.2 Hz, 1H), 1.84 (s, 1H), 1.77 – 1.67 (m, 2H), 1.59 – 1.31 (m, 12H), 1.29 – 1.17 (m, 2H), 1.05 
(d, J = 13.5 Hz, 6H).  13C NMR (126 MHz, CDCl3)  202.12, 201.61, 172.04, 171.78, 171.13, 
171.00 (2C), 170.35, 157.39, 155.98, 133.50, 130.33, 129.90, 129.59, 128.88 (2C), 128.73 (2C), 
128.61 (2C), 128.16 (2C), 78.53, 75.35, 75.17, 73.08, 64.03, 62.78, 53.51, 52.74, 52.25, 52.17, 
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51.77, 51.06, 42.13, 41.64, 39.62, 38.02, 37.89, 37.33, 35.41, 35.31, 30.89, 30.68, 21.07, 20.82, 
18.24, 18.18, 16.61, 16.54, 15.56, 14.88.  HRMS (m/z): [M+Na] calcd for C26H31NO8Na, 
508.1947; found, 508.1949.  HPLC tR = 13.52, 15.54 min; purity = 24.16, 75.44% as determined 
on a Phenomenex Luna column (250 × 4.5 mm, 5 µm) using 40 CH3CN:60 H2O as the mobile 
phase. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((hydroxyimino)(3-(trifluoromethoxy) 
phenyl)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate (189). 
Compound 189 was synthesized from 177 using Procedure E to afford 0.221 g (52.6%) as a 
white solid, mp 139 – 145 ºC; 1H NMR (500 MHz, CDCl3)  8.76 (s, 1H), 7.89 (s, 1H), 7.49 – 
7.43 (m, 2H), 7.38 (dd, J = 1.6, 4.9 Hz, 2H), 7.33 – 7.27 (m, 4H), 5.98 (dd, J = 5.8, 12.1 Hz, 1H), 
5.34 (dd, J = 5.6, 11.7 Hz, 1H), 5.28 – 5.20 (m, 1H), 5.18 – 5.11 (m, 1H), 3.72 (d, J = 10.6 Hz, 
6H), 2.71 (td, J = 6.5, 10.7 Hz, 2H), 2.60 (dd, J = 5.8, 13.3 Hz, 1H), 2.38 – 2.24 (m, 5H), 2.18 (d, 
J = 6.8 Hz, 6H), 2.07 (dd, J = 12.3, 22.8 Hz, 4H), 1.87 – 1.67 (m, 4H), 1.63 – 1.36 (m, 12H), 
1.08 (d, J = 4.9 Hz, 6H). 13C NMR (126 MHz, CDCl3)  202.13, 201.85, 171.82, 171.76, 170.72, 
170.70, 170.63, 170.39, 156.17, 154.27, 149.49 (d, J = 1.8 Hz), 149.28 (d, J = 1.8 Hz), 135.29, 
132.17, 130.23, 130.20, 127.12, 126.42, 121.99, 121.94, 121.54, 120.72, 120.61 (q, J = 258.1 
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Hz, 2C), 78.24, 75.26, 75.19, 72.56, 64.07, 63.69, 53.53, 53.35, 52.19 (2C), 51.67, 51.21, 42.16, 
42.04, 39.53, 38.08, 38.04, 37.96, 35.69, 35.35, 30.89, 30.87, 20.90, 20.82, 18.28, 18.24, 16.56 
(2C), 15.55, 15.05.  HRMS (m/z): [M+Na] calcd for C27H30F3NO9Na, 592.1770; found, 
592.1767.  HPLC tR = 7.15, 7.69 min; purity = 27.16, 72.22% as determined on a Phenomenex 
Luna column (250 × 4.5 mm, 5 µm) using 55 CH3CN:45 H2O as the mobile phase. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((hydroxyimino)(thiophen-2-yl)methyl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (190). 
Compound 190 was synthesized from 117 using Procedure E to afford 0.178g (69.1%) as a 
white solid, mp 152 – 157 ºC; 1H NMR (500 MHz, CDCl3)  8.88 (s, 2H), 7.60 (dd, J = 1.0, 3.9 
Hz, 1H), 7.56 (dd, J = 1.0, 5.1 Hz, 1H), 7.33 (dt, J = 3.4, 6.8 Hz, 1H), 7.20 – 7.16 (m, 1H), 7.12 
(dd, J = 3.9, 5.1 Hz, 2H), 7.03 (dd, J = 3.7, 5.1 Hz, 1H), 6.03 (dd, J = 5.9, 12.0 Hz, 1H), 5.62 
(dd, J = 6.0, 10.5 Hz, 1H), 5.17 (dd, J = 9.7, 20.1 Hz, 2H), 3.76 – 3.69 (m, 6H), 2.86 – 2.70 (m, 
2H), 2.51 (dd, J = 5.9, 13.3 Hz, 1H), 2.39 (dd, J = 6.0, 13.7 Hz, 1H), 2.34 – 2.21 (m, 7H), 2.21 – 
2.08 (m, 7H), 2.05 (dt, J = 3.6, 12.5 Hz, 1H), 1.98 (dd, J = 10.7, 13.6 Hz, 1H), 1.79 – 1.48 (m, 
7H), 1.45 (d, J = 7.3 Hz, 6H), 1.10 (d, J = 4.2 Hz, 6H). 13C NMR (126 MHz, CDCl3)  202.48, 
202.01, 171.91, 171.90, 171.36, 171.20, 170.56, 170.37, 152.62, 148.23, 135.07, 130.89 (2C), 
130.46, 129.42, 127.93, 127.58, 126.50, 77.05, 75.28, 75.26, 72.41, 64.20, 63.48, 53.53, 53.36, 
52.21, 52.18, 51.37, 50.72, 42.26, 42.13, 39.41, 38.11, 38.05, 37.93, 35.66, 35.56, 30.97, 30.90, 
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20.89, 20.85, 18.35, 18.31, 16.59, 16.54, 16.14, 15.07.  HRMS (m/z): [M+Na] calcd for 
C24H29NO8SNa, 514.1512; found, 514.1519.  HPLC tR = 15.93, 16.95 min; purity = 27.25, 
69.83% as determined on a Phenomenex Luna column (250 × 4.5 mm, 5 µm) using 40 
CH3CN:60 H2O as the mobile phase. 
 
Binding and Activity Studies 
 
Radioligand Binding Studies 
MOP receptor binding sites were labeled using [3H]D-Ala2-MePhe4,Gly-ol5]-enkephalin 
([3H]DAMGO, SA = 44 – 48 Ci/mmol) while DOP receptor binding sides were labeled using 
[3H][D-Ala2, D-Leu5]-enkephalin ([3H]DADLE, SA = 40 – 50 Ci/mmol)  in rat brain 
homogenates.  KOP receptor binding sites were labeled using [3H]N-methyl-2-phenyl-N-
[(5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]dec-8-yl]acetamide ([3H]U69,593, SA = 50 
Ci/mmol).  On the day of the assay, Cell pellets were thawed on ice for 15 minutes followed by 
homogenization with a polytron in 10 mL/pellet of ice-cold 10mM Tris-HCl, pH 7.4.  The 
membranes were centrifuged at 30,000 × g for 10 minutes, then resuspended in 10 mL/pellet ice-
cold 10mM Tris-HCl, pH 7.4 followed again by centrifugation at 30,000 × g for 10 minutes.  
Membranes were then resuspended in 25°C 50 mM Tris-HCl, pH 7.4 (~100 mL/pellet hMOP-
CHO, 50 mL/pellet hDOP-CHO, and 120 mL/pellet hKOP-CHO).  All assays were performed in 
50 mM Tris-HCl, pH 7.4 in a final assay volume of 1.0 mL, with a protease inhibitor cocktail: 
bacitracin (100 µg/mL), bestatin (10 µg/mL), leupeptin (4 µg/mL) and chymostatin (2 µg/mL).  
Drug dilution curves were determined with buffer containing 1 mg/mL BSA. 20 μM levallorphan 
([3H]DAMGO and [3H]DADLE) or 10 μM (-)-U69,593 (for [3H]U69,593 binding) was used to 
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account for nonspecific binding.  [3H]Radioligands were used at concentrations of approximately 
2 nM.  After 2 hours of incubation at 25°C, triplicate samples were filtered with Brandell Cell 
Harvesters (Biomedical Research & Development Inc., Gaithersburg, MD), over Whatman GF/B 
filters.  The filters were the punched into 24-well plates in which 0.6 mL of LSC-cocktail 
(Cytoscint) was added.  After an overnight extraction, the samples were counted in a Trilux 
liquid scintillation counter at 44% efficiency.  Approximately 30 μg protein was in each assay 
tube for the opioid binding assays.  The inhibition curves were determined by displacing a single 
concentration of radioligand by 10 concentrations of drug. 
 
Functional Activity Studies 
[35S]GTPS Assay 
The [35S]GTPS assays were conducted previous described.  Buffer A is is 50 mM Tris-
HCl, pH 7.4, containing 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA and buffer B is buffer A 
with the addition of  1.67 mM dithiothreitol (DTT) and 0.15% bovine serum albumin (BSA).  On 
the day of the assay, cells were thawed on ice for 15 min and homogenized using a polytron in 
50 mM Tris-HCl, pH 7.4, containing a protease inhibitor cocktail: bacitracin (100 µg/mL), 
bestatin (10 µg/mL), leupeptin (4 µg/mL) and chymostatin (2 µg/mL). The homogenate was 
centrifuged at 30,000 × g for 10 minutes at 4°C, and the supernatant discarded. The membrane 
pellets were then resuspended in buffer B and used for [35S]GTPS binding assays.  50 µL of 
buffer A plus 0.1% BSA, 50 µL of GDP in buffer A/0.1% BSA (final concentration = 40 µM), 
50 µL of drug in buffer A/0.1% bovine serum albumin, 50 µL of [35S]GTPS in buffer A/0.1% 
BSA (final concentration = 50 pM), and 300 µL of cell membranes (50 µg of protein) in buffer B 
were added in test tubes.  Final concentration of reagents in assay were: 50 mM Tris-HCl, pH 
 
136 
 
7.4, containing 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM DTT, 40 μM GDP, and 0.1% 
BSA. Media was incubated at 55°C for 3 hours.  Non-specific binding was accounted for and 
determined using GTPS (40 µM).  Vacuum filtration through Whatman GF/B filters separated 
bound and free [35S]GTPS.  The filters were punched into 24-well plates followed by the 
addition of 0.6 mL of liquid scintillation media (Cytoscint).  An overnight extraction was 
performed and samples were counted in a Trilux liquid scintillation counter at an efficiency of 
27%. 
 
FLIPR Assay 
All cells were maintained in F-12 nutrient medium (Ham), supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin and streptomycin (p/s), and 0.2% normocin. Cell culture 
supplies were from Invitrogen (Carlsbad, CA) unless otherwise specified.  Chinese hamster 
ovary (CHO) cells stably expressing MOR- or KOR-Gαq16 were removed from their flasks 
using Versene and quenched with the Ham media, centrifuged and re-suspended in media. Cells 
were counted with a Cellometer Auto T4 (Nexcelom Bioscience, Lawrence, MA) and 30,000 
cells were transferred to each well of a black Costar 96-well optical bottom plate (Corning 
Corporation, Corning, NY). Each plate was incubated at 37°C overnight to confluence. The 
culture media was removed from the plates and cells were subsequently loaded with a 
fluorescent calcium probe (Calcium 5 dye, Molecular Devices, Sunnyvale, CA) in an HBSS-
based buffer containing 20 mM HEPES, 0.25% BSA, 1% DMSO, and 10 μM probenecid 
(Sigma) in a total volume of 225 µL. Cells were incubated at 37°C for 1 h and then stimulated 
with DAMGO, U69,593 or test compounds at various concentrations using a Flexstation 3 plate-
reader, which automatically added 25 µL of the compounds at 10X concentration to each well 
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after reading baseline values for ∼17 sec. Agonist-mediated change in fluorescence (485 nm 
excitation, 525 nm emission) was monitored in each well at 1.52 sec intervals for 60 sec and 
reported for each well. Data were collected using Softmax version 4.8 (MDS Analytical 
Technologies) and analyzed using Prism software (GraphPad, La Jolla, CA). Nonlinear 
regression analysis was performed to fit data and obtain maximum response (Emax), EC50, 
correlation coefficient (r2) and other parameters. All experiments were performed at least 3 
times to ensure reproducibility and data reported as mean ± standard error, unless noted 
otherwise. 
 
Solubility Studies 
Sample Preparation 
Excess salvinorin A was added into duplicate 2 mL screw cap vials which contained 
approximately 1 mL of the Captisol® solution.  The vials were sonicated in a Branson 1510 
sonicator for 72 hours and then set at room temperature for 24 hours.  Vials were then 
centrifuged at 7700 rpms for 10 minutes and HPLC analysis immediately followed.  The samples 
were filtered with 0.45 µm, nylon, non-sterile Fisherbrand® syringe filters and analyzed without 
diluting for HPLC. 
 
HPLC Measurements 
HPLC was carried out on an Agilent 1100 Series capillary HPLC system with diode array 
detector.  Peaks were detected at 209 and 214 nm.  A Agilent Eclipse XDB-C18 column (250  
10 mm, 5 µm) was used.  Acetonitrile and water at the ratio of 60:40 was used as the mobile 
phase.  The flow rate was 5.000 mL/min and the injection volume was 100 µL for all samples. 
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APPENDIX A: 1H NMR SPECTRA 
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
010
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
16
7
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
010
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
16
8
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
-5
00
0
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
60
00
0
65
00
0
16
9
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
17
0
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
17
1
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
0
10
00
15
00
20
00
25
00
30
00
35
00
40
00
45
00
50
00
17
2
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-5
00
050
0
10
00
15
00
20
00
25
00
30
00
35
00
40
00
45
00
50
00
55
00
60
00
65
00
17
3
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
17
4
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-50510152025303540455055
17
5
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
010
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
17
6
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
17
7
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
17
8
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
17
9
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
-5
00
0
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
18
0
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
010
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
18
1
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-2
00
0
020
00
40
00
60
00
80
00
10
00
0
12
00
0
14
00
0
16
00
0
18
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
34
00
0
18
2
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
-5
00
0
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
60
00
0
65
00
0
18
3
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
010
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
18
4
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
18
5
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
9.
5
10
.0
10
.5
11
.0
11
.5
12
.0
12
.5
f1
 (
pp
m
)
-1
00
010
0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
90
0
10
00
11
00
12
00
13
00
14
00
15
00
16
00
17
00
18
00
19
00
18
6
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
18
7
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
18
8
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
18
9
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
19
0
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-2
00
0
020
00
40
00
60
00
80
00
10
00
0
12
00
0
14
00
0
16
00
0
18
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
34
00
0
19
1
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
19
2
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
19
3
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
-2
00
0
020
00
40
00
60
00
80
00
10
00
0
12
00
0
14
00
0
16
00
0
18
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
19
4
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
19
5
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
19
6
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-2
00
0
020
00
40
00
60
00
80
00
10
00
0
12
00
0
14
00
0
16
00
0
18
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
19
7
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-2
00
0
020
00
40
00
60
00
80
00
10
00
0
12
00
0
14
00
0
16
00
0
18
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
19
8
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
19
9
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
20
0
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
20
1
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-2
00
0
020
00
40
00
60
00
80
00
10
00
0
12
00
0
14
00
0
16
00
0
18
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
34
00
0
36
00
0
38
00
0
20
2
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
f1
 (
pp
m
)
-5
00
0
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
60
00
0
65
00
0
70
00
0
75
00
0
20
3
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-5
00
0
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
60
00
0
65
00
0
20
4
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
f1
 (
pp
m
)
-1
00
00
010
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
1E
+
05
1E
+
05
20
5
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
9.
5
10
.0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
20
6
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
9.
5
10
.0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
20
7
-0
.5
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
8.
5
9.
0
9.
5
10
.0
f1
 (
pp
m
)
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
20
8
 
209 
APPENDIX B: HPLC CHROMATOGRAMS 
21
0
21
1
21
2
21
3
21
4
21
5
21
6
21
7
21
8
21
9
22
0
22
1
22
2
22
3
22
4
22
5
22
6
22
7
22
8
22
9
23
0
23
1
23
2
23
3
23
4
23
5
23
6
23
7
23
8
23
9
24
0
24
1
24
2
24
3
24
4
24
5
24
6
24
7
24
8
24
9
25
0
25
1
25
2
25
3
25
4
25
5
25
6
25
7
25
8
25
9
26
0
26
1
26
2
26
3
26
4
26
5
26
6
26
7
26
8
26
9
27
0
27
1
27
2
27
3
27
4
27
5
27
6
